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ABSTRACT OF THE DISSERTATION
OVERWEIGHT/OBESITY AND HIV DISEASE PROGRESSION IN HIV+ ADULTS IN
BOTSWANA
by
Sabrina Sales Martinez
Florida International University, 2015
Miami, Florida
Professor Adriana Campa, Major Professor
Studies indicate that overweight and obesity protect against HIV-disease
progression in antiretroviral therapy (ART)-naïve patients. We examined retrospectively
the relationship of overweight/obesity with HIV-disease progression in ART-naïve HIV+
adults in Botswana in a case-control study with 18-month follow-up, which included 217
participants, 139 with BMI 18.0-24.9 kg/m2 and 78 with BMI ≥25 kg/m2. Archived
plasma samples were used to determine inflammatory markers: leptin and bacterial
endotoxin lipopolysaccharide (LPS), and genotype single nucleotide polymorphisms
(SNPs) of the Fat Mass and Obesity Associated Gene (FTO).
At baseline, BMI was inversely associated with risk for AIDS-defining conditions
(HR=0.218; 95%CI=0.068, 0.701, P=0.011), and higher fat mass was associated with
reduced risk of the combined outcome of CD4+cell count ≤250/µL and AIDS-defining
conditions, whichever occurred earlier (HR=0.918; 95%CI=0.847, 0.994, P=0.036) over
18 months, adjusting for age, gender, marriage, children, and baseline CD4+cell count
and HIV-viral load.
FTO-SNP rs17817449 was associated with BMI (OR=1.082; 95%CI=1.001,
1.169; P=0.047). Fat mass was associated with the risk alleles of rs1121980 (OR=1.065;
95%CI=1.009, 1.125, P=0.021), rs8050136 (OR=1.078; 95%CI=1.021, 1.140; P=0.007),
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and rs17817449 (OR=1.086; 95%CI=1.031, 1.145; P=0.002), controlling for age, gender,
tribe, total energy intake, and activity. There were no associations of SNPs with markers
of disease progression.
Leptin levels were positively associated with BMI (β=1.764; 95%CI=0.788, 2.739;
P=0.022) and fat mass (β=0.112; 95%CI=0.090, 0.135; P<0.001), but inversely with viral
load (β=-0.305; 95%CI=-0.579, -.031; P=0.030). LPS levels were inversely associated
with BMI (OR=0.790, 95%CI=0.630, 0.990; P=0.041), and fat mass (OR=0.852,
95%CI=0.757, 0.958; P=0.007) and directly with viral load (OR=2.608, 95%CI=1.111,
6.124; P=0.028), adjusting for age, gender, smoking and %fat mass.
In this cohort, overweight/obesity predicted slower HIV-disease progression.
Obesity may confer an advantage in maintaining fat stores to support the overactive
immune system. FTO-SNPs may contribute to the variation in fat mass; however, they
were not associated with HIV-disease progression. Our findings suggest that the obesity
paradox may be explained by the association of increased LPS with lower BMI and
higher viral load; while viral load decreased with increasing leptin levels. Studies in
African populations are needed to clarify whether genetic variation and inflammation
mediate the obesity paradox in HIV-disease progression.
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CHAPTER I: INTRODUCTION
Statement of Problem
The prevalence of obesity is increasing worldwide, including developing African
nations.1,2 Botswana is experiencing an increase in obesity, which is also observed
among the HIV+ adults.3 At the same time, Botswana is experiencing one of the worst
epidemics of HIV with a prevalence rate of 23.0% among those between the ages 15 to
49 years.4 An obesity paradox has been documented in many conditions including HIV,
where those who are obese may have a survival advantage or improved disease
outcomes.5 It is described as paradox in HIV since obesity has been associated with
higher CD4 cell counts and delayed time to AIDS defining conditions.6-9 Studies on HIV
and obesity are mainly conducted in settings where the patients are treated with
antiretroviral therapy (ART), and where being or becoming obese is a disadvantage for
physical and mental reasons, as obesity increases the risk for comorbidities with
confounding findings and interpretations.10,11 In addition, inflammation accompanies
both obesity and HIV disease, and its role in HIV disease progression has not been
described in the ART naïve population, specifically as related to markers of inflammation
such as Leptin, C-reactive protein and immune activation and bacterial
lipopolysaccharide (LPS) endotoxin.
Genetics has a strong influence on obesity12 which has been estimated to
account for 40-70% of the variation in human adiposity.13 The association of the Fat
Mass and Obesity Associated (FTO) gene has been reported to be strong with obesity,
however, it has not been replicated in all populations and currently there are no
published studies on the FTO gene variants in HIV disease or in a population in
Botswana.
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The objective of this study was to examine the relationship between
overweight/obesity and HIV disease progression, inflammatory markers, and SNPs of
the FTO gene in HIV+ adults who are not on ART in Botswana.

Significance of Study
The proposed research is important since there are several studies in the literature
indicating that overweight or obesity provides some protection from accelerated HIV
disease progression,6-9 but the potential mechanisms for such relationships are lacking.
This study design allows for the examination of the effects of HIV before ART initiation to
obtain a better understanding of how obesity and genetic factors are interrelated and
affect HIV disease progression. In addition, as HIV becomes a chronic disease with the
advent of more effective and accessible treatments, and the risks for obesity and its
comorbidities increase, recognizing genetic susceptibility for obesity will help design
interventions that are tailored to an individual’s genetic variations.14
The evidence from the literature generates the following questions:
•

Is the “obesity advantage” related to the genetically acquired energy efficiency,
regardless of fat accumulation, or it is associated with fat accumulation that
provides a protection to rapid wasting, which is one of the most powerful signs of
HIV-disease progression and associated with shorter time to death?

•

Could it be the result of both factors?

•

How does the interaction of obesity and HIV affect inflammation and the immune
response?

•

Could those without a genetic risk for obesity benefit from early aggressive
nutrition intervention and ART to prevent wasting?
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Botswana is one of the first resource-limited countries to provide ART on a sizeable
scale,15 however, many countries, especially in sub-Saharan Africa, still have challenges
in providing ART and maintaining adherence.16 Of the 21.2 million people in Africa
eligible for ART under the 2013 WHO guidelines, only 7.6 million are receiving ART.17
Therefore, acquiring information on factors that may delay disease progression and
possible mechanisms related to these risks is significant and timely. Moreover, the
findings from this study could be translated and contribute towards clinically relevant
recommendations.

Innovation
This is the first study exploring the role of genetic susceptibility to obesity as a positive
factor to delay HIV disease progression in ART naïve patients.
In the following three studies, hypotheses were tested and results presented as research
papers.

Specific Aims and Hypothesis
CHAPTER III: EFFECT OF BMI AND BODY COMPOSITION ON HIV DISEASE
PROGRESSION IN HIV INFECTED ART NAÏVE ADULTS IN BOTSWANA
Specific Aim 1: To determine the relationship between being overweight/obese (BMI ≥
25 kg/m2) and HIV disease progression (CD4 cell count, HIV viral load and AIDS
defining conditions) in HIV+ asymptomatic adults in Botswana not on antiretroviral
therapy (ART) over 18 months.
Hypothesis 1a: (Primary outcome) The overweight/obese group will present
less clinically significant CD4 cell count decline from Baseline (≥ 25%) over 18
months than the normal weight group.
Hypothesis 1b: The overweight/obese will have significantly lower levels of HIV
viral load over 18 months than the normal weight group.
Hypothesis 1c: Significantly less AIDS defining conditions will occur over 18
months in the overweight/obese group compared to the normal weight group.

3

CHAPTER IV: PRELIMINARY ASSOCIATION STUDY OF THE FAT MASS
AND OBESITY GENE POLYMORPHISMS WITH HIV DISEASE
PROGRESSION
Specific Aim 2: To determine the interrelationships among being overweight/obese,
markers of genetic propensity for obesity (single nucleotide polymorphisms (SNPs) in
FTO) and HIV disease progression (CD4 cell count, HIV viral load and AIDS defining
conditions) in HIV+ asymptomatic adults in Botswana not on ART over 18 months.
Hypothesis 2a: The FTO gene SNPs will be associated with being
overweight/obese.
Hypothesis 2b: The FTO gene SNPs will be associated with delayed HIV
disease progression over 18 months.
Hypothesis 2b1: The FTO gene SNPs will be associated with
significantly higher CD4 cell count.
Hypothesis 2b2: The FTO gene SNPs will be associated with
significantly lower HIV viral load.
Hypothesis 2b3: The FTO gene SNPs will be associated with
significantly less AIDS-defining conditions.
CHAPTER V: ASSOCIATION OF INFLAMMATORY MARKERS WITH BODY
COMPOSITION AND HIV DISEASE PROGRESSION IN ART NAÏVE HIV+
ADULTS IN BOTSWANA
Specific Aim 3: To evaluate the relationship between the inflammatory markers (leptin,
C-reactive protein and bacterial lipopolysaccharide) and HIV disease progression in
HIV+ asymptomatic adults not on ART in Botswana over 18 months.
Hypothesis 3a: Higher levels of leptin, C-reactive protein and bacterial
lipopolysaccharide will be associated with significantly faster HIV disease
progression.
Hypothesis 3a1: Higher levels of inflammatory markers will be
associated with lower levels of CD4 cell count.
Hypothesis 3a2: Higher levels of inflammatory markers will be
associated with higher HIV viral load.
Hypothesis 3a3: Higher levels of inflammatory markers will be
associated with greater AIDS-defining conditions.
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Table 1: Statistical Analysis of Hypotheses
Hypothesis

Dependent
Variable
(Outcome
Variable)

Measurement
of Dependent
Variable

Type of
Dependent
Variable

Independent
Variable

Measurement
of
Independent
Variable

Type of
Independent
Variable

Statistical Analysis

1a

CD4 cell
count
(decrease of
≥ 25%)

CD4 cell count
in blood

Dichotomous
variable (0=no
decrease ≥ 25%
and 1=yes
decrease
≥ 25%)

Body Mass
Index (BMI)

BMI measured
as weight in
kg/ height in
meters
squared

Dichotomous
variable (0=BMI
2
18.0-24.9kg/m
and 1=BMI ≥ 25
kg/m2)

Proportional Hazard
Survival Model will be
performed to compare
hazard ratios on time to
event (CD4 cell count
decrease ≥ 25%) over 18
months.

1b

HIV viral load

HIV viral load in
blood

Continuous
variable

Body Mass
Index (BMI)

BMI measured
as weight in
kg/ height in
meters
squared

Dichotomous
variable (0=BMI
18.0-24.9kg/m2
and 1=BMI ≥ 25
2
kg/m )

Pearson and Spearman
correlations, as deemed
appropriate and
scatterplots will be
performed to evaluate the
relationship between HIV
viral load and BMI groups.
Linear regression will be
used to examine the
relationship between HIV
viral load, at baseline and
18 months, and BMI
groups

1c

AIDS
Defining
Conditions

Presence of
AIDS Defining
Condition
Recorded by
Study Physician

Dichotomous
variable (0=no
and 1=yes)

Body Mass
Index (BMI)

BMI measured
as weight in
kg/ height in
meters
squared

Dichotomous
variable (0=BMI
18.0-24.9kg/m2
and 1=BMI ≥ 25
kg/m2)

Proportional Hazard
Survival Model will be
performed to compare
hazard ratios on time to
event (AIDS defining
conditions) over 18
months.

2a

Body Mass
Index (BMI)

BMI measured
as weight in kg/
height in meters

Dichotomous
variable (0=BMI
18.0-24.9kg/m2
and 1=BMI ≥ 25

Genotypes
for FTO
SNPs

5 Genotypes
for FTO SNPs
determined by
TaqMan

Dichotomous
variable (0=nonrisk alleles and

Logistic Regression will
be performed to see the
relationship between FTO
SNPs and BMI groups.

5

squared

kg/m2)

Discrimination
Assay

1=risk allele)

Cox Proportional Hazard
Survival Model will be
performed to compare
hazard ratios on time to
2
event (BMI ≥ 25 kg/m )
over 18 months.

2b1

CD4 cell
count

CD4 cell count
in blood

Continuous
variable

Genotypes
for FTO
SNPs

5 Genotypes
for FTO SNPs
determined by
TaqMan
Discrimination
Assay

Dichotomous
variable (0=nonrisk alleles and
1=risk allele)

Pearson and Spearman
correlations, as deemed
appropriate, will be
performed to evaluate the
relationship between
markers of disease
progression (CD4 cell
count and HIV viral load)
and FTO SNPs. Logistic
regression will be used to
examine the relationship
between markers of
disease progression and
FTO SNPs over 18
months.

2b2

HIV viral load

HIV viral load in
blood

Continuous
Variable

Genotypes
for FTO
SNPs

5 Genotypes
for FTO SNPs
determined by
TaqMan
Discrimination
Assay

Dichotomous
variable (0=nonrisk alleles and
1=risk allele)

Pearson and Spearman
correlations, as deemed
appropriate, will be
performed to evaluate the
relationship between
markers of disease
progression (CD4 cell
count and HIV viral load)
and FTO SNPs. Logistic
regression will be used to
examine the relationship
between markers of
disease progression and
FTO SNPs over 18
months.

2b3

AIDS

Presence of

Dichotomous

Genotypes

5 Genotypes

Dichotomous

Logistic Regression will

6

3

Defining
Conditions

AIDS defining
conditions
recorded by
study physician

variable (0=no
and 1=yes)

for FTO
SNPs

for FTO SNPs
determined by
TaqMan
Discrimination
Assay

variable (0=nonrisk alleles and
1=risk allele)

be performed to see the
relationship between
AIDS defining conditions
and FTO SNPs. Cox
Proportional Hazard
Survival Model will be
performed to compare
hazard ratios on time to
event (AIDS defining
condition) over 18
months.

Leptin, CRP
and LPS

Plasma leptin
and LPS
measured with
ELISA and
plasma high
sensitivity CRP
provided from
parent grant

Continuous
Variable

CD4 cell
count, HIV
viral load
and AIDS
Defining
Conditions

CD4 cell count
and HIV viral
load in blood
and presence
of AIDS
defining
conditions
recorded by
study
physician

Continuous
variable for CD4
cell count and
HIV viral load

Pearson and Spearman
correlations, as deemed
appropriate, will be
performed to evaluate the
relationship between
inflammatory markers and
markers of disease
progression (CD4 cell
count and HIV viral load).
Student’s t-test will be
performed to compare the
differences in
inflammatory markers and
presence of AIDS defining
conditions. Linear and
logistic regressions will be
used to examine the
relationship between
inflammatory markers and
markers of disease
progression over 18
months.
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Dichotomous
variable for AIDS
Defining
Conditions (0=no
and 1=yes)
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Potential Mechanisms for the Obesity Paradox
BMI does not differentiate between fat and lean body mass and cannot account for
the quantity of adiposity of an individual.5 Some investigators have suggested the use of
waist circumference as a measurement of body fat distribution instead of BMI since it
has been shown to be associated with all-cause mortality6 and inflammatory markers7,8
independent of BMI. Visceral or abdominal adiposity has been shown to be associated
with an inflammatory state,9 however, BMI does not indicate fat distribution in visceral,
peripheral or lower body. Therefore, the positive outcomes in the overweight/obese
populations that have been observed may be due to variations of body fat mass and
presence of a higher proportion of lean body mass.
Bacterial lipopolysaccharide or LPS is an endotoxin and a stimulator of inflammatory
cytokine production and lipoproteins can bind LPS. Models of endotoxaemia in mice
and rats have shown that lipoproteins such as LDL, VLDL, HDL, triglycerides and
chylomicrons can affect LPS bioactivity.10-13 Although obesity is associated with an
increase in inflammation, there may be an obesity paradox present in some conditions
where a reduced inflammatory response is observed. This hypothesis has been coined
the “endotoxin-lipoprotein hypothesis.” 14 The theory is that LPS binds to lipoproteins
through the generation of micelles, therefore reducing cytokine proliferation and
inflammation.15 Rauchhaus et al.10 proposed that higher levels of cholesterol may be
beneficial since lipoproteins can moderate the inflammatory immune response.
Valentijn et al.,4 also considers genetics as a possible explanation for the survival
advantage in overweight/obese. Genetic polymorphisms may have variable effects on
body composition through its effect on food intake, energy expenditure and BMI.16
These variable effects may produce differing survival effects in the overweight/obese
populations.

11

This study examined the obesity paradox in a Botswana population with HIV and
ART naïve. The impact of obesity on HIV disease progression over time were explored.
The relationship between being overweight/obese and HIV disease progression and its
interrelationship between genetic propensity for obesity and inflammatory markers was
investigated.

Obesity in Botswana
Growth in economy, urbanization, and diminished physical activity is contributing to a
rise in obesity in African countries, such as Botswana.17 The prevalence of overweight
and obesity in 2011 were different throughout sub-Saharan Africa and generally was
higher in women compared to men.17 Botswana has the following rates of overweight
(18.5-24.9 kg/m2): 53.5% in women and 41.6% in men, and obesity (>25 kg/m2) 17.7% in
women and 6.9% in men.18 A nationally representative study19 showed that
approximately 23.3% of women were overweight compared to 12.9% in men, and 15.7%
of women compared to 3.2% of men were obese. The mean BMI for women and men
were 24.4 kg/m2 and 21.7 kg/m2 respectively. Increasing age and education was
associated with higher BMI. BMI increased in women with high parity and remained
constant for men. Data on overweight and obese and its relationship to health outcomes
are lacking in the general and HIV populations in Botswana.

HIV and Obesity
In 2008, an estimated 1.4 billion people around the world were obese and about
65% of the population in the world live in countries where more people die from being
overweight and obese than from being underweight.20 An increase of obesity has also
been observed in HIV+ adults, especially when on antiretroviral treatment (ART),21 and
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rates of obesity are more common now than the occurrence of wasting in developed
countries.22,23 It’s been estimated that in sub-Saharan Africa 10% of women had a BMI
of less than 18.5 kg/m2 with wasting still prevalent in some areas.24 However, subSaharan Africa is experiencing a nutrition transition with a rapid rise in overweight and
obesity.25 Studies conducted to investigate obesity and its effect on HIV disease
progression have so far been inconclusive, with some studies reporting an association
and others reporting no association between CD4 cell counts, a measure of HIV disease
progression, and obesity. 21, 26-29

HIV Disease Progression and Obesity
Studies have shown that obesity may be protective of further HIV disease
progression before initiation of ART. Jones et al.27 showed in 871 women who were
recruited from a multicenter prospective cohort in the United States (US) that a higher
baseline BMI was associated with a lower chance of reaching CD4 cell count <200
cells/µL for the first time. All women were ART naïve at baseline. A higher BMI was
also negatively associated with experiencing HIV-related events, with a 3.1 times greater
odds of HIV-related death in the lowest BMI category compared to those in the highest
category (95% CI, 1.2–8.1). An average change in CD4 cell count of 1.65 cells/µL per
unit change in BMI (95% CI, 0.05–3.25) was experienced and the authors indicated that,
positive changes in BMI tended to be associated with positive changes in CD4 cell
count, even controlling for previous CD4 cell count and BMI, albeit not significant. ShorPosner and colleagues26 studied 125 HIV+ ART naïve adults in Miami, Florida. They
followed over 18 months HIV+ obese (BMI >27kg/m2) adults. Patients had proportionally
lower clinically significant decrease in CD4 cell count (decrease of > 25% cells from
baseline) in obese than nonobese HIV+ adults (18.8% vs.60.5%, p=0.004). In addition,
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BMI during the 18 months was negatively associated with death, even after adjusting for
CD4 cell count of < 200 cells/µL at baseline. Shuter et al.28 through a retrospective
review of 189 medical records from New York, showed that being overweight was
independently associated with lack of an AIDS diagnosis before clinic enrollment
(OR=3.16; CI: 1.44, 6.96). In addition, lower baseline BMI and decreasing BMI during
follow-up were independently predictive of advancement to AIDS.
Currently, only one study has shown that immune markers (CD3, CD8, and total
lymphocyte counts) were associated with obesity in HIV+ ART treated adults with
undetectable viral loads. Adeyemi et al.29 conducted a study with 216 HIV+ patients with
diabetes in Chicago and demonstrated that obese patients (BMI 30-39.9kg/m2) had
CD3 counts 26% higher than patients with normal BMI (p=0.004) and CD8 counts 28%
higher (p=0.01), after controlling for age, sex, ethnicity, renal function, A1C, and duration
since HIV diagnosis. The result may also be evaluated in a dose-response manner as an
absolute increase in CD3 counts of 27 and CD8 of 16 for every increase of 1 kg/m2 in
BMI. There was also a 17% higher total lymphocyte count among the obese patients due
to the higher CD3 and CD8 cells after controlling for the same covariates (p=0.04).
Availability of longitudinal studies on BMI and HIV disease progression are
lacking. A study conducted by Crum-Cianflone et al.30 compared immune cell counts and
BMI in 1,097 HIV+ patients in seven centers throughout the US in the pre-ART and ART
eras. They showed that, at the time of HIV diagnosis, white blood cell count and immune
counts (CD4, CD8, CD4/CD8 ratio, CD3, CD19 and CD56) were not statistically
significant by BMI categories. In a longitudinal analysis those diagnosed in the pre-ART
era had less mean postdiagnosis decreases in white blood cell count, total lymphocyte
count, CD4 cell count, CD4%, and CD4/CD8 ratio as BMI category increased (all with
P<0.05). Obese participants who were diagnosed in the ART era had significantly higher
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increases in CD4 cell counts, CD4% and CD4/CD8 ratio (all with P<0.05) compared to
normal weight participants. A longitudinal retrospective study in HIV+ ART naïve
individuals in South Carolina who were starting ART was conducted by Johnson et al.31
They demonstrated that when comparing normal weight individuals, those who were
obese had larger increases in CD4 cell count (5.5 cells/uL, P<0.001). Mean CD4 cell
count in the obese group was higher at diagnosis (611.2 cells/µL) than the normal weight
group (550.5 cells/µL, P<0.019). Excess weight in the pre-ART era and even after
initiation of ART seems protective of disease progression and contributes to immune
recuperation, possibly by preserving energy and nutritional stores in order to deal with
HIV and AIDS-related illnesses.
Factors associated with weight gain were investigated in a study conducted by
Tate et al.32 The participants included in the study were from Alabama, ART naïve and
initiating ART. Over two years, the prevalence of overweight/obesity increased from 45%
to 56%. Those with a BMI of <18.5 kg/m2 had lower CD4 cell counts and higher viral
load at baseline (P<0.05) at baseline than the rest. Greater increases in BMI were
observed in patients with baseline CD4 count <50 cells/µL and boosted protease
inhibitor use, but did not account for all of the variation observed in weight change.
Obesity was highly prevalent, however, and the study did not examine how weight gain
affected disease progression.
The protective effect provided by obesity has been hypothesized to be related to
extra available energy in the form of fat available for use in time of crisis during the HIV
disease that would spare protein’s use33 and also help to preserve the immune system,
especially innate immunity that is not directly affected by the infection.28,34 HIV and its
secondary infections are known to generate a hypermetabolic state that is sustained
throughout the disease.35 The HIV patient is susceptible to infections, in which the body
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will require energy to battle continuous infections and immune activation. Those who
are obese may also have a genetic advantage in maintaining fat stores and utilizing
energy more efficiently to fuel the immune system. Mechanistic studies in this area are
needed.

HIV Disease Progression and Body Composition
Although BMI can provide a simple measure of obesity, its association with body
fat mass can vary by age, gender, race/ethnicity, and degree of fitness.36,37 Measuring
body composition to be able to differentiate between body compartments such as lean
body mass and fat mass can provide useful information and can be easily completed
with the use of bioelectrical impedance (BIA). A safe electric current can be sent through
the body to measure resistance and body fat will provide more resistance than lean
mass. With the use of equations body fat can be estimated.38 In addition, BIA can
provide an estimate of the amount of intracellular and extracellular water and
metabolically active tissues, known as body cell mass. In HIV, BIA has been shown to
be an effective approach to detect total and area specific fat mass.39 While alterations in
body composition, also known as HIV associated lipodystrophy syndrome (HALS)40,
have been well-documented in patients taking ART, alterations in body composition and
its association to HIV disease progression in ART naïve patients are not as well known.
Some studies have shown significant associations between body composition
measurements and HIV disease progression in ART naïve adults. In a study conducted
by Swanson et al.,41 in 56 HIV infected women in Chicago, bioelectrical impedance was
used to characterize body composition and examine its relationship with measures of
HIV disease. Correlations were found with positive associations with CD4 cell count and
fat-mass adjusted for height (r=0.32, P=0.01). Body cell mass adjusted for height was
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also correlated with viral load (r=0.32, P=0.05). Visnegarwala and colleagues42
analyzed gender differences in body composition and stage of HIV disease in 422 HIV+
ART naïve adults from patients recruited in 15 US cities. In men, body cell mass was
inversely associated with prior AIDS defining conditions (coefficient -1.7kg, P<0.005) and
HIV viral load (-0.92 kg, P=0.02). In women, those with prior AIDS defining conditions
had lower total body fat (-9.54 kg, P<0.005) and total body fat was also associated with
CD4 cell count (+1.64 kg, P=0.02). Hamill et al.43 compared body composition in South
African women with CD4 cell count >350 cells/µL (n=74) and low CD4 cell count (~200
cells/µL) (n=74). Those with CD4 cell count >350 cells/µL had significantly higher fatmass in kg (P<0.001) and lean body mass in kg (P=0.005). In addition, the group with
higher CD4 cell count had a higher fat mass squared/lean body mass squared ratio
(P=0.002). They concluded that biological variations between men and women may
have contributed to the different findings with the different body compartments and
disease progression parameters. The studies conducted on body composition in ART
naïve HIV infected adults had a cross-sectional design and included populations in the
US. Changes may occur through time in body composition that may ultimately have an
effect on HIV disease progression.

The Fat Mass and Obesity Associated (FTO) Gene in African Populations
The Fat Mass and Obesity Associated (FTO) gene was first identified in 200744
and has been associated with obesity and obesity related traits.45,46 The gene was
originally found in mice and was responsible for the fused toe (Ft) phenotype and also
provided the gene its name.47 The hypothalamus is the site where the FTO gene is
mainly expressed48 and may be involved in energy homeostasis,49 and fat cell lipolysis
which may regulate body fat.50 Specifically, the single nucleotide polymorphism (SNP) of
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the FTO gene rs9939609 A allele is most commonly associated with obesity. 44,46,51 Five
of the SNPs previously shown to be associated with BMI were included in this study
(rs9939609, rs1421085, rs8050136, rs17817449, and rs1121980). Currently, there are
no published studies on the FTO gene and its association to obesity and adipokines in
HIV+ patients or in a population in Botswana.
Henning and colleagues52 were the first to investigate the polymorphisms of the
FTO gene in an African population. The effect of the FTO gene on BMI was assessed in
2208 slender Gambian children and adults. In adults, BMI and weight for height was not
associated with any of the genotypes of the FTO gene. In addition, the 95% confidence
interval of the effect size for variant rs9939609 did not correspond to that of Europeans
reported in other research studies. The findings of this study may not be relevant to
other populations where obesity is prevalent or an abundance of food is available.
Adeyemo et al. 53 conducted a study that assessed the genetic variation in the
FTO gene in 517 West Africans and 968 African Americans and its association to
obesity as measured by BMI, waist circumference and fat mass percentage. The variant
of the FTO gene rs9939609 did not show any associations with obesity in the two
populations, however two other gene variants rs1121980 and rs7204609 were
associated with obesity in the West African participants (p<0.05).
A genetic association study completed by Lombard et al,54 assessed the
association of SNPs from FTO and other obesity related genes with BMI in 990 black
adolescent South Africans. Seven FTO SNPs were included; rs9939973, rs9940128,
rs1421085, rs1121980, rs17817449, rs8050136, and rs9939609. The FTO SNP
rs1781749, the minor allele or G, was associated with increased BMI (effect size 1.9,
p<0.05) after adjusting for sex, age, and pubertal age. Sex specific associations were
not found with SNPs of the FTO gene. In a model that included the SNPs for FTO
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rs1781749, LEP (leptin) rs10954174, LEP rs6966536, and MCAR (melanocortin 4
receptor) rs17782313 the effect size for the FTO SNP was 2.2, p=0.007. This finding
was adjusted for age, sex and sex-specific pubertal age. The effect corresponded to the
estimated percent change in BMI of each allele independent of the covariates. Based on
the available data from studies on FTO, the most common SNP rs9939609 was not
associated with BMI in the African populations but concluded that more studies are
needed to investigate these relationships in other African populations. The results from
this study are relevant to Botswana, who are closely related culturally and genetically to
South Africans, with whom they share borders, language and ancestors.55 However,
Botswana and other African nations are known to be a heterogeneous population with
many ethnic groups.56

Replication studies in diverse African populaces are need to

identify the SNPs that may cause the variations seen in obesity relevant to the pertaining
population. GWAS studies in African populations are lacking to identify novel SNPs that
are appropriate to the population is of importance.

The Fat Mass and Obesity Associated (FTO) Gene and HIV Disease Progression
Currently, in the literature there are no know studies evaluating markers of HIV
disease progression and SNPs of the FTO gene in an HIV mono-infected population.
Recently, Pineda-Tenor et al.57 carried out a cross-sectional study in 261 HIV/HCV coinfected participants in Spain. Those with the rs9939609 AA genotype had higher levels
of BMI (p=0.016) when compared to the AT/TT genotypes remained significant after
adjusting for age, gender, markers of HIV disease progression, markers of HCV disease
progression, liver fibrosis and ART. However, the genotypes for rs9939609 were not
associated with CD4 cell count or HIV viral load.
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Obesity and Inflammation
Inflammation is a condition in which the homeostasis between pro and antiinflammatory markers in the body are out of balance and may lead to a prolonged stage
of inflammation which in turn may affect the progression or outcomes of many conditions
and/or diseases.58 Obesity is known to be associated with a chronic state of low grade
inflammation. Inflammation in obesity is due to many mechanisms which include
disordered secretion of adipokines within adipose tissue resulting in insulin resistance
and metabolic disorders.59 Adipokines can affect many processes in the body such as
metabolism, growth, blood pressure, vascularization, coagulation and inflammation and
a variation in fat mass can change their production.60 It has also been shown that an
accumulation of macrophages occurs in obesity and this affects the increased release of
TNF-α, a pro-inflammatory cytokine.61 TNF-α release, mainly derived from
macrophages, initiates a pro-inflammatory cascade of events and can block insulin
activity leading to insulin resistance.62 Obesity may also reduce the production of other
inflammatory products as a result of the “endotoxin-lipoprotein hypothesis.”14 Higher
levels of lipoproteins are usually found in obesity which can bind bacterial endotoxin
such as LPS therefore affecting the release of pro-inflammatory cytokines. There is
conflicting information in the literature regarding obesity and inflammation, which
requires further research.

HIV Disease Progression and Inflammation
Diminishing CD4 cells is one of the main features of HIV progression and
eventually the diagnosis of AIDS. There are many mechanisms described as to why a
loss of immune related cells occur in HIV and inflammation is a key culprit. Loss of
immune function in HIV may be due to a persistent immune activation. Inflammation is
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involved in the depletion of T-cells, and chronic immune activation drives the general
and HIV-specific losses of immune function.63 Continuous inflammation induces proinflammatory cytokines which has been shown to produce thymic and T cell progenitor
dysfunction.64 It has also been shown that triggered or activated CD4 cells are a favored
target for viral infection and replication. Inflammation may also set up non-infected CD4
cells and other immune cells for death by programmed cell death or apoptosis.65 This
constant state of inflammation also predisposes the patients to the occurrence of nonHIV related complications such as cardiovascular disease.66 The role of obesity in
inflammation in HIV infection is not clear and the literature is contradictory, therefore, it is
important to examine the interrelationships that exist between inflammation, obesity, and
HIV disease progression to elucidate the potential mechanisms involved and how it
could later be translated into clinically relevant recommendations.

Pro-Inflammatory Markers
Leptin
Adipocytokines or adipokines are biologically active molecules that are secreted
by adipocytes.67 Adipose tissue, now deemed to be an endocrine organ,68 secretes
hormones such as leptin that may play an important role in body weight regulation.69
Leptin was the first adipokine to be isolated and it is involved in weight, inflammatory,
and immune regulation. Leptin is considered to be pro-inflammatory and can increase T
cell activation and cytokine release proliferation thereby promoting a Th1 response.69
Leptin levels are increased in obesity and have been shown to also act upon monocytes
and prompt the release of cytokines such as TNF-α or IL-6.70 Serum levels of leptin are
proportional to body fat mass.71 Females tend to have higher levels of leptin due to
higher body fat mass, and sex steroids may also increase leptin mRNA levels72,73 The
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adipose tissue of obese individuals contain a larger amount of macrophages that when
activated will secrete cytokines such as TNF-α and IL-6.74
Leptin as a proinflammatory cytokine may have effects on the innate and
adaptive immune responses. It has been suggested that leptin does not begin an
immune response but instead may impact the outcome by inducing proinflammatory
cytokines from different cell types, such as T cells.75 Inflammatory stimuli such as
lipolysaccharide (LPS), a bacterial endotoxin, increases leptin gene expression and its
concentration rapidly increases after the first stimulus. LPS binds to a Toll-like receptor
on adipose cells and expression of other toll-like receptors occurs, which then increases
the release of leptin and other inflammatory cytokines.76 Leptin also binds to CRP during
an immune response.77 Leptin deficient mice have shown impaired responses to
microbial pathogens such as tuberculosis.75,78 Therefore, leptin plays an important role
in the immune system and may respond differently depending on the stimuli.
Leptin is considered to be a pleiotropic molecule with not only metabolic roles but
also endocrine and immune regulation.79 Higher levels of leptin in some studies have
been shown during infection and inflammation, however the results in human studies
have been inconsistent in various diseases, including HIV.79 Leptin is involved in the
proliferation of T- cells including CD4 and CD8 cells.80 In addition, leptin has antiapoptotic properties for many cell types including lymphocytes.81 Higher levels of leptin
found in obese individuals82 may enhance the immunity through its role in proliferation
and anti-apoptotic effects on lymphocytes. The interplay between leptin and the immune
response is an area of importance in HIV as it may assist in determining possible
mechanisms for the protective effect of obesity often seen in HIV.
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HIV Disease Progression and Leptin in HIV ART Naïve
Most of the research on adipokines, like leptin, and HIV have been conducted in
ART treated patients and information on how leptin affects HIV disease progression in
HIV ART naïve is lacking. Below are a few of the studies conducted on ART naïve
participants, however, some of the findings still remain inconclusive.
Changes in body fat distribution such as, lipodystrophy, is common in ART
treated HIV+ persons. This side effect is closely associated with the use of Protease
Inhibitors (PIs).83 Leptin levels are decreased in HIV associated lipodystrophy and the
metabolic or immunological effect is only shown once the patients become
hypolipidemic.84 The action of leptin is affected by ART.83
Prabha and colleagues85 investigated the role of leptin levels in the coinfection of
HIV and tuberculosis (TB) in 20 HIV infected ART naïve participants, 20 HIV and TB
infected ART naïve participants and 20 healthy controls in India. Mean serum levels of
leptin in the group with HIV and TB was significantly lower than that of the control HIV
group and healthy control group (p<0.01). Women had higher levels of leptin than men
in all groups, which included the HIV control group (14±4 vs. 5±1, p<0.01). In all groups
leptin increased consistently with BMI and in all groups combined for every unit increase
in BMI a 1.8 fold increase was observed in leptin. CD4 cell counts and leptin were not
statistically correlated in any group, even after adjusting for BMI.
A study conducted in Nigeria by Onyemelukwe et al.86 examined serum leptin
levels in ART naïve HIV infected adults in relation to BMI, CD4 cell count, asymptomatic
and symptomatic HIV and AIDS. Groups for this study included 26 healthy HIV negative
controls, 20 normal weight participants, and 20 underweight participants. The median
serum leptin levels was lower in the normal weight group and underweight group
compared to the control group (Z=-2.26, p=0.024 and Z=-2.56, p=0.009 respectively).
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The median leptin level of symptomatic participants were lower compared to
asymptomatic participants (27.9 ng/mL IQR=4.9-36.4 vs. 43.7 ng/mL IQR=11.8-48.2, Z=2.07, p=0.038). Leptin levels were lower in the AIDS cases compared to the non-AIDS
cases (22 ng/mL, IQR=3.8-40 vs. 35 ng/mL, IQR=25.9-45.6) but was not statistically
significant. Female HIV+ participants had lower median leptin levels as compared to
male HIV+ participants (7.42 ng/mL IQR=3.2-44.3 vs. 35.6 ng/mL IQR=27.7-43.2,
p=0.05). In this study, HIV+ participants with normal weight had similar leptin levels as
the healthy HIV negative controls unless there was a difference in weight or symptomatic
HIV related conditions.
Azzoni et al,87 investigated the association between HIV viral load, cellular
activation, and adipose tissue related measures in 83 HIV infected ART naïve South
African women with a CD4+ cell count of 200-350 cells/µL. The results showed that
women with high viral load (> study median) had a higher BMI, waist circumference,
subcutaneous abdominal fat, and trunk fat mass. Leptin levels were associated with BMI
(r = 0.699, p<0.001), visceral abdominal fat (r = 0.542, p<0.0001) and total fat mass, (r =
0.764, p<0.001). In a multivariate regression model the relationship between leptin levels
and log10 viral load remained (effect estimate = -0.0186653, p = 0.03), even after
controlling for subcutaneous abdominal fat area. These results support a direct
association between leptin levels and HIV viral replication, independent of the amount of
adipose tissue. Since these women were ART naïve, they may have been newly
infected which would explain the higher viral load and the reason they may be healthier
suggested by the higher BMI and fat mass. The data may also suggest that the cytokine
dysregulation produced by obesity and related to inflammation might not be the source
of the protective effect of obesity previous to ART. Instead, the energy advantage may
delay wasting and maintain an active innate immune response. The studies discussed
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above have limitations that warrant further research, including small sample sizes,
inconsistent findings, and cross-sectional design. Although, some studies include
African populations, heterogeneity in Africans is present and including other nations
would provide relevant information to their respective regions.

The Fat Mass and Obesity Associated (FTO) Gene and Leptin
Obesity affects the release of adipokines such as adiponectin, leptin, cytokines
IL-6 and TNF-α from adipose tissue which may further lead to fat deposits.88
Contradictory evidence of an association with the FTO gene and adipokines and
inflammatory markers exists in the literature. Zimmermann and colleagues89 did not
show an association across FTO gene SNP rs9939609 genotypes and inflammatory
markers including TNF-α, IL-6 and leptin in healthy Danish middle-aged men. A study by
Zabena et al,90 investigated the association of rs9939609 SNP of the FTO gene with
obesity-related measures, to assess the FTO gene expression in subcutaneous and
visceral adipose fat in morbidly obese patients in Spain and the relationship with
adipocytokine gene expressions. The rs9939609 A allele was more frequent in the
morbidly obese patients as compared to the control group, who had no diabetes and
were not obese, (0.52 and 0.34), even after controlling for age and sex (OR 2.26; 95%
CI 1.19–4.30, p=0.013). FTO mRNA expression was associated with leptin (r=0.695,
p<0.001). Qi et al, 91 investigated the longitudinal relationships of the FTO gene variant
rs9939609 with obesity and plasma adiponectin and leptin levels in men and women
from prospective studies, The Nurses’ Health Study and the Health Professional FollowUp Study. The AA genotype of the SNP rs9939609 was associated with BMI in a 26year follow-up in women (p<0.05) and 16-year follow-up in men (p<0.05) after adjusting
for age and diabetes status and correlated with greater obesity risk during follow-up in
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both women and men in contrast to genotypes TA and TT. A trend was shown in the
allele A between higher leptin levels when adjusted for age (p=0.06). No significant
associations were seen in men with the FTO gene polymorphism and leptin levels.
Terra et al.92 demonstrated that the FTO gene is associated with an anti-inflammatory
profile in adipose tissue of morbidly obese (BMI >40 kg/m2) women. Adiponectin
expression was greater than any other cytokine measured in both subcutaneous and
visceral fat and decreased when comparing morbidly obese women to a control group
(BMI<25 kg/m2) (4.03±0.47 vs.10.50±1.74, p=0.019). In subcutaneous fat, FTO
expression was negatively associated with BMI (r=-0.457, p=0.004) and leptin (r=-0.475,
p=0.026). Inconsistent findings were present in the studies on FTO and leptin and
between genders. The FTO SNP rs9939609 was most commonly researched in the
above studies. Studies with African populations on possible relationships between FTO
and leptin are currently not available.

C-Reactive Protein
C-reactive protein or CRP is considered a sensitive systemic marker of
inflammation and an acute phase reactant.

CRP is produced and released mainly by

hepatocytes in response to proinflammatory cytokines, such as IL-1 and IL-6.93,94 Within
adipose tissue, adipocytes and monocyte-derived macrophages may release
proinflammatory cytokines boosting hepatic production of CRP.95 Higher levels of CRP
have also been associated with obesity and specifically abdominal obesity.96 High
sensitivity CRP (hsCRP) allows for a lower limit of detection and a value of > 10 mg/L
may indicate the presence of a subclinical infection or inflammation.97 CRP is currently
used in many diagnostic, clinical, and research settings as an acute and chronic
measure of inflammation.98 CRP is considered to be a stable molecule to measure and
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many inexpensive methodologies are available to determine CRP.99 Such measures are
attractive for resource limited settings, like many countries in Africa. A recent study
showed that CRP >1.2 mg/L had a specificity of 68.87% for predicting CD4 cell counts of
<200 cell/µL in HIV adults, which shows that CRP may be a sensitive biomarker beyond
cardiovascular disease.100

HIV Disease Progression and C-Reactive Protein in HIV ART Naïve
Lau et al.101 examined the association between CRP and immune suppression
and progression to AIDS in 513 HIV-infected men recruited into a multicenter cohort in 6
US cities who were ART naïve at baseline. CRP was negatively correlated with CD4 cell
count (r=-0.17, p<0.001) and positively correlated with HIV RNA levels (r=0.20,
p<0.001). Those with higher concentrations of CRP had shorter times to AIDS (overall
log-rank test, P<0.001). Median times to AIDS were 5.07 years (95% CI: 4.15-7.26
years) for those with CRP levels of 1.3 – 2.3 mg/L and 4.48 years (95% CI: 3.17, 5.61)
for those with CRP levels more than 2.3 mg/L. Accelerated progression to AIDS was
only seen in those with CRP levels of >1.2 mg/L. Using Cox proportional hazard models,
it was observed that increased hazards for the development of AIDS in those with higher
levels of CRP remained after adjusting for CD4 cell counts and log10 HIV viral load. CRP
increased over time for participants with and without AIDS, however, those who
progressed to AIDS had more of a rapid increase in CRP concentrations than those
without progression to AIDS. Using a random-effects model, those that progressed to
AIDS had 8.5% change per year in CRP concentrations compared to those that did not
progress to AIDS, which had a 4.5% change per year. This study demonstrated a steady
increase in CRP concentrations before participants’ progress to AIDS.
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Guimarães et al.102 compared hsCRP between 42 HIV+ ART naïve patients and
129 HIV treated patients in Brazil. They investigated the relationship between hsCRP
and cardiovascular risk factors with HIV disease progression. ART treated participants
had higher levels of hsCRP compared to ART naïve participants (1.14±1.17 mg/l vs.
0.3±1.16 mg/L; p<0.001). The ART treated participants had a higher percentage with
values >3 mg/dL, associated with a higher cardiovascular risk, compared to the ART
naive group (56% vs. 26%: OR=3.56; 95% CI: 1.55-8.29, p=0.001). There were no
statistically significant correlations between CRP and measures of HIV disease
progression, CD4 cell counts and HIV viral load.
Chaudhary and colleagues103 explored possible associations of CRP with CD4
cell counts and survival in 119 HIV infected ART naïve adults and 33 healthy individuals
in India. CRP was negatively correlated with CD4 cell counts (r=-0.148, p=0.045). Using
a Cox proportional hazard model, higher CRP category (>12mg/dL) was associated with
AIDS related mortality (RH=1.23, 95% CI: 1.12, 1.25, p=0.0047) after 1 year, albeit only
8 participants were included in this analysis. CRP was suggested by the authors as
another measure of disease progression in a resource limited setting.
A retrospective study by Baker et al. 104 compared markers of inflammation and
coagulation in 254 ART naïve or not receiving ART for 6 months to 128 patients who
initiated ART from various centers in the US during a 6 months follow-up. At baseline
there were no statistical differences in CRP between the ART naïve or the ART initiated
group. In addition, CRP was not associated with baseline CD4 count or HIV RNA level.
After initiating ART, CRP did not significantly change from baseline.
A published study of inflammatory markers in 546 HIV pre-ART participants by
Ledwaba and colleagues105 looked at whether elevated levels of inflammatory markers
would be associated with increased risk of death after initiation of ART in South African
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participants. Prior to commencing ART, median hsCRP was significantly higher in the
case group that included those who died during a median follow-up period of 24 months
compared to a control group containing 80 uninfected adults (11.25 IQR=2.90-51.90 vs.
3.6 IQR=1.50-11.30, P=<0.001). At baseline participants with advanced HIV infection
had lower levels of hsCRP compared to patients with early HIV (3.05 IQR=1.2-6.2 vs.
4.30 IQR=1.95-12.3, P=0.002). Advanced disease, which was accompanied by higher
levels of CRP, was related to death after starting ART. The studies investigating the
relationship between CRP and HIV disease progression have inconsistent results as
some did not show significant findings. Since CRP is affected by ART, studies that
include ART naïve are of importance to see the true associations with HIV disease
progression. Studies among African populations are limited in this area of research.

The Fat Mass and Obesity Associated (FTO) Gene, and CRP
Adipose tissue may also determine levels of circulating CRP through IL-6, as its
presence in adipose tissue affects production of CRP by the liver.106 FTO seems to
affect the amount of adipose tissue and therefore levels of CRP. In a recent study
completed by Fall et al.,107 over ninety-one thousand adults of European descent
contributed to an analysis used to confirm causal effects of adiposity, the FTO gene
variant rs9939609 and cardiometabolic traits, including CRP. Both BMI and FTO SNP
were associated with CRP (P<0.05).

Fisher et al.108 studied the association of the FTO

rs9939609 SNP and CRP levels in 2,415 adult men and women in Germany and found
that using a regression model that FTO SNP was associated with higher CRP levels in
men (~14% higher) and women (~12%, P=0.02) for the A allele. This model was
adjusted for age, BMI, waist-to-hip ratio, common diseases (myocardial infarction,
stroke, and diabetes), education, engagement in sports, and smoking. Zimmerman and
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colleagues89 also looked at the association of CRP and FTO rs9939609 SNP. No
statistically significant results analyzing CRP were observed. Studies on FTO SNPs and
its relationships with adipokines and markers of inflammation such as CRP that were
discussed above have been mainly conducted using European populations. Studies with
African populations are lacking. Overall, studies in this subject are limited and more
research is warranted to examine possible pleiotropic effects of FTO.

Lipopolysaccharide (LPS)
Microbial translocation or the movement of bacterial products from the intestinal
lumen into systemic circulation is measured by bacterial products such as
lipopolysaccharide (LPS).109 Microbial translocation may have a role in persistent
immune activation and can provoke pro-inflammatory reactions.110 During HIV, microbial
translocations may occur due to epithelial damage to the intestine, loss of T-helper-17
cells and a reduced removal of microbial products by phagocytes are observed.110
Increased secretion of pro-inflammatory cytokines can also contribute to increased T cell
activation and specifically can increase CD8 T cell activation and depletion of CD4 T
cells.111 Conversely, a theory for the obesity paradox includes the endotoxin-lipoprotein
hypothesis.14 This theory states that during obesity there are a large number of
lipoproteins circulating and LPS binds to lipoproteins through the formation of micelles in
the gut. Lower circulating LPS would reduce the inflammatory response. This
hypothesis merits investigation in a HIV infected population that is ART naïve that may
be protective of further disease progression by obesity.
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HIV Disease Progression and Lipopolyssacharide (LPS) in HIV Infection without
ART
Redd et al.112 observed in 107 HIV+ ART naïve adults the longitudinal
relationship between microbial translocation, which included LPS, and inflammatory
cytokine response in a cohort with varying rates of HIV disease progression in Uganda.
Markers of microbial translocation were also compared to 24 HIV uninfected adults in the
US. At baseline there were no statistical differences in the levels of LPS between the
HIV infected group in Uganda and the US uninfected group. When comparing groups
stratified by HIV disease progression there were still no differences at baseline or over
time in LPS. The authors proposed that the different levels of microbial translocation
markers such as LPS, may be a symptom but not a direct cause of HIV disease
progression.
Marchetti and authors113 investigated microbial translocation, as measured by
LPS, in 379 HIV ART naïve participants in Italy. Participants were recent seroconverters
with high CD4 cell counts, and who were followed for an average of 3 years. Participants
were separated into two groups based on the median LPS level (110 pg/mL) and there
were no differences at baseline in CD4 cell counts and HIV viral load between the
groups. In a subset that included 17 participants, LPS did not change significantly over
time (13-25 months). The group above the LPS median had a shorter median time to
event (AIDS defining condition, death, CD4 cell count <200 cells/µL or start of ART,
whichever happened first) of 1.5 years (95% CI: 1.0, 2.0) as compared to those below
the median who had an average time to event of 4 years (95% CI: 3.1, 5.6), P=0.0002.
This association remained significant after controlling for proinflammatory cytokines,
age, CD4, viral load, HCV, HBV and duration of HIV (RH=1.85, 95% CI: 1.32, 2.58,
p<0.001). In this study LPS was a strong predictor of HIV disease progression
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independent of CD4 cell count and HIV viral load. In summary, the evidence points
towards an association between LPS levels and disease progression, but is weak in
elucidating whether the relationship is of cause-and-effect or mediated by other factors.
Additionally, few studies are available on LPS in HIV ART naïve participants and the
sample size over time quite small.

Currently, there are no published literature

examining the relationship between FTO SNPs and LPS in humans.

Summary
There is evidence in the literature of an obesity paradox, where higher BMI seems
to be protective of mortality and disease-related outcomes in several conditions,
including HIV.3 Obesity may boost the innate immune system even in ART, which is
probably why it is protective before ART. Fat available for use in time of crisis in HIV
disease may spare protein’s use.33 However, factors generating this paradox are not well
understood and the mechanism for the associated benefits of higher BMI are lacking.
The prevalence of overweight and obesity are increasing globally, including sub-Saharan
countries like Botswana.17 Botswana also has the second highest prevalence rate of HIV
in the world.114 Before the initiation of ART, BMI and body composition measures such
as fat mass and body cell mass seem to be protective of HIV disease progression,
however, longitudinal studies in African populations are lacking.
Studies that examine the relationships between being overweight/obese and HIV
disease progression and its interrelationship between genetic propensity for obesity and
inflammatory markers, such as the study reported in this dissertation, are needed. The
studies conducted on body composition in HIV infected, ART naïve patient populations
were cross-sectional and included populations in the US. Changes may occur through
time in body composition that may ultimately have an effect on HIV disease progression.
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Replication studies in diverse African populations are needed to identify the SNPs that
may cause the variations seen in obesity that is relevant pertaining to the population.
Most of the studies discussed above have limitations that warrant further research,
including small sample sizes, inconsistent findings, and cross-sectional design. In
addition, studies that include ART naïve patients are of importance in determining the
true associations with HIV disease progression. Although, some studies include African
populations, heterogeneity among Africans is present and including other ethnicities is
likely to provide relevant information. The role of obesity in inflammation in HIV infection
is not clear and the literature is contradictory, therefore, it is important to examine the
interrelationships that exist between inflammation, overweight/obesity, and HIV disease
progression to elucidate the potential mechanisms involved and how it could later be
translated into clinically relevant recommendations.
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Table 1: Studies Conducted in Obesity and HIV Disease Progression
Author/Study
Design

Study Purpose

Population

Main
Outcome(s)

Study Findings

Johnson et al,
2014

To investigate the longitudinal
association of BMI at HIV
diagnosis with disease
progression as evaluated by
CD4 cell counts obtained
during routine medical care.

396 ART naïve
and had one
follow-up visit

CD4 cell
counts

Longitudinally, the mean CD4 count was
611.2 cells/mm3 for obese individuals, 598.1
cells/mm3 for overweight individuals and
550.5 cells/mm3 for normal weight individuals.
When compared to the normal weight
category, the obese category had significantly
larger increases in CD4 count (5.5 cells/mm3,
P < 0.001) versus the overweight category (2.1 cells/mm3, P < 0.001).

To evaluate factors associated
with change among patients
receiving ART.

681 ART
treatment naïve
patients who
maintained ART
therapy for 2
years.

BMI

At 24 months, 20% of patients moved from
normal to overweight/obese or overweight to
obese BMI categories. Underweight
participants had lower CD4 counts and Higher
viral load at ART initiation. Greater increases
in BMI were observed in patients with
baseline CD4 count <50 cells/µL and boosted
protease inhibitor use, but did not account for
all of the variation observed in weight change.

To investigate relationship
between body weight and a
variety of immune cell counts
at diagnosis and over the
course HIV infection among a
cohort of documented HIV
seroconverters who had serial
immune cell measurements
and longitudinal weight data.

1097 HIV
seroconverters
who were
participants in
the US Military
HIV Natural
History Study
(NHS) (96%
male).

Immune cell
counts

Immune cell counts at HIV diagnosis did not
significantly differ by BMI category. In the
longitudinal models for those diagnosed
before the advent of the highly active
antiretroviral therapy (HAART) era, mean
postdiagnosis decreases in the white cell
count, total lymphocyte count, CD4 count,
CD4 percentage, and CD4/CD8 ratio were
less as the BMI category increased (all with P
values of <0.05). Among HIV seroconverters
diagnosed in the HAART era, obese
compared to normal-weight patients had

Retrospective
Longitudinal
Cohort Study

Tate et al., 2012

Prospective
Longitudinal
Cohort Study

Crum-Cianflone
et al., 2011

Retrospective
Longitudinal
Cohort Study
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significantly smaller increases in CD4 counts,
CD4 percentages, and the CD4/CD8 ratio (all
with P values of <0.05). Similar findings were
also noted among underweight versus
normal-weight patients.
Adeyemi et al.,
2009

To explore the effects of
obesity on lymphocyte
subsets in HIV-positive
patients with diabetes.

Cross-sectional
Study

White blood
cell count and
the following

216 HIV+
patients with
Diabetes on
HAART and
undetectable
viral load.

lymphocyte
subgroups,
defined by
surface
antigens: CD3
(T cells), CD4
(helper T cells),
CD8 (cytotoxic
or suppressor

As BMI increased, there were significant
increases in CD3, CD8, and total lymphocyte
counts. For total white blood cell count and
the other lymphocyte subgroups (CD4, CD19,
and CD56), the relationship with BMI was not
significant. Obese patients had CD3 counts
26% higher than patients with normal weight
and CD8 counts 28% higher, controlling for
age, sex, ethnicity, renal function, HbA1c, and
duration since HIV diagnosis.

T cells), CD19
(B cells), and
CD56 (natural
killer cells).
Jones et al.,
2003

Longitudinal
Prospective
Cohort Study

To examine the association of
BMI with HIV disease
outcomes.

871 HIV+
women 16-55
years of age
with history of
IDU or high-risk
sexual contact
without prior
AIDS-defining
clinical illness
and ART naïve
at baseline
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Time to first
CD4 cell count
<200
cells/mm3, first
CD4 cell count
<100
cells/mm3,
opportunistic
infection and
HIV-related
death

Mean CD4 cell count at baseline
progressively higher and mean log viral load
progressively lower as BMI increased. A
higher baseline BMI was associated with a
lower rate of occurrence of the first CD4 <200
cells/mm3. In analysis using time-varying
BMI, underweight and normal women had
increased risk of clinical AIDS and
underweight women had increased risk of
HIV-related death, compared with obese
women.

Shuter et al.,
2001

To determine the prevalence
and predictive value of
overweight in an urban HIV
clinic.

189 HIV+
patients from
Jacobi Medical
Center HIV
Clinic

Progression to
AIDS and CD4
cell count

Female gender and lack of AIDS diagnosis
were independently associated with
overweight. Among patients without AIDS,
there was a trend towards slower disease
progression and lower viral load in overweight
patients, despite similar baseline CD4 cell
count and similar time to initiation of HAART.
In multivariate proportional hazards analyses,
lower baseline BMI and falling BMI during
follow-up were independently predictive of
progression to AIDS.

To compare immune
measures and disease
progression in obese and
nonobese HIV-1–

125 HIV-1–
infected and
148

HIV-1 related
mortality, CD4
cell count <200
cells/µL and
25% decline in
CD4 cell count

Over an 18-month period, 60.5% of the
nonobese HIV-1–seropositive patients
exhibited a 25% decline in CD4 cell count,
compared with 18% of the obese patients.
During the follow-up period, 38% of the lean
and 13% of the nonobese study subjects died
of HIV-1–related causes. Measurements of
BMI were inversely associated with
progression to death, independent of CD4
count <200 cells/mm3.

Retrospective
Case-Control
Study

Shor-Posner et
al, 2000

Longitudinal
Prospective
Cohort Study

seropositive men and women
in the pre-HAART era.

seronegative
male and
female drug.
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Table 2: Genetic Association Studies on the FTO Gene in African Populations
Author/Study
Design

Study Purpose

Population

FTO SNPs
Analyzed

FTO Results with BMI

Other Results

Lombard et al.,
2012

To assess the
association of
candidate loci with
BMI in black South
Africans. The
authors focused on
SNPs in the FTO,
LEP, LEPR, MC4R,
NPY2R and POMC
genes.

990 randomly
selected adolescents
from

rs9939973
rs9940128
rs1421085
rs1121980
rs17817449
rs8050136
rs9939609

FTO rs17817449, the minor
allele (G in both cases) is
associated with increased
BMI. The seven FTO SNPs in
this study explain 0.6% of
variation in log(BMI) after
adjusting for age-, genderand sex-specific pubertal
stage and 1.4% unadjusted.
FTO rs17817449 (p=0.022)
associated with BMI after
adjustment for above factors.

Sex, sex-specific
pubertal stage and
exact age together
explain 14.3% of
variation in log(BMI).
Each risk allele was
associated with an
estimated average
increase of 2.5% BMI.

262 tag single
nucleotide
polymorphisms

The combined effect size for
BMI for the top SNPs from
meta-analysis was 0.77 kg/m2
(P = 0.009, rs9932411) and
0.70 kg/m2 (P =0.006,
rs7191513). Two previously
reported associations with
intron 1 SNPs (rs1121980
and rs7204609, r2 = 0.001)
were replicated among the
West Africans.

Both African-ancestry
samples showed
weaker linkage
disequilibrium (LD)
patterns compared to
other continental (e.g.,
European) populations.
Several intron 8 SNPs,
in addition to intron 1
SNPs, showed
significant associations
in both study samples.

FTO SNPs not associated
with birth weight (BWT), early

Not Applicable

Genetic
Association Study
(Cross-sectional)

the larger Birth to
Twenty cohort (a
longitudinal birth
cohort study of health
and development in
Africans) born in the
metropolitan area of
Soweto,
Johannesburg,

Adeyemo et al.,
2010

Genetic
Association Study
(Cross-sectional)

Hennig et al., 2009

To evaluate genetic
variation in the FTO
gene and
investigate
associations with
obesity in West
Africans and African
Americans.

Two independent
subsets:

To assess the effect
of 16 FTO SNPs on

2208 Lean Gambians
(Children and Adults)

1) 968 unrelated
African Americans in
Washington, D.C.,
and

(SNPs) across
the entire gene.

2) 517 unrelated West
Africans enrolled as
control subjects as
part of the AfricaAmerica Diabetes
Mellitus (AADM)
Study.
rs6499642
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Genetic
Association Study
(Cross-sectional)

body mass in a
large population of
predominantly lean
Gambians
participating in a
long-term
surveillance
program providing
contemporary and
early-life
anthropometric
measurements.

rs6499643
rs7206790
rs9940646
rs12447107
rs17817288
rs16945088
rs17817449
rs8063946
rs8063946
rs3751812
rs3751813
rs9939609
rs9931494
rs7190492
rs72046609
rs9935403
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weight gain in 1–2 year olds,
BMI in adults (≥ 18 y), or
weight-for-height (WFH) zscore across all ages. No
association was seen
between genotype and WFH
z-score or other measures of
body mass.

Table 3: Studies Conducted on Leptin and HIV Disease Progression in ART Naïve
Author/Study
Design

Study Purpose

Population

Main
Outcome(s)

Study Findings

Azzoni et al.,
2010

To assess the
relationship of fat or
markers related to
glucose and lipid
metabolism with
viral load in a crosssectional sample of
83 ART-naïve HIV-1
infected South
African women.

83 ART naïve South African
women

Cell activation,
innate
immunity
effector levels
and adipose
tissue-related
measures
including
leptin

Women with viral load greater than the
population median had lower serum leptin.
Leptin levels were inversely associated with
viral replication, independent of the amount of
adipose tissue.

To determine serum
leptin levels in ART
naïve HIV-1 infected
adults in relation to
BMI, CD4 cell count
and presence or
absence of
symptomatic HIV
disease or features
of AIDS.

40 consecutive matched,
HIV infected adults (20
normal weight and 20
underweight) and 26 sex
matched HIV negative,
healthy normal weight
controls in Nigeria

Leptin

Female patients tended to have lower leptin
than males. Median leptin was lower in
underweight when compared to normal weight
patients and also lower in symptomatic
patients when compared to asymptomatic
patients but not significantly different between
AIDS and non-AIDS cases. Among healthy
controls, leptin levels positively correlated with
CD4 T counts but in HIV/AIDS patients the
correlation was not significant.

To determine the
leptin levels in HIV
and HIV with active
pulmonary TB and
to see whether leptin
levels are altered
with co-infection.

20 asymptomatic, ART
naïve HIV infected patients,

Leptin

Serum leptin levels and BMI were significantly
lower in the patients with HIV-TB than control
and HIV subjects. Multivariate regression
analysis showed that serum leptin was
significantly dependent on BMI and sex but
not on age and the disease groups. Leptin did
not correlated with either with CD4 cell count
so with any of the serum cytokines in HIV and
HIV-TB patients.

Cross-sectional
Study

Onyemelukwe
et al., 2009

Cross-sectional
Study

Prabha et al.,
2005

Cross-sectional
Study

20 asymptomatic ART
naïve HIV infected patients
with TB,
20 healthy control subjects
(All participants from India)
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Table 4: Studies Conducted on C-Reactive Protein and HIV Disease Progression in ART Naïve
Author/Study
Design

Study Purpose

Population

Main
Outcome(s)

Study Findings

Ledwaba L et al.,
2012

To assess in an ART naïve
group of patients with
advanced HIV infection
whether pre-ART levels of
inflammatory and coagulation
biomarkers are associated
with mortality. In addition, to
assess whether initiation of
ART lowered levels of these
biomarkers, and compared
pre-ART biomarker levels
among patients with early
versus late HIV infection and
HIV uninfected patients.

187 HIV infected
ART-naïve
patients with
CD4 cell count
<200 cells/µL
who died

Mortality

Median baseline biomarkers levels for cases
and controls, respectively, were 11.25 vs. 3.6
mg/L for hsCRP, HIV viral load was
correlated with hsCRP. Adjusted odds ratios
for the highest versus lowest quartile of
baseline biomarker levels were 3.5 (95% CI:
1.9–6.7) for hsCRP, 2.6 (95%CI 1.4–4.9) for
D-dimer, and 3.8 (95% CI: 1.8–7.8) for IL-6.
These associations were stronger for deaths
that occurred more proximal to the biomarker
measurements. Levels of D-dimer and IL-6,
but not hsCRP, were significantly lower at
month 6 after commencing ART compared to
baseline.

To determine whether ART
initiation in ART naïve or
those off of ART (≥6 months)
reduced markers of
inflammation.

254 HIV+ ART
naïve or off of
ART (≥6 months)
at baseline (126
differed initiation
of ART (DC) and
128 had
immediate
initiation of ART
(VS)

D-dimer, ILand CRP

At month 6, 62% of VS group had HIV RNA
<400copies/mL and median CD4 count was
190 cells/mm3 higher than for the DC group
(590 vs. 400 cells/mm3). Compared with DC,
the VS group had 32% lower D-dimer levels
at month; differences were not significant for
hsCRP or IL-6 levels.

To elucidate association of
CRP with CD4 counts and
survival in HIV-1 infected

119 HIV-infected
ART naïve
patients

AIDS related
mortality and
CD4 cell count

CRP was correlated with CD4 count and
mortality at 1 year. CRP was negatively
correlated with CD4 counts with levels of
CRP being highest in the group with CD4 cell

Nested CaseControl Substudy

Baker et al.,
2011

Retrospective
Longitudinal
Study

Chaudhary et al.,
2008

359 HIV infected
ART-naïve
patients with
CD4 cell count
<200 cells/µL
matched controls
80 uninfected
(South African
Cohort)

40

individuals

33 healthy
individuals

To compare hsCRP in HIVinfected patients treated or
not with ART and to correlate
hsCRP levels with traditional
cardiovascular risk factors
and to factors related to the
HIV infection.

129 HIV+ ARTtreated

To elucidate the relationship

513 HIV
serpopostive
men randomly
chosen MACS
participatns ART
naïve at baseline

Prospective
Longitudinal
Study
Guimaraes et al.,
2008

Cross-sectional
Study

Lau et al., 2006

Retrospective
Longitudinal
Cohort Study

between HIV disease and the
concentration of CRP.

counts below 200 cells/µL. Higher CRP
category (>12 mg/dL) was associated with
AIDS-related deaths in a Cox proportional
Hazard Model after adjusting for CD4 cell
count.
CRP

42 HIV+ ART
naive

hsCRP levels were higher in ARV-treated
compared to ARV-naive patients. Seventytwo (56%) ARV-treated patients and
11 (26%) ARV-naıve patients had hsCRP
concentrations >3 mg/dl (high risk for
cardiovascular complications). No correlation
was found between hsCRP levels and CD4
cell counts and HIV-viral load. Independent
factors associated with hsCRP levels were
therapy with current non-nucleoside reverse
transcriptase inhibitors (NNRTI), waist-to-hip
ratio, fasting glucose and glucose levels 2 h
after load in multivariate analysis model 1
and current NNRTI therapy, protease
inhibitor therapy and cardiometabolic
syndrome in multivariate analysis model.
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Time to AIDS

The cross-sectional associations between
log10
CRP were correlated inversely with CD4
lymphocyte counts and directly with log10
HIV RNA levels. Levels of CRP of more than
2.3 mg/L were associated with a decreased
time to the development of AIDS (relative
time to AIDS, compared with individuals with
CRP levels of 1.2 mg/L or less, which
remained significant after adjustment for
CD4 lymphocyte counts and HIV RNA and
hemoglobin concentrations. Levels of CRP

significantly increased over time with mean
slopes of 8.5% and 4.5% per year for
individuals with and without progression to
AIDS, respectively. Individuals had a
geometric mean CRP level of 2.5 mg/L in the
6-month interval before progression to AIDS,
which was an increase from a nadir of 1.0
mg/L at 6.5 years before progression to
AIDS.

Table 5: Studies Conducted on LPS and HIV Disease Progression in ART Naïve
Author/Study
Design

Study Purpose

Population

Main Outcome(s)

Study Findings

Marchetti et al.,
2011

To evaluate the role of
immune activation and
microbial translocation in HIV
infected ART naïve patients
with high CD4 cell count in the
first years of chronic infection
in predicting HIV disease
progression. Also, to crosssectionally evaluate the
correlations between markers
of immune activation,
microbial translocation, and
CD4 cell count and HIV
viraemia and their
modifications during untreated
infection.

379 HIV+
patients ART
naive with
CD4>200 cells/
µL

AIDS defining
condition, death,
CD4 cell count of
<200 cells/µL or
start of ART

A median of 3.1 years after the estimated
serconversion date median LPS marker 110
pg/mL (IQR 75-215). LPS was the only
biomarker associated with primary composite
outcome independently of age, HIV-RNA and
CD4 RR=1.04 per loge higher, 95% CI: 1.181.66, p<0.001).

To examine the longitudinal

107 HIV+ ART

LPS, soluble

Multiple markers for microbial translocation

Retrospective
Longitudinal
Study

Redd et al., 2009
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Retrospective
Longitudinal
Study

relationship between microbial
translocation and circulatory
inflammatory cytokine
responses in a cohort of
people with varying rates of
HIV-1 disease progression in
Rakai, Uganda.

naïve Ugandan
patients and 24
HIV uninfected
US adults
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CD14, LPS,
EndoCAb, LPS
binding protein
and inflammatory
cytokines

(lipopolysaccharide, endotoxin antibody, and
sCD14) did not change significantly during
HIV-1 disease progression. Moreover,
circulating immunoreactive cytokine levels
either decreased or remained virtually
unchanged throughout disease progression.

References
1.

Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the shortterm and long-term outcomes after percutaneous coronary intervention: the
obesity paradox? J Am Coll Cardiol 2002;39:578-584.

2.

Degoulet P, Legrain M, Réach I, et al. Mortality risk factors in patients treated by
chronic hemodialysis. Report of the Diaphane collaborative study. Nephron
1982;31:103-110.

3.

McAuley PA, Blair SN. Obesity paradoxes. J Sports Sci 2011;29:773-782.

4.

Valentijn TM, Galal W, Tjeertes EK, Hoeks SE, Verhagen HJ, Stolker RJ. The
obesity paradox in the surgical population. Surgeon 2013;11:169-176.

5.

Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass
index in diagnosing obesity in the adult general population. Int J Obes (Lond)
2008;32:959-966.

6.

Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all-cause
mortality in a large US cohort. Arch Intern Med 2010;170:1293-1301.

7.

Festa A, D’Agostino R Jr, Williams K, et al. The relation of body fat mass and
distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord
2001;25:1407-1415.

8.

Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The
implication of obesity and central fat on markers of chronic inflammation: the
ATTICA study. Atherosclerosis 2005;183:308-315.

9.

Haslem DW, James WP. Obesity. Lancet 2005;366:1197-1209.

10.

Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of
endotoxin-induced monokine release by human lowand high-density lipoproteins
and by apolipoprotein A-I. Infect Immun 1993;61:5140-5146.

11.

Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density
lipoproteins and chylomicrons can protect against endotoxininduced death in
mice. J Clin Invest 1990;86:696-702.

12.

Levine DM, Parker TS, Donelly TM, Walsh A, Rubin AL. In vivo protection
against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA
1993;90:12040-12044.

13.

Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent
septic death in rats. J Exp Med 1995;182:267-72.

14.

Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis.
Lancet 2000;356:930-933.

44

15.

Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD.
Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a
cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-1035.

16.

O'Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central
control of energy balance. Int J Obes (Lond) 2008;32:S55-S61.

17.

Walker AR, Adam F, Walker BF. World pandemic of obesity: the situation in
Southern African populations. Public Health 2001;115:368-372.

18.

Onen CL. Epidemiology of ischaemic heart disease in sub-Saharan Africa.
Cardiovasc J Afr 2013;24:34-42.

19.

Letamo G. The Prevalence of, and Factors Associated with, Overweight and
besity in Botswana. J Biosoc Sc 2011;43:75-84.

20.

The World Health Organization, Overweight and Obesity Fact Sheet. Available
at: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed August 5,
2014.

21.

Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing Rates of Obesity
among HIV-Infected Persons during the HIV Epidemic. PLoS ONE 2010;5:
e10106.

22.

Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics. The
intersection between obesity and HIV infection in Philadelphia. J Acquir Immune
Defic Syndr 2005;9:557–561.

23.

Hodgson LM, Ghattas H, Pritchitt H, et al. Wasting and obesity in HIV
outpatients. AIDS 2001;15:2341-2342.

24.

Uthman OA. Prevalence and pattern of HIV-related malnutrition among women in
sub-Saharan Africa: a meta-analysis of demographic health surveys. BMC Public
Health 2008;8:226–233.

25.

Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of
obesity in developing countries. Nutr Rev 2012;70:3-21.

26.

Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a
longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J
Acquir Immune Defic Syndr 2000;23:81-88.

27.

Jones CY, Hogan JW, Snyder B, et al. Overweight and human immunodeficiency
virus (HIV) progression in women: associations HIV disease progression and
changes in body mass index in women in the HIV epidemiology research study
cohort. Clin Infect Dis 2003;37:S69-80.

45

28.

Shuter J, Chang CJ, Klein RS. Prevalence and predictive value of overweight in
an urban HIV care clinic. J Acquir Immune Defic Syndr 2001;26:291-297.

29.

Adeyemi OM, Vibhakar S, Evans AT. Obesity and lymphocyte subsets in
virologically suppressed HIV-infected patients. Metabolism 2009;58:1285-1287.

30.

Crum-Cianflone NF, Roediger M, Eberly LE, et al. Impact of weight on immune
cell counts among HIV-infected persons. Clin Vaccine Immunol 2011;18(6):940946. doi: 10.1128/CVI.00020-11.

31.

Johnson KD, Cai B, Duffus W, et al. Longitudinal Association Between BMI at
Diagnosis and HIV Disease Progression. AIDS Behav 2014;18:2249-2257. doi:
10.1007/s10461-014-0805-0.

32.

Tate T, Willig AL, Willig JH, et al. HIV infection and obesity: where did all the
wasting go? Antivir Ther 2012;17:1281-1289. doi: 10.3851/IMP2348.

33.

Carlson MG, Snead WL, Campbell PJ. Fuel and energy metabolism in fasting
humans. Am J Clin Nutr 1994;60:29-36.

34.

Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr
1997;66:460S-463S.

35.

Melchior JC. Metabolic aspects of HIV associated wasting. Biomed Pharm
1997;51:455-460.

36.

Gallagher D, Heymsfield SB, Heo M, Jebb SA, MurgatroydPR, Sakamoto Y.
Healthy percentage body fat ranges: an approach for developing guidelines
based on body massindex. Am J Clin Nutr 2000;72:694-701.

37.

Seagle HM, Strain GW, Makris A, Reeves RS. Position of theAmerican Dietetic
Association: weight management. J Am Diet Assoc 2009;109:330-346.

38.

Hu F. Measurements of Adiposity and Body Composition. In: Hu F, ed. Obesity
Epidemiology. New York City: Oxford University Press, 2008;53-83.

39.

Pérez-Matute P, Pérez-Martínez L, Blanco JR, et al. Multiple frequency
bioimpedance is an adequate tool to assess total and regional fat mass in HIVpositive patients but not to diagnose HIV-associated lipoatrophy: a pilot study. J
Int AIDS Soc 2013;16:18609. doi: 10.7448/IAS.16.1.18609.

40.

Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy,
hyperlipidaemia and insulin resistance in patients receiving HIV protease
inhibitors. AIDS 1998;12:F51-F58.

41.

Swanson B, Hershow R, Sha BE, Benson CA, Cohen M, Gunfeld C. Body
Composition in HIV Infected Women. Nutrition 2000;16:1064-1068.

46

42.

Visnegarwala F, Raghavan SS, Mullin CM et al. Sex differences in the
associations of HIV disease characteristics and body composition in
antiretroviral-naive persons. Amer J Clin Nutr 2005;82:850-856.

43.

Hamill MM, Ward KA, Pettifor JA, Norris SA, Prentice A. Bone mass, body
composition and vitamin D status of ARV-naïve, urban, black South African
women with HIV infection, stratified by CD4 count Osteoporos Int 2013;24:28552861.

44.

Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene
is associated with body mass index and predisposes to childhood and adult
obesity. Science 2007;316:889-894.

45.

Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows
genetic variants in the FTO gene are associated with obesity-related traits. PLoS
Genet 2007;3:e115.

46.

Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood
obesity and severe adult obesity. Nat Genet 2007;39:724-726.

47.

van der Hoeven F. Programmed cell death is affected in the novel mouse mutant
Fused toes (Ft). Development 1994;120:2601-2607.

48.

Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes
a 2-oxoglutarate-dependent nucleic acid demethylase. Science 2007
30;318:1469-1472.

49.

Fredriksson R, Hägglund M, Olszewski PK, et al. The obesity gene, FTO, is of
ancient origin, up-regulated during food deprivation and expressed in neurons of
feeding-related nuclei of the brain. Endocrinology 2008;149:2062-2071.

50.

Wåhlén K, Sjölin E, Hoffstedt J. The common rs9939609 gene variant of the fat
mass- and obesity-associated gene FTO is related to fat cell lipolysis. J Lipid Res
2008;49:607-611.

51.

Kring SI, Holst C, Zimmermann E, et al. FTO gene associated fatness in relation
to body fat distribution and metabolic traits throughout a broad range of fatness.
PLoS ONE 2008;3:e2958.

52.

Hennig BJ, Fulford AJ, Sirugo G, Rayco-Solon P, Hattersley AT, Frayling TM,
Prentice AM. FTO gene variation and measures of body mass in an African
population. BMC Med Genet 2009;10:21.

53.

Adeyemo A, Chen G, Zhou J, Shriner D, Doumatey A, Huang H, Rotini C. FTO
Genetic Variation and Association with Obesity in West Africans and African
Americans. Diabetes 2010;59:1548-1554.

47

54.

Lombard Z, Crowther NJ, van der Merwe L, Pitamber P, Norris SA, Ramsay M.
Appetite regulation genes are associated with body mass index in black South
African adolescents: a genetic association study. BMJ Open 2012;2: e000873
doi:10.1136/bmjopen-2012-000873.

55.

South African History Online: towards a people’s history. Accessed August
http://www.sahistory.org.za/people-south-africa/tswana

56.

Hjort J. Pre-colonial culture, post-colonial economic success? The Tswana and
the African economic miracle. Econ Hist Rev 2010;63:688-709.

57.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, et al. FTO rs9939609
polymorphism is associated with metabolic disturbances and response to HCV
therapy in HIV/HCV-coinfected patients. BMC Med 2014;12:198. doi:
10.1186/s12916-014-0198-y.

58.

Tahergorabi Z, Khazaei M. The relationship between inflammatory markers,
angiogenesis, and obesity. ARYA Atheroscler 2013;9:247-253.

59.

Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade
inflammation and insulin resistance in human obesity. Curr Pharm Des
2008;14:1225-1230.

60.

Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and
skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch
Physiol Biochem 2011;117:47–56.

61.

Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role
in the development of obesity-related insulin resistance. J Clin Invest 2003;
112:1821-1830.

62.

HotamisligilGS,ShargillNS, SpiegelmanBM.Adipose expression of tumornecrosis
factor- alpha:direct role in obesity-linked insulin resistance. Science 1993;259:8791.

63.

Theofilopoulos AN,Baccala R, Beutler B,Kono DH.Type I interferons (alpha/beta)
in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-336.

64.

Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection 14. Annu Rev
Immunol 2003;21:265–304.

65.

Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in
human immunodeficiency virus and AIDS. J Gen Virol 2003;84:1649-1661.

66.

Ipp H, Zemlin A. The paradox of the immune response in HIV infection: when
inflammation becomes harmful. Clin Chim Acta 2013;416:96-99.

48

67.

Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K.
Analysis of an expression profile of genes in the human adipose tissue. Gene
1997;190:227-235.

68.

Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the
release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes
from visceral and subcutaneous abdominal adipose tissues of obese humans.
Endocrinology 2004;145:2273-2282.

69.

Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: A review. World J
Diabetes 2010;1:76-88.

70.

Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in
inflammation and immune regulation. J Physiol Pharmacol 2003;54:469-487

71.

Considine RV, Sinha MK, Heiman ML, et al. Serum imunorective-leptin
concentrations in normal-weight and obese humans. N Engl J Med
1999;334:292-295.

72.

Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin
concentration. J Clin Endocrinol Metab 1997;82:579-584.

73.

Brann DW, De Sevilla L, Zamorano PL, Mahesh VB. Regulation of leptin gene
expression and secretion by steroid hormones. Steroids 1999;64:659-663.

74.

Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose
tissue. J Clin Invest 2003;112:1785-1788.

75.

Lord GM. Leptin as a Proinflammatory Cytokine. Contrib Nephrol 2006;151:151164.

76.

Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE. The
lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces synthesis of the
closely related TLR-2 in adipocytes. J Biol Chem 2000;275:24255-24263.

77.

Chen K, Li F, LI J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M,
Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance
through direct interaction of C-reactive protein with leptin. Nat Med 2006;12:425432.

78.

Wieland CW, Florquin S, Chan ED, et al. Pulmonary Mycobacterium tuberculosis
infection in leptin-deficient ob/ob mice. Int Immunol 2005;17:1399-1408.

79.

Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation and
hematopoiesis. J. Leukoc. Biol 2000;68:437-446.

80.

Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human
leptin enhances activation and proliferation of human circulating T lymphocytes.
Cell. Immunol 2000;199:15–24.

49

81.

Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH. Protection
against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl2 expression. Proc Natl Acad Sci USA 1998;95:9558–9561.

82.

Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin
concentrations in normal-weight and obese humans. N Engl J Med
1996;334:292-295.

83.

Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to
HIV lipodystrophy. AIDS 2007;21:895-904.

84.

Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology
and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol
Metab 2006;2:318-327.

85.

Prabha C, Karthic S, Das SD, Swaminathan S, Subramaniam S, Sukumar B.
Impact of Tuberculosis on Serum Leptin Levels in Patients with HIV infection.
Horm Res. 2005;63:228-233.

86.

Onyemelukwe GC, Ogoina D, Bakari AG. Serum Leptin Levels in Antitretroviral
Therapy Naïve HIV-1 Infected Patients in Zaria, Nigeria. Int J Endocrinol Metab
2009;3:162-169.

87.

Azzoni L, Crowther NJ, Firnhaber C, et al. Association between HIV replication
and serum leptin levels: an observational study of a cohort of HIV-1-infected
South African women. J Int AIDS Soc 2010;13:33.

88.

Perseghin G, Lattuada G, De Cobelli F, et al. J Clin Endocrinol Metab
2007;92:4883-4888.

89.

Zimmermann E, Skogstrand K, Hougaard DM, et al. Influences of the Common
FTO rs9939609 Variant on Inflammatory Markers Throughout a Broad Range of
Body Mass Index. PLoS ONE 2011;6: e15958.

90.

Zabena C, Gonzalez-Sanchez JL, Martinez-Larrad MT, Torres-Garcia A. The
FTO Obesity Gene. Genotyping and Gene Expression Analysis in Morbidly
Obese Patients. Obes Surg 2009;19:87-95

91.

Qi L, Kang K, Zhang C, van Dam RM, Kraft P, Hunter D, Lee CH, Hu FB. Fat
mass-and obesity-associated (FTO) gene variant is associated with obesity:
longitudinal analyses in two cohort studies and functional test. Diabetes
2008;57:3145-3151.

92.

Terra X, Auguet T, Porras JA, et al. Anti-inflammatory profile of FTO gene
expression in adipose tissues from morbidly obese women. Cell Physiol Biochem
2010;26:1041-1050.

50

93.

Ablij H, Meinders A. C-reactive protein: history and revival. Eur J Intern Med
2002;13:412.

94.

Pepys M B, Hirschfield G M C-reactive protein: a critical update. J Clin Invest
2003;111:1805-1812.

95.

Eckel R H, Grundy S M, Zimmet P Z The metabolic syndrome. Lancet
2005;365:1415-1428.

96.

Pitsavos C, Panagiotakos DB, Tzima N, et al. Diet, exercise, and C‑reactive
protein levels in people with abdominal obesity: the ATTICA epidemiological
study. Angiology 2007;58:225-233.

97.

Pearson T A, Mensah G A, Alexander R W, et al Markers of inflammation and
cardiovascular disease: application to clinical and public health practice: A
statement for healthcare professionals from the Centers for Disease Control and
Prevention and the American Heart Association. Circulation 2003;107:499-511.

98.

Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest
2003;111:1805-1812.

99.

Roberts WL, CDC. CDC/AHA Workshop on Markers of Inflammation and
Cardiovascular Disease: Application to Clinical and Public Health Practice:
laboratory tests available to assess inflammation--performance and
standardization: a background paper. AHA Circulation 2004;110(25):e572-576.

100.

Ramana KV1, Sabitha V, Rao R. A Study of Alternate Biomarkers in HIV Disease
in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.
J Clin Diagn Res 2013;7:1332-1335. doi: 10.7860/JCDR/2013/5306.3138.

101.

Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, Gange SJ. CReactive Protein Is a Marker for Human Immunodeficiency Virus Disease
Progression. Arch Intern Med 2006;166:64-70.

102.

Guimaraes MM, Greco DB, Figeredo SM, Foscolo RB, Oliveira AR, Machados
LJ. High-sensitivity C-reactive protein levels in HIV-infected patients treated or
not with antiretroviral drugs and their correlation with factors related to
cardiovascular risk and HIV infection. Atherosclerosis 2008;201:434-439.

103.

Chaudhary M, Kashyap B, Gautam H, Saini S, Bhalla P. Role of C-Reactive
Protein in HIV Infection: A Pilot Study. Viral Immun 2008;21:263-266.

104.

Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation
biomarkers: a randomized comparison of immediate versus deferred
antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr
2011;56:36-43.

51

105.

Ledwaba L, Tavel JA, Khabo P, et al. Pre-ART levels of inflammation and
coagulation markers are strong predictors of death in a South African cohort with
advanced HIV disease. PLoS One 2012;7:e24243.

106.

Maachi M, Piéroni L, Bruckert E, et al. Systemic low grade inflammation is
related to both circulating and adipose tissue TNFa, leptin and IL-6 levels in
obese women. Int J Obes 2004;28:993-997.

107.

Fall T, Hägg S, Mägi R et al. The role of adiposity in cardiometabolic traits: a
Mendelian randomization analysis. PLoS Med 2013;10:e1001474. doi:
10.1371/journal.pmed.1001474.

108.

Fisher E, Schulze MB, Stefan N, et al. Association of the FTO rs9939609 single
nucleotide polymorphism with C-reactive protein levels. Obesity (Silver Spring).
2009;17:330-334. doi: 10.1038/oby.2008.465.

109.

Ziegler TR, Luo M, Estívariz CF, et al. Detectable serum flagellin and
lipopolysaccharide and upregulated anti-flagellin and lipopolyssharide and
upregulated anti-flagellin and lopolysaccharide immunoglobins in human short
bowel syndrome. AM J Physiol Regul Integr Comp. Physiol 2008;294:R402R410.

110.

Sandler NG, Douek DC. Microbial translocation in HIV infection: causes,
consequences and treatment opportunities. Nat Rev Microbiol 2012;10:655-666.

111.

Hunt PW, Brenchley J, Sinclair E, et al., Relationships between T cell activation
and CD4 T cell count in HIV-seropositive individuals with undetectable plasma
HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-133.

112.

Redd AD, Eaton KP, Kong X, et al. C-reactive protein levels increase during HIV1 disease progression in Rakai, Uganda, despite the absence of microbial
translocation. J Acquir Immune Defic Syndr 2010;54(5):556-559.

113.

Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts
disease progression of HIV-infected antiretroviral-naive patients with high CD4+
cell count. AIDS 2011;25:1385-1394.

114.

Prevalence of HIV, total (% of population ages 15-49). World Bank. Available at:
http://data.worldbank.org/indicator/SH.DYN.AIDS.ZS. Accessed June 9, 2014.

52

CHAPTER III: EFFECT OF BMI AND BODY COMPOSITION ON HIV DISEASE
PROGRESSION IN HIV INFECTED ART NAÏVE ADULTS IN BOTSWANA
Abstract
Background: An obesity paradox has been documented in many conditions including
HIV. Several studies indicate that overweight or obesity provides some protection from
accelerated HIV disease progression in patients not receiving antiretroviral therapy
(ART). Studies conducted to investigate obesity and its effect on HIV disease
progression have been inconclusive and are lacking in African settings. This research
investigates the relationship between overweight and obesity and HIV disease
progression in HIV+ asymptomatic adults not on ART in Botswana over a period of 18
months.
Methods: A retrospective, cohort study in asymptomatic, ART naïve, HIV+ adults was
conducted that included 217 participants, 139 with BMI 18.0-24.9 kg/m2 and 78
participants with BMI ≥ 25 kg/m2. The primary outcome was time to event (25% or
greater decrease in CD4 cell count) during 18 months of follow-up and secondary
outcomes were time to event of CD4 cell count <250 cells/µL, and AIDS defining
conditions. Proportional survival hazard models were used to compare hazard ratios on
time to events of HIV disease progression between BMI groups and BMI and body
composition as continuous variables over 18 months.
Results: Using Cox Proportional Hazards model, higher baseline BMI was associated
with significantly lower risk of having an AIDS defining condition over an 18 months
follow-up (HR, 0.218; 95% CI, 0.068-0.701, P=0.011). Higher fat mass at baseline was
also significantly associated with a decreased risk of having AIDS defining conditions
(HR, 0.855; 95% CI, 0.741-0.987, P=0.033) and the combined outcome of having CD4
cell count ≤ 250/µL and AIDS defining conditions, whichever occurred earlier (HR, 0.918;
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95% CI: 0.847-0.994, P=0.036). All models were adjusted for age, gender, marital
status, children (yes or no) and baseline CD4 cell count and baseline HIV viral load.
There was no significant effect of BMI on HIV viral load over 18 months.
Conclusions: Higher BMI and fat mass were associated with slower disease
progression in HIV infected ART naive adults in Botswana. Mechanistic research is
needed to evaluate the association of obesity and HIV disease progression.

Keywords: HIV infection, ART naïve, BMI, disease progression, body composition, BIA
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Introduction
The importance of good nutrition in maintaining good health and delaying
disease progression for the HIV patient has been well documented in the literature.1,2 At
the beginning of the HIV epidemic, wasting was one of the main nutritionally related
concerns, however, today rates of obesity are more common than the occurrence of
wasting, particularly in developed countries,3-5 especially with antiretroviral treatment
(ART).6
An obesity paradox has been documented in many conditions including HIV
infection, where those who are obese may have a survival advantage or improved
disease outcomes.7 The protective effect of obesity has been hypothesized to be related
to extra available energy in the form of available fat for use in time of crisis during the
HIV disease that would spare protein use,8 and also help to preserve the immune
system response. Studies on HIV and obesity were mainly conducted in settings where
the patients are treated with ART, which may confound some of the findings and
interpretations, as ART has been associated with lipodystrophy and obesity.5 Increased
obesity has been documented in countries with limited resources,9 however, studies
conducted in African settings on the relationship between HIV and obesity are lacking. It
has been estimated that in sub-Saharan Africa, 10% of women have a BMI of less than
18.5 kg/m2, with wasting still prevalent in some areas.10 However, sub-Saharan Africa is
experiencing a nutrition-related transition with a rapid rise in overweight and obesity.11
Botswana is also experiencing an increase in obesity.12 Growth in economy,
urbanization, and diminished physical activity is contributing to the rise in obesity in
Southern Africa.13 Studies conducted to investigate obesity and its effect on HIV disease
progression have so far been inconclusive, with some studies reporting an association
and others reporting no association between CD4 cell counts and obesity.6,14-17
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Botswana is also experiencing one of the worst epidemics of HIV with a prevalence
rate of 23.4%, among those in the range between 15 and 49 years of age in men and
women.18 Botswana has been one of the first developing countries to provide universal
access to ART.19 Currently, HIV+ adults in Botswana can receive ART once their CD4
cell counts are less than 500 cells/µL. Countries especially in sub-Saharan Africa are still
having many challenges in providing ART and maintaining adherence.20 Therefore,
having information on delaying disease progression, and its relationships to nutritionrelated measures, in those regions where the two epidemics are co-occuring, is timely.
The objective of this study was to examine the relationship between overweight
and obesity and HIV disease progression in HIV+ asymptomatic adults not on ART in
Botswana over 18 months. The primary outcome was time to the first occurrence of a
25% or greater decrease in CD4 cell count during the course of the study and the
secondary outcomes were time to reaching CD4 cell count <250 cells/µL, AIDS defining
conditions, and changes in HIV viral load. This study was conducted in HIV+ adults who
were ART naïve and had CD4 cell counts >350 cells/µL.
Methods
Study Design and Participants
A retrospective, cohort study analyzing data from 219 HIV+ men and women
from the placebo group of a clinical trial in Botswana was conducted. This trial was a
multifactorial, randomized, double-blinded, placebo-controlled clinical trial which
investigated whether supplementation with multivitamins and selenium could improve
immune function and prolong time to AIDS in ART naïve HIV+ adults.21 The study was
conducted between December 2004 and July 2009. The placebo group was used to
avoid any confounding effects from the micronutrient supplementation on the outcome
measures. Participants were eligible for the parent study with documentation of HIV
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seropositive test results, CD4 cell count was >350 cells/µL, BMI was >18 kg/m2 for
women and 18.5 kg/m2 for men, age ≥ 18 years, lack of a past history of AIDS-defining
conditions, participation in another clinical trial and taking ART. Women were excluded if
pregnant or had intention to become pregnant. All participants provided informed
consent and were recruited from the Botswana-Harvard AIDS Initiative Partnership
(BHP) in Gaborone, Botswana. The study protocol was approved by the Florida
International University Institutional Review Board (IRB), the Harvard School of Public
Health IRB and the Botswana Health Research Unit of the National Ministry of Health.
Appropriate informed consent was obtained and clinical research was conducted in
accordance with guidelines for human experimentation as specified by the US
Department of Health and Human Services, the researchers’ institutions, or both.
Clinical Data
At baseline and every three months, physical examination and medical history
were performed by a trained nurse or a physician. Anthropometrics were also obtained
and body mass index (BMI) was calculated by dividing the weight in kilograms by height
in meters squared. Waist and hip circumference was measured using a tape measure.
Waist circumference was measured at the narrowest part of the waist between the
lowest rib and the iliac crest and the hip circumference at the widest portion of the
buttocks. Bioelectrical impedance analysis (BIA) using the Biodynamics body
composition analyzer (model BIA-310; Biodynamics Corp., Seattle, WA), determined
impedance and calculated body composition. Subjects were measured without shoes
and socks, and electrodes were placed on the participant’s right hand and wrist and right
foot and ankle. Blood pressure was measured in the left arm with the elbow flexed to
heart level. Morbidity information including AIDS-defining conditions, were collected by
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questionnaires at screening, and at every monthly visit, and confirmed by documentation
in the medical chart.
Laboratory Data
At baseline and every three months blood was drawn for CD4 and CD8 cell
counts. Every six months, blood was also drawn to evaluate HIV viral load, lipid panel,
and blood chemistry. Lymphocyte phenotype was determined with a four-color
immunophenotyping panel of monoclonal antibodies. Differential counts were
determined using a Coulter MaxM hematology instrument and corroborated with
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).
The lipid panel was measured using Roche reagent kits (Branchburg, NJ) on a COBAS
Integra 400 plus auto-analyzer using enzymatic methods according to standard
operating procedures.
Nutritional Data
Twenty-four hour recalls were conducted at baseline and every 3 months by
trained clinical staff. Macronutrient and fiber intakes were calculated using the NutriBase
Professional, V.9 (Cybersoft, Phoenix, AZ) program modified by the South Africa
database, including native foods for which information was available. An average of at
least 3 dietary recalls were used to obtain their estimated energy, carbohydrate, protein,
fat and fiber intakes.
Statistical Analysis
BMI was stratified into two groups: 1. normal weight (BMI=18.0-24.9 kg/m2) and
2. overweight/obese (BMI ≥ 25 kg/m2). The overweight and obese BMI categories were
combined to increase the sample size for the analyses. Laboratory markers of HIV
infection and disease progression included in the analyses were CD4 cell count, CD4%,
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CD8 cell count, CD8%, CD4/CD8 ratio and HIV viral load. Descriptive statistics such as
frequencies, percentages, medians and interquartile ranges were used to characterize
the total population, the two groups stratified by BMI and the study variables (primary
and secondary outcomes) at baseline. Mann Whitney U and Chi-square tests were used
to determine differences in HIV disease progression markers and markers of nutritional
status between the BMI groups and by gender. Linear and logistic regressions at
baseline and 18 months were conducted to observe the relationship between BMI and
HIV disease progression and body composition measures from BIA using BMI as a
continuous variable and dichotomous variable. The multiple regression analysis also
included a measure to check for multicollinearity known as variance inflation factor (VIF).
All models had a VIF <5, therefore multicollinearity was not a problem. Proportional
survival hazard models were used to compare hazard ratios on time to events of HIV
disease progression outcomes with BMI groups, BMI as a continuous variable and body
composition over 18 months. The primary outcome was time to the first occurrence of a
25% or greater decrease in CD4 cell count during the course of the study and secondary
outcomes were time to CD4 cell count <250 cells/µL, and AIDS defining conditions.
These events were documented from the time of inclusion into the study to the date of
the visit in which the event was recorded. All models were adjusted for covariates. For all
analyses, a two sided test was used and P<0.05 was considered statistically significant.
Statistical analyses were completed using SPSS version 21.
Results
Demographics and Clinical Characteristics
A total of 219 participants were assigned randomly into a placebo group by the
parent study.21 Two participants had missing data and were excluded from the final
analysis. Seventy-eight participants at baseline had BMI ≥ 25 kg/m2 and 139 had
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BMI=18.0-24.9 kg/m2. BMIs were stable throughout the 18 months of follow-up and did
not statistically change within the normal and overweight/obese groups (Table 1). Most
of the participants were female (75.1%) with a median age of 33 years, reflecting the
characteristics of the epidemic in Botswana.22 Almost half (45.2%) of the participants
had at least a secondary education level and most had children (85.7%).
There were differences in demographic factors among the BMI groups. Those
with BMI ≥ 25 kg/m2 were older and more likely female, married and have children (Table
1). There were no differences in laboratory markers of HIV infection at baseline between
the BMI groups. As shown on Table 2, those with BMI ≥ 25 kg/m2 had a larger waist
circumference and higher levels of total cholesterol, triglycerides, LDL cholesterol,
glucose, and blood pressure. Albumin levels were higher in those with BMI 18-24.9
kg/m2. Dietary intake was statistically different between the BMI groups. The
overweight/obese group had higher basal metabolic rate and fat mass, but lower lean
body mass, body cell mass and extracellular mass. Physical activity was not statistically
different between the BMI groups (data not shown).
Correlations between Laboratory Markers of HIV Infection and Body Composition
BMI was significantly correlated with measures of body composition but not with
the markers of HIV infection (Table 4). Waist circumference was associated with CD4%
(r=-.17, P<.05) and CD4/CD8 ratio (r=-.19, P=.05). Waist-to-hip ratio showed a
correlation with CD4% (-.33, p<0.01), CD8 cell count (r=.22, P<.01), and CD4/CD8 ratio
(r=-.26, P<.01). Both fat mass and lean mass were associated with CD4 cell count (r=.14, r=.14, P<.05, respectively).
Effect of BMI on Laboratory Markers of HIV Infection and Disease Progression
Table 5 displays the results from logistic regression analysis that compared the
BMI groups at baseline, 18 months and the change over 18 months in the laboratory
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markers of HIV infection and disease progression. No significant associations were
found with viral load, CD4 cell count, CD4%, CD8 cell count, CD8%, and CD4/CD8 ratio.
However, there was a trend where CD4% showed those with BMI ≥ 25 kg/m2 to be more
likely to have a higher change in CD4% over 18 months (OR=1.076, 95% CI=.988,1.166,
P=.077). All models were controlled for age, gender, marital status, and children
(whether they had children, yes or no).
Linear regressions using BMI as a continuous variable were also conducted to
compare with measures of HIV disease progression at baseline, 18 months, and the
change over 18 months (Table 6). There was a trend in the association between CD8
cell count and BMI at 18 months (β=.002, 95% CI= .000, .004, P=.082). The change in
CD4% between baseline and 18 months was significantly associated with BMI, showing
that for every unit increase in BMI there was .214 increase in the difference in CD4%
(β=.214, 95% CI= .051, .376, P=0.011). All models were adjusted for age, gender,
marriage and children. No significant differences were found with CD4 cell count,
CD8%, and CD4/CD8 ratio.
Table 7 shows that after controlling for age, gender, marital status, children,
baseline CD4 cell count and viral load, there were no significant differences between
BMI groups in the main outcome of 25% decline in CD4 cell count over 18 months (HR=
.744; 95% CI= .489, 1.131; P=.166). No significant differences were also observed in
the secondary outcomes of CD4 cell count ≤ 250/μL, AIDS defining conditions, or the
combined outcome of CD4 cell count ≤ 250/μL, AIDS defining conditions, whichever
occurred first. As shown in Table 8, using continuous baseline BMI, higher BMI was
associated with a protective effect on the risk of having an AIDS defining condition (HR=
.218; 95% CI= .068, .781; P=.011) after adjusting for age, gender, marriage, children
and baseline CD4 cell count and viral load. Significant associations were not found
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between continuous BMI and CD4 cell count ≤250/μL, AIDS defining conditions and the
combined outcome of CD4 cell count ≤250/μL, AIDS defining conditions, whichever
occurred first.
Effect of Body Composition on Laboratory Markers of HIV Infection and Disease
Progression
There were no significant associations using linear regression between
measures of HIV disease progression and fat mass, lean body mass, and body cell
mass at baseline, 18 months and the difference between these visits (Table 5).
A trend towards significance was seen with the outcome of 25% decline in CD4
cell count and fat mass (HR= .974; 95% CI= .945, 1.003, P=.083) (Table 9). Higher fat
mass was protective of having an AIDS defining condition (HR= .855; 95% CI= .741,
.987; P=.033). Higher fat mass was protective against the combined outcome of CD4
cell count ≤ 250/μL and AIDS defining conditions, whichever occurred first (HR= .918;
95% CI= .847, .994; P=.036). The effect of lean body mass on disease progression was
similar to fat mass, as shown on Table 10. As lean body mass increased there was a
higher risk of having ≥ 25% decline in CD4 cell count during the 18 months of follow-up
but was trending towards significance (HR= 1.027; 95% CI= .997, 1.059, P=.082).
Higher lean body mass was associated with higher risk of having an AIDS defining
condition (HR= 1.169, 95% CI= 1.013, 1.349; P=.033), and higher risk of CD4 cell count
≤ 250/μL and AIDS defining condition albeit not significant (HR= 1.075; 95% CI= .995,
1.161; P=.068). These models were also adjusted for age, gender, marital status, having
children and baseline CD4 count and viral load.
Discussion
This study showed that BMI and fat mass were protective by delaying the time to
the first AIDS defining condition in HIV+ ART naïve adults in Botswana during 18 months

62

of follow-up. The fat stores would have provided the extra energy needed to maintain the
innate immune system responding to protect against opportunistic infections and
delaying wasting. There were no significant findings over 18 months when comparing
the main outcome of a clinically significant decline of CD4 cell count (25%) and BMI
stratified into two groups, BMI=18.0-24.9 kg/m2 and BMI ≥ 25 kg/m2. This finding
suggests that the protective effect of fat stores are not enough to counteract the focused
viral attack to the specific immune response, a suggestion supported by the results that
show no association between BMI and HIV viral load. Shor-Posner et al.17 found a
significant difference between obese and nonobese when comparing clinically significant
25% decline in CD4 cell count over 18 months. However, these participants were drug
users and may have been in worse nutritional status and have had HIV for longer
duration and were in more advanced stage. BMI at baseline as a continuous variable
was associated with 78% lower risk of having an AIDS defining condition for every one
unit increase in BMI. Past incidence of >1 AIDS defining condition was associated with
1.3 fold higher risk of having BMI <20 kg/m2 and AIDS defining conditions were also
associated with a higher risk of wasting.23
Higher BMI was also associated with a higher CD4% after 18 months of followup. CD4% is considered to be more steady than absolute CD4 cell counts and provide a
better prognostic information before ART is initiated.24,25 Recently, it was shown to be a
good predictor of disease progression for those starting ART with a CD4 cell count of
>350 cells/µL.26 Other investigators have also found that immune counts are affected by
weight and/or BMI in HIV.14,27 In a cross-sectional study14 with patients on ART, an
absolute increase of 16 units of CD8 cell count was seen for every 1kg/m2 increase of in
BMI. Crum-Cianflone and colleagues27 compared normal weight to obese HIV+ adults at
diagnosis and through HAART or ART initiation and concluded that those who were
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obese had smaller reductions in CD4% through time, regardless of whether diagnosis
took place in the pre-HAART era or after. They also found similar results with CD4/CD8
counts and only significant differences between normal weight and overweight in the
HAART era with CD8 counts. Our findings in ART-naïve population, early in HIV
disease showed that there were no significant effects of BMI with CD4/CD8 or CD8 cell
count. Interestingly, Crum-Cianflone and colleagues27 also showed that weight did not
have an effect on immune cells at HIV diagnosis, but instead the effect of weight on
immune cells was seen as the disease progressed. This study also did not have any
significant differences at baseline between the normal weight and overweight/obese
groups, because the great majority started their participation early in the disease at
diagnosis.
This is the first study that demonstrated a longitudinal association between
reduced AIDS defining conditions with higher fat mass. Higher fat mass was also
associated with the combined outcome of CD4 cell count ≤ 250/μL and AIDS defining
conditions. On the outcome of a decline in the CD4 cell count of 25% or greater, the
survival analysis showed a positive trend association with fat mass and negative
association with lean body mass, a finding supported by cross-sectional significant
findings in our larger (N=878) cohort in Botswana.28 Supporting this relationship over
time, Visnegarwala and colleagues29 demonstrated in a cross-sectional study that
women with a prior AIDS defining condition had lower total body fat in kilograms.
Maintaining a large lean mass has higher energy costs. Stored protein is less available
than dietary protein and provides less energy than the same weight in fat,30 this might be
one of the reasons why lean mass was not protective, but might be even
counterproductive to maintain adequate immune response before ART.
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Findings from this study indicate that higher fat mass may provide protection
from advanced HIV disease. This protective effect has been hypothesized to be related
to extra available energy for use in times of emergency during the HIV disease that
would reduce protein’s use8 and also help to preserve the immune system, especially
the innate immunity that is not directly affected by the infection.16,31 HIV and its
secondary infections are known to generate a hypermetabolic state that is sustained
throughout the disease.32 The HIV patient is susceptible to infections, in which the body
will require energy to battle continuous infections and immune activation. Those who
are obese may have a genetic advantage in maintaining fat stores and utilizing that
energy more efficiently to fuel the immune system.
Although there seems to be an obesity paradox in HIV, being obese is a risk
factor for mortality and chronic conditions or diseases such as cardiovascular diseases,
diabetes, hypertension, and cancer.33-36 The participants of this study in the
overweight/obese group had higher levels of total cholesterol, triglycerides, glucose,
although not clinically significant, and higher LDL and blood pressure. These differences
could over a period of time potentially increase their risks for chronic conditions.
Evidence from the literature supports that once a patient receives ART, their
cardiovascular and liver risks increases, and obesity becomes an adverse factor for
health and survival.5 Stevens and colleagues37 have stated concerns over providing
confusing messages when discussing the obesity paradox and the possible harm it will
have on public health efforts related to reducing obesity rates to lower the risk of chronic
diseases. Conversely, other researchers38 theorize that our view of normal or optimal
weight or BMI categories are too strict and may be biologically unsuitable. They also
argue that those with an established disease diagnosis may benefit from an emphasis
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on lifestyle recommendations regarding physical activity and nutrition rather than
intentional weight loss or gain.
The limitations of this study include the sample size, not having sufficient
numbers of participants to be able to examine differences between overweight and
obese groups separately, and the predominance of women among the participants. The
exact time since HIV diagnosis was not available, however, it was known that the
participants were asymptomatic, never had a diagnosis of AIDS and did not qualify for
ART. The majority were referred from the clinics where they were diagnosed.
Participants with BMI in the range of underweight category were not included in the
parent study as those ranges are strong prognostic indicators of AIDS.21 This HIV
population was in the early stage of the disease in order to study ART naïve individuals
and the finding cannot be generalized to all HIV seropositive patients. The early stage of
disease may be one of the reasons why we did not see a significant decline of CD4 as a
main outcome. In HIV, bioimpedance (BIA) has been shown to be an effective method
for detecting fat mass,39 however, BIA have limitations, since its values can be
influenced by body arrangement, hydration, ingestion of food and drinks, air and body
temperature and exercise.40 Our BIA measurement protocol provided for these
limitations by giving detailed instructions to the participants on their preparation for their
visit, and standardizing the measurement parameters. The strengths of this study
consists of capturing and analyzing longitudinal data from HIV+ participants in
Botswana, that we collected from early asymptomatic stage through defined health
outcomes, and that this type of information is lacking in African populations.
In summary, the results of this study demonstrate that higher BMI and fat mass
were protective in delaying HIV disease progression in this group of HIV+, ART naïve
adults in Botswana. BMI separated into two groups, normal weight and
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overweight/obese groups, did not show a significant effect on decline of CD4 cell count
over 18 months and may have been due to limited sample size and to the participants’
early stage of the disease. Mechanistic studies on the relationship between BMI and
body composition on disease progression are needed to clarify the obesity paradox in
HIV.
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Table 1: Change in BMI* from Baseline to 18 Months by BMI Groups
Groups
Baseline BMI
18 Months BMI
P-value
Overall
22.8 (20.7-27.2)
24.1 (20.4-27.2)
.511
Normal BMI
21.2 (19.9-22.6)
20.9 (19.3-22.5)
.338
Overweight/Obese
28.5 (26.6-30.1)
28.1 (26.1-30.4)
.466
*Reported as median (interquartile range); BMI expressed as kg/m2
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Table 2: Demographic Characteristics by BMI Group at Baseline
Total
(N=217)

Normal BMI
(N=139)

Overweight/
Obese BMI
(N=78)
35 (30-43)

Variable
Age (years)a
33 (28-39)
31 (28-38)
Gender
Male
54 (24.9)
44 (31.7)
10 (12.8)
Female
163 (75.1)
95 (68.3)
68 (87.2)
Marital Status
Single
124 (59.0)
86 (65.2)
38 (48.7)
Married
24 (11.4)
9 (6.8)
15 (19.2)
Other
62 (29.5)
37 (28.0)
25 (32.1)
Education
None
13 (6.2)
9 (6.8)
4 (5.1)
Primary
83 (39.5)
52 (39.4)
31 (39.7)
Secondary
95 (45.2)
59 (44.7)
36 (46.2)
Tertiary
19 (9.0)
12 (9.1)
7 (9.0)
Income (pula)
17 (21.8)
31 (23.5)
48 (22.9)
None
8 (10.3)
12 (9.1)
20 (9.5)
<300
15 (19.2)
26 (19.7)
41 (19.5)
300-600
18 (23.1)
33 (25.0)
51 (24.3)
601-1000
16 (20.5)
27 (20.5)
43 (20.3)
1001-6000
4 (5.1)
2 (1.5)
6 (2.9)
>6000
0 (0.0)
1 (0.8)
1 (0.5)
Unsure
Electricity
34 (43.6)
49 (37.1)
Yes
83 (39.5)
83 (62.9)
44 (56.4)
No
127 (60.5)
Children
Yes
180 (85.7)
107 (81.1)
73 (93.6)
No
30 (14.3)
25 (18.9)
5 (6.4)
2 a
BMI (kg/m )
22.8 (20.7-27.2)
21.2 (19.9-22.6)
28.5 (26.6-30.1)
CD4 Cell Count
411.3 (326.3415.9 (324.7401.2 (331.2(cells/µL)a
546.7)
548.9)
545.2)
CD8 Cell Count
838.6 (617.5804.1 (588.8891.3 (669.0(cells/µL)a
1194.9)
1229.0)
1177.8)
CD4/CD8 Ratioa
0.5 (0.3-0.7)
0.5 (0.4-0.7)
0.5 (0.3-0.7)
HIV Viral Load
4.3 (3.5-4.8)
4.3 (3.6-4.8)
4.2 (3.3-4.8)
(Log10 copies/mL)a
a
Reported as median (interquartile range); all other variables reported as n (%)
b
Statistically significant, P<.05
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Pvalue
.005b
.002b
.010b

.984

.849

.354
<.001b
.012b
.908
.251
.375
.525

Table 3: Nutrition Related Characteristics by BMI Group at Baseline
Total
Normal BMI
Variablea
(N=217)
(N=139)
Waist (inches)
32.3 (29.9-35.7) 30.7 (29.1-32.3)
Waist-to-hip Ratio
0.8 (0.8-0.9)
0.8 (0.8-0.9)
Total Cholesterol
3.7 (3.0-4.3)
3.5 (2.9-4.0)
(mmol/L)
Triglycerides
0.8 (0.6-1.0)
0.7 (0.5-0.9)
(mmol/L)
HDL (mmol/L)
1.1 (0.9-1.3)
1.1 (0.9-1.4)
LDL (mmol/L)
2.4 (2.0-2.9)
2.4 (1.8-2.7)
Glucose (mmol/L)
4.5 (4.3-4.8)
4.5 (4.2-4.7)
Hemoglobin (g/dL)
12.9 (11.8-14.0) 12.7 (11.4-14.1)
Hematocrit (%)
39.4 (36.3-42.3) 39.0 (35.4-42.6)
Albumin (g/L)
41.0 (39.3-43.4) 41.6 (39.0-44.5)
Iron (µmol/L)
9.3 (6.3-13.0)
9.5 (6.0-13.2)
Systolic Blood
119 (110-130)
114 (108-128)
Pressure (mm Hg)
Diastolic Blood
76 (69-82)
72 (65-80)
Pressure (mm Hg)
Total Energy Intake 1507.1 (1177.5- 1496.4 (1178.6(kcal)
1902)
1933.2)
Protein Intake (%)
16.3 (14.0-19.6) 16.9 (14.1-20.7)
Carbohydrate
65.6 (57.1-71.8) 65.6 (57.3-71.4)
Intake (%)
Fat Intake (%)
17.4 (12.4-22.9) 17.4 (12.1-22.8)
Fiber Intake
(grams)
16.0 (12.0-21.6) 16.1 (12.1-21.4)
Basal Metabolic
1401 (12681338 (1209Rate (kcal)
1564)
1498)
Fat Mass (%)
29.0 (23.9-33.9) 25.1 (19.9-29.3
Lean Mass (%)
71.0 (66.1-76.1) 74.9 (70.6-80.1)
Body Cell Mass (%) 34.1 (31.6-37.3) 35.9 (33.4-39.5)
Extracellular Mass
36.8 (33.7-40.0) 38.9 (36.2-41.0)
(%)
a
All variables reported as median (interquartile range)
b
Statistically significant, P<.05
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Overweight/Obes
e BMI (N=78)
37.6 (34.8-39.3)
0.8 (0.8-0.9)
4.0 (3.5-4.7)

Pvalue
<.001b
.017b
<.001b

0.8 (0.6-1.2)

<.001b

1.1 (0.9-1.2)
2.6 (2.2-3.0)
4.6 (4.4-5.1)
13.0 (12.2-14.0)
40.0 (37.3-4.9)
39.8 (37.7-42.6)
8.8 (6.6-12.7)
122 (111-139)

.301
.043b
.002b
.251
.359
.010b
.959
<.001b

80 (70-88)

<.001b

1568.0 (1175.61890.7)
15.9 (14.0-18.6)
65.9 (56.6-72.7)

.749

17.4 (12.7-23.2)

.959
.202
.524
.871

15.6 (11.8-22.2)
1532 (1382-1696)

<.001b

34.9 (32.5-37.9)
65.1 (62.1-67.5)
31.2 (30.-33.2)
33.3 (31.8-35.4)

<.001b
<.001b
<.001b
<.001b

Table 4: Spearman Correlation Coefficients at Baseline
BMI

Waist

Waist
-tohip

Fat
mass

Lean
mass

CD4
cell
count

CD4%

CD8
cell
count

CD8
%

CD4/
CD8
ratio

BMI

1.00

Waist

.82**

1.00

Waist-to-hip

.16*

.53**

1.00

Fat mass

.72**

.58**

.03

1.00

Lean mass

-.72**

-.58**

.03

-1.00**

1.00

CD4 cell
count
CD4%

-.03

-.08

-.04

-.14*

.14*

1.00

-.09

-.24**

-.32**

-.08

.08

.50**

1.00

CD8 cell
count
CD8%

.06

.14

.22**

-.03

.03

.26**

-.61**

1.00

-.05

.04

.11

-.01

.01

.29**

.72**

.73**

1.00

-.05

-.19*

-.26**

-.06

.06

.44**

.94**

-.71**

-.89**

1.00

-.08

-.06

.10

-.02

.02

-.23**

-.40**

.29**

.42**

-.43**

CD4/
CD8 ratio
Viral load

*Statistically significant, P<0.05, **Statistically significant, P<0.01
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Viral
Load

1.00

Table 5: Logistic Regression at Baseline, 18 Months and the Change Over 18 Months by BMI Groups*
Baseline
18 Months
Change Over 18 Months
Variable
OR
95% CI
P-value
OR
95% CI
P-value
OR
95% CI
P-value
CD4 cell count 1.000
.999, 1.002 .603
1.000
.999, 1.002 .640
1.001
.998, 1.004 .399
CD4%
.984
.946, 1.024 .424
.994
.952, 1.038 .783
1.076
.988, 1.166 .077
CD8 cell count 1.000
.999, 1001 .966
1.000
1.000, 1.001 .433
1.000
1.000, 1.001 .381
CD8%
.991
.964, 1.019 .536
.993
.962, 1.026 .691
.976
.910, 1.046 .486
CD4/CD8 ratio .767
.286, 2.056 .598
.554
.139, 2.215 .554
.781
.308, 1.983 .603
HIV viral load
1.054
.748, 1.485 .764
.886
.590, 1.330 .558
.900
.519, 1.561 .707
*Dependent variable = BMI groups; reference category=BMI ≥25kg/m2; Individual models analyzed for each independent variable
and adjusted for age, gender, marriage, and children.

Table 6: Linear Regression at Baseline, 18 Months and the Change Over 18 Months by Continuous BMI*a
Baseline
18 Months
Change Over 18 Months
Variable
Slope 95% CI
P-value
Slope
95% CI
P-value
Slope
95% CI
P-value
CD4 cell count .001
-.002, .005 .469
.003
-.002, .008
.240
-.004
-.010, .002
.165
CD4%
-.036 -.116, .043 .371
.052
-.063, .168
.374
.214
.051, .376
.011b
CD8 cell count <.001 -.001, .011 .938
.002
.000, .004
.082
.001
-.001, .002
.399
CD8%
-.031 -.087, .024 .270
-.069
-.155, .017
.116
-.076
-.225, .073
.371
CD4/CD8 ratio -.818 -2.878, 1.243 .435
-3.258 -7.323, .807
.115
-.673
-2.613,1.266 .494
HIV viral load
.007
-.715, .728 .986
.204
-.789, 1.196
.686
.625
-.609, 1.859
.318
*Individual models analyzed for each independent variable and adjusted for age, gender, marriage, and children
a
Dependent variable for baseline analysis included continuous BMI at baseline, dependent variable for 18 months analysis
included continuous BMI at 18 months, and dependent variable for difference between visits analysis included continuous BMI at
baseline.
b
Statistically significant, P<.05
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Table 7: Adjusted Hazard Ratios on the Effect of BMI Groups on HIV Disease
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18
Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
.744
.489, 1.131
.166
CD4 cell count ≤ 250/μL
1.021
.381, 2.740
.966
AIDS Defining Conditions
.500
.047, 4.465
.500
CD4 cell count ≤ 250/μL & AIDS
1.089
.453, 2.619
.849
Defining Conditions
*Cox proportional hazards model were used to examine the effect of BMI groups (0=BMI
18.0-24.9 kg/m2 and 1=BMI ≥25kg/m2) on individual HIV disease progression outcomes.
All individual HIV disease progression outcomes were analyzed as separate models and
adjusted for age, gender, marriage, children and baseline CD4 count and viral load.
a
Statistically significant, P<.05
b
HR= Hazard Ratio
c
CI=Confidence Interval

Table 8: Adjusted Hazard Ratios on the Effect of Baseline BMI on HIV Disease
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18
Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
.963
.919, 1.009
.113
CD4 cell count ≤ 250/μL
1.043
.932, 1.167
.462
AIDS Defining Conditions**
.218
.068, .701
.011a
CD4 cell count ≤ 250/μL & AIDS
.904
.796, 1.028
.124
Defining Conditions
*Cox proportional hazards model were used to examine the effect of baseline continuous
BMI on individual HIV disease progression outcomes. All individual HIV disease
progression outcomes were analyzed as separate models and adjusted for age, gender,
marriage, children and baseline CD4 count and viral load.
**Model adjusted for age, gender, children and baseline CD4 cell count and viral load
a
Statistically significant, P<.05
b
HR= Hazard Ratio
c
CI=Confidence Interval
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Table 9: Adjusted Hazard Ratios on the Effect of Baseline Fat Mass on HIV Disease
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18
Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
.974
.945, 1.003
.083
CD4 cell count ≤ 250/μL
.984
.909, 1.065
.793
AIDS Defining Conditions
.855
.741, .987
.033a
CD4 cell count ≤ 250/μL & AIDS
.918
.847, .994
.036a
Defining Conditions
*Cox proportional hazards model were used to examine the effect of baseline continuous
fat mass % on individual HIV disease progression outcomes. All individual HIV disease
progression outcomes were analyzed as separate models and adjusted for age, gender,
marriage, children and baseline CD4 count and viral load.
a
Statistically significant, P<.05
b
HR= Hazard Ratio
c
CI=Confidence Interval

Table 10: Adjusted Hazard Ratios on the Effect of Baseline Lean Mass on HIV Disease
Progression Outcomes in HIV+ Adults in Botswana During a Follow-up Period of 18
Months*
95% CIc
P-value
Outcome
HRb
≥ 25% decline in CD4 cell count
1.027
.997, 1.059
.082
CD4 cell count ≤ 250/μL
1.008
.939, 1.100
.692
AIDS Defining Conditions
1.169
1.013, 1.349
.033a
CD4 cell count ≤ 250/μL & AIDS
1.075
.995, 1.161
.068
Defining Conditions
*Cox proportional hazards model were used to examine the effect of baseline continuous
lean mass % on individual HIV disease progression outcomes. All individual HIV disease
progression outcomes were analyzed as separate models and adjusted for age, gender,
marriage, children and baseline CD4 count and viral load.
a
Statistically significant, P<.05
b
HR= Hazard Ratio
c
CI=Confidence Interval
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CHAPTER IV: PRELIMINARY ASSOCIATION STUDY OF THE FAT MASS AND
OBESITY ASSOCIATED GENE POLYMORPHISMS WITH HIV DISEASE
PROGRESSION
Abstract
Objective: Being overweight or obese in HIV has been shown to be protective in
delaying disease progression. The objective of this study was to assess whether
polymorphisms of the fat mass and obesity associated gene (FTO) are associated with
body composition and HIV disease progression in HIV+, ART naïve adults in Botswana.
Methods: A retrospective study was completed with 215 participants from the placebo
group of a randomized controlled trial previously conducted and published. Five SNPs
of the FTO gene were examined for their association with body composition and
measures of HIV disease progression.
Results: A total of 137 normal weight and 78 overweight/obese participants were
studied. Only rs17817449 was associated with BMI in the dominant genetic risk model.
FTO SNPs were not associated with laboratory markers of HIV infection at baseline. Fat
mass and lean mass both were associated with rs1121980, rs8050136, and rs17817449
with the risk alleles having a higher percentage of fat mass and lower lean body mass
compared to the non-risk homozygous allele. Over 18 months, FTO SNPs were not
associated with outcomes of HIV disease progression.
Conclusions: FTO SNPs may contribute to the variation in body fat mass and lean
mass in adults in Botswana. FTO SNPs were not associated with a protective effect on
HIV disease progression. Further studies including GWAS are needed in African
populations to clarify whether genetic variation mediates the obesity paradox.

Keywords: HIV infection, ART naïve, BMI, disease progression, FTO gene
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Introduction
Studies have shown that obesity may be protective of further HIV disease
progression before initiation of antiretroviral therapy (ART).1-4 Obesity was even found to
be protective after initiation of ART.5 Higher CD4 cell counts and delayed diagnosis of
AIDS have been found in those who were overweight or obese.1-3,6,7 Those who are
obese may have a genetic advantage in maintaining fat stores and utilizing energy to
fuel the immune system. Conversely, obesity may also increase one’s risk for
developing chronic conditions such as cardiovascular diseases, diabetes and cancer.8-10
It is also a concern for the HIV patient that is now living longer due to increasing use of
antiretrovirals. Information on mechanisms for the potential benefits of obesity in
delaying HIV disease progression are lacking.
Obesity has a strong genetic background11 which has been estimated to account
for 40-70% of the variation in human adiposity.12 The Fat Mass and Obesity Associated
(FTO) gene was first identified in 200713 and has been associated with obesity and
obesity related traits.14,15 The hypothalamus is the site where the FTO gene is mainly
expressed16 and may be involved in energy homeostasis,17 and fat cell lipolysis which
may regulate body fat.18 Specifically, the single nucleotide polymorphism (SNP) of the
FTO gene rs9939609 (A allele) is most commonly associated with obesity;13,15,19
however this relationship has not been replicated in an African population. Currently,
there are no published studies on the FTO gene and its association with obesity in HIV+
patients or in a population in Botswana.
Botswana is experiencing one of the worst epidemics of HIV, with a prevalence
rate of 23.4% among those who are 15 and 49 years of age.20 Botswana has the first
successfully implemented ART program in Africa and provides universal access to ART
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when CD4 cell counts reach < 350 cells/µL.21 Botswana, like other African countries, is
also experiencing a lifestyle transition that includes increasing rates of obesity.22-24
The aim of this preliminary study was to determine the interrelationships among
being overweight/obese, markers of genetic propensity for obesity (SNPs in FTO) and
HIV disease progression in HIV+ asymptomatic adults in Botswana not on ART over 18
months.
Methods
Study Design and Participants
We completed a retrospective study analyzing frozen laboratory specimens from
215 HIV-positive men and women from the placebo group of a multifactorial,
randomized, double-blinded, and placebo-controlled clinical trial in Botswana. 25 This
parent study originally included 219 participants in the placebo group, however only 215
participants had sufficient samples for laboratory analysis. The parent study
investigated whether supplementation with multivitamins and selenium can improve
immune function and prolong time to AIDS in ART naïve HIV infected adults.25 The
study was performed between December 2004 and July 2009. Confounding effects from
the micronutrient supplementation on the outcome measures were avoided by using the
participants from the placebo group for the current study. Participants were eligible for
the parent study with documentation of HIV seropositive test results, CD4 cell count >
350 cells/µL, BMI > 18 kg/m2 for women and > 18.5 kg/m2 for men, age ≥ 18 years, lack
of a past history of AIDS-defining conditions, lack of current participation in another
blinded clinical trial and still ineligible for receiving ART in Botswana during the study
period. Women were excluded if pregnant or had intention to become pregnant. All
participants provided informed consent and approval to use their stored blood for future
studies. Participants were recruited from the Botswana-Harvard AIDS Initiative
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Partnership (BHP) in Gaborone, Botswana. We obtained approval to use their stored
blood for genotyping SNPs from the FTO gene from the Florida International University
Institutional Review Board (IRB), the Harvard School of Public Health IRB, and the
Botswana Health Research Unit of the National Ministry of Health.
Clinical Data
At baseline and every three months, physical examination and medical history
were performed by a trained nurse or a physician. Anthropometrics were also obtained
and body mass index (BMI) was calculated by dividing the participants’ weight in kg by
their height in meters2.
Waist and hip circumference was measured using a non-stretchable tape
measure. Waist circumference was measured at the narrowest part of the waist
between the lowest rib and the iliac crest and the hip circumference at the widest portion
of the buttocks. Bioelectrical impedance analysis (BIA) was performed using the
Biodynamics body composition analyzer (model BIA-310; Biodynamics Corp., Seattle,
WA), which provides a print-out of measured impedance and calculated body fat and
lean mass. Subjects were measured fasting, without shoes and socks, and electrodes
were placed on the participant’s right hand and wrist and right foot and ankle. Medical
history included intercurrent health events and currently prescribed medications; a
review of records was used to verify prescriptions and determine changes in health
status. Morbidity information was collected by questionnaires at screening, and at every
monthly visit, and confirmed by documentation in the medical chart. Participants were
followed medically by the research physicians at the same facilities where the research
was conducted to improve compliance with study visits.
Twenty-four hour recalls were conducted at baseline and every 3 months by
trained clinical staff. Macronutrient and fiber intakes were calculated using the NutriBase
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Professional, V.9 (Cybersoft, Phoenix, AZ) program modified by the South Africa
database, including native foods for which information was available. An average of at
least 3 dietary recalls were used to obtain their estimated energy, carbohydrate, protein,
fat and fiber intakes. A questionnaire on activity patterns to obtain data on physical
activity was completed. Time spent walking was used a measure of physical activity.
Laboratory Data
At baseline and every six months, blood was also drawn to evaluate HIV viral
load, lipid panel, and blood chemistry. Every three months blood was drawn for CD4 and
CD8 cell counts. Lymphocyte phenotype was determined with a four-color
immunophenotyping panel of monoclonal antibodies. Differential counts were
determined using a Coulter MaxM hematology instrument and corroborated with
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).
Single Nucleotide Polymorphisms for the FTO gene
The Qiagen QIAamp DNA Blood kit was used to isolate total DNA from plasma
samples stored at -80° C. The DNA purification procedure was done using a standard
microcentrifuge and QIAamp Mini spin columns. A minimum of 200 µL of plasma was
used to isolate sufficient DNA for analysis.
Polymorphism for the SNPs rs9939609, rs1421085, rs8050136, rs17817449, and
rs1121980 of the FTO gene that have previously been associated with BMI were
genotyped by TaqMan allelic discrimination assays from Life Technologies Inc.
(Carlsbad, CA). Fluorescence was visualized through a real-time PCR system, Bio-Rad
CFX96 real-time PCR machine (Hercules, CA). Bio-Rad SsoFast Supermix was used
with the TaqMan assay. PCR amplification was completed using 10 µL volume. PCR
thermal cycling included enzyme activation at 95°C for 2 minutes, 49 cycles of
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denaturation at 95°C for 5 seconds and annealing and extension at 61°C for 5 seconds.
A random 10% of samples were re-genotyped to assess genotyping reproducibility.
Statistical Analysis
BMI was stratified into two groups: 1. normal weight (BMI=18.0-24.9 kg/m2) and
2. overweight/obese (BMI= ≥ 25 kg/m2). Laboratory markers of HIV infection and
disease progression included in the analyses were CD4 cell count, CD4%, CD8 cell
count, CD8%, CD4/CD8 ratio and HIV viral load. Descriptive statistics such as
frequencies, percentages, medians and interquartile ranges were used to characterize
the two stratified BMI groups at baseline and its relation to the FTO SNPs. KruskalWallis test was used to determine differences in body composition and HIV disease
progression markers between the FTO SNP alleles. Chi-square tests were used to
determine differences in gender, AIDS defining conditions, BMI groups and FTO SNPs.
Logistic regression was used to assess the associations between the BMI groups and
the presence of the FTO SNPs. Logistic regression was also used for the dominant
genetic risk model in which the subjects homozygous and heterozygous for the variant
allele were compared to the wild-type homozygous group for measures of body
composition and HIV disease progression. Proportional survival models were used to
compare hazard ratios on time to HIV disease progression outcomes between FTO
alleles, using the dominant model over 18 months. HIV disease progression outcomes
included time to ≥ 25% decline in CD4 cell count, CD4 cell count ≤ 250 and/or AIDS
defining conditions over 18 months. Models were adjusted for covariates that included
age, gender, tribes, baseline CD4, baseline HIV viral load, total dietary kcal intake, and
activity. For all analyses, a two sided test was used and P<0.05 was considered
statistically significant. Statistical analyses were completed using SPSS version 21.
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Results
Genotype Frequencies and Demographics
The genotype and allele frequencies of all SNPs are shown in Table 1. Overall,
99% of the samples were successfully genotyped. Ten percent of the samples were regenotyped with 96% concordance. All of the SNPs, except for rs1421085, were in
Hardy-Weinberg equilibrium, (P>.01). Further analysis with SNP rs1421085 was not
performed since the minor allele frequency was less than 5% in this sample and it was
not in Hardy-Weinberg equilibrium.
Baseline description of the study participants separated by BMI groups is
provided in Table 2. A total of 215 participants, 137 in the normal BMI group and 78 in
the overweight/obese BMI were included in the analysis, as four participants were
excluded for having missing data. The overweight/obese group was older (median
(IQR)) (35.00 (30.00-43.00)) than the normal BMI group (31.00 (28.00-38.00), P<.004)
and had a greater proportion of women (87.20% vs. 69.30, P<.001). There were no
statistically significant differences between these groups in laboratory markers of HIV
infection at baseline.
Association of FTO SNPs, Body Composition and Laboratory Markers of HIV
Infection
SNPs rs1121980, rs8050136, and rs9939609 genotypes were not associated
with measures of body composition and laboratory markers of HIV infection at baseline
(Tables 3-6). As shown in Table 6, the SNP rs17817449 had a marginal additive model
association with BMI (P=.088), fat mass (P=.088), and lean mass (P=.085) reflecting a
possible gene-dosage effect. Subjects with the GG genotype had higher BMI and fat
mass and lower lean mass compared to the other genotypes, albeit not statistically
significant.
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Regression analysis was completed using the dominant model for all SNPs for
examination of their relationships with measures of body composition and laboratory
markers of HIV infection (Tables 7-10). A significant relationship with rs8050136 was
seen with fat mass (OR=1.078; 95% CI= 1.021, 1.140; P=.007) and lean mass
(OR=.928; 95% CI= .878, .981; P=.008). SNP rs17817449 was the only SNP
associated with BMI (OR=1.082; 95%CI= 1.001, 1.169; P=.047). SNP rs17817449 was
also associated with fat mass (OR=1.086; 95% C=, 1.031, 1.145; P=.002) and lean
mass (OR=.921; 95% CI= .874, .971; P=.002). Similarly, rs1121980 had significant
relationships with fat mass (OR=1.065; 95% CI= 1.009, 1.125, P=.021) and lean mass
(OR=.939; 95% CI= .889, .991; P=.022).
Separate analyses were conducted by gender using logistic regression models to
examine relationships between FTO SNPs, body composition and laboratory markers of
HIV infection. In females, rs8050136 in the dominant model showed a statistically
significant association with fat mass (OR=1.102; 95% CI= 1.029, 1.179; P=.005) and
lean mass (OR=.909; 95% CI= .849, .973; P=.006). The SNP rs17817449 was also
significantly associated with fat mass (OR=1.099; 95% CI= 1.031, 1.171; P=.008) and
lean mass (OR=.911; 95% CI =.855, .971; P=.004). No other SNPs had significant
results for gender-specific associations.
Although none of the SNPs had significant findings using the dominant model
with laboratory markers of HIV infection, rs8050136 did have a trend relationship with
HIV viral load (OR=.705; 95% CI= .481, 1.035; P=.074), showing a protective effect. As
shown in Tables 12-15, the FTO SNPs were not associated with HIV disease
progression outcomes of 25% decline in CD4, CD4 ≤ 250 cells/µL and/or AIDS defining
conditions over 18 months using Cox proportional hazard models.
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Discussion
This study provides preliminary data on the influence of FTO variants on the risk
of being overweight/obese in HIV+ adults in Botswana. No significant associations were
found with the SNP variants and waist or waist-to-hip ratio. The variant rs17817449
showed a trend towards higher BMI with the risk allele (GG) compared with the non-risk
allele (TT). This variant also had a significant association with BMI, showing a greater
odds of having higher BMI when the risk allele is present, after controlling for age,
gender, tribe, total kcal intake and activity. In a study conducted in South African
adolescents, rs17817449 was also associated with BMI after adjusting for age, gender
and pubertal stage.26 They showed a 1.9% effect size increase in BMI for each risk
allele. The relationship between measures of obesity and FTO variants has been
contradictory among indigenous African populations. In West Africans,27 several SNPs
were associated with BMI, waist circumference and percent fat mass; however, no
association was found with rs9939609, which is the most replicated SNP in the literature.
A replication study completed with lean Gambian adults did not show any associations
between 16 FTO SNPs and measures of body mass, but phenotypic comparisons of
obesity could not be evaluated since participants that were obese were not part of the
study.28
Fat mass and lean mass were associated with rs1121980, rs8050136, and
rs17817449 with the risk alleles having a higher percentage of fat mass and lower lean
body mass compared to homozygosity for the non-risk allele. Adeyemo et al.27 also
investigated percent body fat in West Africans and showed significant relationships with
FTO SNPs; however, the investigators did not report significant findings with any of the
SNPs included in our study. Although the exact mechanism for the effect of FTO on
weight is unknown, it is hypothesized that it may affect food intake and energy
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expenditure.29 FTO is highly expressed in the hypothalamus region of the brain, where
food intake is controlled.16 In several studies, rs9939609 was shown to be associated
with higher food intake in children and adults.30-33 Greater levels of FTO mRNA have
also been found in the adipose tissue of obese persons.34-35 Although, FTO may regulate
adiposity, factors that influence mobilization of adipose tissue such as leptin, have not
been consistently demonstrated.
This is the first study that examined FTO SNPs in HIV+ adults in Africa.
Botswana is known to be a heterogeneous population with many ethnic groups.36 All of
the SNPs were in Hardy Weinberg equilibrium, except for rs1421085, which also had a
minor allele frequency of less than 5% in this sample. The SNP rs1421085 was
excluded from the analyses; however, similar genotype frequencies for this SNP were
also seen in the reference population of the Yoruba tribe from Africa.37 The
heterogeneity present in this population may also be a limitation for this study.
Studies have shown that obesity may be protective of further HIV disease
progression.4,38 We showed in this same cohort that higher fat mass was associated with
a decreased risk of AIDS defining conditions and CD4 cell count <250 cells/µL
(unpublished data). This protection provided by fat may be explained partially through
its association with leptin, an adipokine secreted by adipose tissue. Higher fat mass is
associated with higher levels of leptin, which has been shown to be associated with
proliferation and reduced apoptosis of immune cells such as CD4+ T-cells.41,42 In the
current analysis, we did not find any significant effects of FTO variants on laboratory
markers of HIV infection and disease progression over time. However, our findings
suggest that FTO SNPs may indirectly influence HIV disease progression through their
effect on fat mass before ART initiation.
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Based on our analyses, further studies should include a larger sample size to be
able to examine the associations with the SNPs of the FTO gene, BMI and HIV disease
progression with greater statistical power. A larger sample size would have allowed for
the examination of the relationship of the FTO variants and body mass in further
stratified subgroups of overweight and obese separately. Including other candidate
SNPs of the FTO gene would also provide a better understanding of the role of the
variants in the FTO gene on BMI or obesity in this population. Controlling for other
variable that might affect BMI such as medications, time of HIV diagnosis, and comorbidities may also provide a better grasp on the effect of the gene on the phenotypic
outcomes.
The FTO still remains the gene most consistently associated with obesity in
various populations,43 but its associations have not been replicated in many African
populations. GWAS studies in African populations are lacking, and identifying SNPs that
are relevant to this population is of importance since the SNPs showing associations in
European and Asian populations may be different from SNPs that will show associations
in African populations. In this study, the SNPs chosen were based on those most
associated with BMI in the literature; however, only rs17817449 had a significant
relationships with BMI. Significant associations were seen with percent body fat mass
and lean mass which have been essential factors in HIV disease progression.44,45 A
recent publication by Monda et al.46 identified new loci within the FTO gene that was
associated with BMI in individuals of African ancestry; however, the authors concluded
that SNPs were not likely to contribute to population differences in obesity, highlighting
the importance of further studies.
This preliminary study did have limitations which may affect the interpretation of
our findings. Our study only included 215 participants and may not have had sufficient
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statistical power, as genetic association studies usually require a large number of
participants. This study was retrospective in design. No underweight participants were
included in the parent study and only a few cases of morbid obesity were present, which
did not allow for the full spectrum of BMI to be examined and lowered the statistical
power. The findings of this study are pertinent to this specific population and not
generalizable to all African populations.
In summary, our data indicate that FTO SNPs may contribute to the variation in
body fat mass and lean mass in adults in Botswana. FTO SNPs were not directly
associated with a protective effect on HIV disease progression. Additional loci within the
FTO gene should be examined in African populations to enhance our comprehension of
their influence on obesity and its benefits and risk factors.
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Table 1: FTO SNP Allele and Genotype Frequencies in HIV+ Adults in Botswana

Major
allele

Minor
allele

Genotype
frequencies

dbSNP ID

(A)

(B)

(AA)

(AB)

(BB)

Major

Minor

rs1121980

T

C

0.241

0.474

0.274

0.516

0.484

rs1421085

T

C

0.917

0.056

0.019

0.953

0.047

rs8050136

A

C

0.239

0.452

0.300

0.530

0.470

rs9939609

A

T

0.247

0.493

0.252

0.502

0.498

rs17817449

T

G

0.366

0.412

0.213

0.577

0.423
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Allele frequencies

Table 2: Demographic Characteristics by BMI Group (N=215)
Variable
Age (years)
Gender a
Male
Female
Waist (inches)
Waist-to-hip ratio
Lean mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4 %
CD8 cell count (cells/µL)

Normal BMI
(N=137)
31.00 (28.00-38.00)

Overweight/
Obese BMI (N=78)
35.00 (30.00-43.00)

Pvalue
.004b

42 (30.70)
95 (69.30)
30.71 (29.13-32.28)
.80 (.78-.85)
74.90 (70.40-80.00)
25.10 (20.00-25.10)
415.87 (324.02546.99)
27.02 (20.19-31.19)
797.05 (588.471225.48)
52.24 (44.18-58.29)
.54 (.37-.67)
4.33 (3.60-4.82)

10 (12.80)
68 (87.20)
37.64 (34.84-39.27)
.85 (.79-.88)
65.10 (62.10-67.50)
34.90 (32.50-37.90)
401.10 (331.24545.24)
23.66 (18.88-30.07)
891.36 (669.201177.81)
49.92 (43.40-59.28)
.49 (.32-.71)
4.22 (3.30-4.82)

.003b
<.001b
<.013b
<.001b
<.001b
.935
.151

CD8 %
.228
CD4/CD8 Ratio
.624
HIV viral load (Log10
.586
copies/mL)
a
Reported as n (%); all other variables reported as median (interquartile range)
b
Statistically significant, P<.05
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Table 3: FTO rs1121980: Association with Body Composition and Measures of HIV Disease Progression
Variable
Age (years)
BMI (kg/m2)
Waist (inches)
Waist-to-hip ratio
Lean mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4%
CD8 cell count (cells/µL)
CD8%
CD4/CD8 ratio
HIV viral load (log10
copies/mL)

TT

TC

CC

33 (29-39)
21.60 (28.83-25.95)
31.10 (29.53-34.65)
.84 (.78-.88)
72.25 (65.65-77.28)
27.75 (22.73-34.35)
409.03 (329.59-566.49)
25.19 (19.32-31.58)
905.58 (650.25-1297.91)
52.45 (44.11-60.19)
.51 (.33-.65)
4.11 (3.28-4.92)

33 (28-39)
23.60 (20.48-27.70)
33.27 (29.92-37.30)
.80 (.79-.85)
70.25 (64.28-75.90)
29.45 (24.10-35.73)
413.58 (324.17-544.17)
25.68 (16.69-30.56)
839.66 (619.65-1159.03)
51.14 (42.80-58.55)
.53 (.34-.72)
4.34 (3.42-4.81)

32 (28-42)
22.60 (20.70-26.60)
32.28 (29.92-35.04)
.82 (.78-.88)
71.10 (65.48-76.03)
28.90 (23.98-33.53)
417.66 (325.80-560.00)
26.45 (19.58-30.61)
789.35 (604.56-1110.60)
50.88 (43.50-58.54)
.51 (.36-.64)
4.37 (3.71-4.82)
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Pvalue
.829
.614
.425
.146
.273
.278
.901
.967
.627
.769
.886
.507

Table 4: FTO rs8050136: Association with Body Composition and Measures of HIV Disease Progression
Variable
Age (years)
BMI (kg/m2)
Waist (inches)
Waist-to-hip ratio
Lean mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4%
CD8 cell count (cells/µL)
CD8%
CD4/CD8 ratio
HIV viral load (log10
copies/mL)

AA

AC

CC

34 (29-39)
23.10 (21.30-27.10)
32.09 (29.92-36.81)
.84 (.79-.84)
71.40 (66.88-75.55)
28.60 (24.45-33.13)
407.53 (325.55-580.64)
26.35 (19.60-31.95)
845.60 (586.65-1249.86)
52.28 (42.66-57.92)
.54 (.36-.71)
4.13 (3.63-4.71)

32 (28-39)
23.65 (20.35-27.33)
33.46 (30.12-36.32)
.81 (.79-.85)
70.05 (64.95-75.88)
29.95 (24.13-35.05)
403.33 (318.04-532.34)
27.36 (19.58-30.56)
773.38 (597.30-1120.43)
48.59 (42.96-58.55)
.56 (.34-.69)
4.34 (3.23-4.90)

32 (28-43)
22.4 (20.45-25.95)
32.28 (29.52-34.45)
.82 (.78-.88)
71.70 (67.50-79.85)
28.30 (20.15-32.50)
415.87 (343.72-545.17)
24.80 (19.74-30.24)
960.91 (667.27-1249.21)
53.54 (46.33-59.40)
.44 (.35-.63)
4.35 (3.67-4.78)
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Pvalue
.343
.641
.272
.396
.162
.159
.533
.794
.280
.217
.474
.577

Table 5: FTO rs9939609: Association with BMI, Body Composition and Measures of HIV Disease Progression
Variable
Age (years)
BMI (kg/m2)
Waist (inches)
Waist-to-hip ratio
Lean mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4%
CD8 cell count (cells/µL)
CD8%
CD4/CD8 ratio
HIV viral load (log10
copies/mL)

AA

AT

TT

31 (28-43)
22.25 (20.05-25.08)
32.28 (29.53-34.25)
.82 (.79-.88)
71.70 (67.50-79.70)
28.30 (20.30-32.50)
414.54 (342.38-537.99)
25.21 (19.20-28.68)
933.94 (613.96-1296.52)
54.01 (47.92-60.58)
.48 (.34-.60)
4.39 (3.68-4.80)

33 (28-39)
24.20 (20.83-27.80)
33.27 (29.92-37.30)
.81 (.78-.87)
70.55 (65.65-75.90)
29.45 (24.10-34.35)
421.13 (319.79-550.40)
27.19 (19.52-31.78)
838.63 (629.54-1171.28)
48.76 (43.91-59.09)
.56 (.33-.71)
4.34 (3.41-4.92)

34 (29-40)
22.80 (21.25-26.60)
31.99 (29.92-35.91)
.83 (.78-.88)
70.40 (65.25-76.00)
29.60 (24.00-34.75)
397.88 (324.59-537.28)
26.42 (19.65-31.50)
813.47 (586.34-1117.45)
52.57 (42.49-56.23)
.50 (.36-.71)
4.19 (3.35-4.74)
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Pvalue
.656
.105
.266
.478
.507
.500
.908
.516
.532
.187
.349
.605

Table 6: FTO rs17817449: Association with Body Composition and Measures of HIV Disease Progression
Variable
Age (years)
BMI (kg/m2)
Waist (inches)
Waist-to-hip ratio
Lean mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4%
CD8 cell count (cells/µL)
CD8%
CD4/CD8 ratio
HIV viral load (log10
copies/mL)

TT

GT

GG

31 (28-40)
22.20 (20.43-25.83)
31.69 (29.53-34.65)
.82 (.78-.88)
73.60 (66.38-80.00)
26.40 (20.00-33.63)
407.04 (323.34-532.84)
25.29 (18.92-30.09)
866.85 (616.07-1115.62)
52.33 (46.42-58.45)
.49 (.34-.62)
4.38 (3.66-4.81)

33 (28-39)
23.60 (20.25-27.38)
33.27 (29.92-36.37)
.80 (.79-.87)
70.30 (65.40-76.40)
29.70 (23.60-34.60)
442.65 (334.44-558.80)
26.59 (19.73-30.88)
839.66 (623.67-1263.82)
51.28 (42.57-59.50)
.55 (.34-.68)
4.35 (3.41-4.950

35 (29-39)
23.95 (21.58-27.85)
32.29 (30.09-34.93)
.82 (.77-.88)
68.75 (65.08-73.70)
31.25 (26.30-34.93)
397.94 (330.16-513.81)
25.93 (19.60-31.88)
783.42 (584.47-1150.51)
51.18 (43.37-56.76)
.55 (.36-.72)
4.10 (3.46-4.65)
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Pvalue
.343
.088
.222
.808
.085
.088
.517
.640
.628
.447
.432
.360

Table 7: Association of FTO rs1121980 with Body Composition and HIV disease
Progression in a Dominant Model*
Variable
ORa
95% CIb
P-value
BMI groups**
1.549
.754, 3.182
.234
BMI (kg/m2)
1.057
.974, 1.147
.183
Waist (inches)
1.049
.951, 1.157
.338
Waist-to-hip ratio
.144
.001, 134.902
.574
Lean mass (%)
.939
.889, .991
.022c
Fat mass (%)
1.065
1.009, 1.125
.021c
CD4 cell count (cells/µL)
1.001
.999, 1.003
.492
CD4%
1.006
.963, 1.050
.804
CD8 cell count (cells/µL)
1.001
.999, 1.001
.397
CD8%
.993
.963, 1.023
.625
CD4/CD8 ratio
1.443
.463, 4.495
.527
HIV viral load (log10 copies/mL)
.736
.498, 1.087
.124
**Dominant model: homozygous and heterozygous for the variant were compared to the
wild-type homozygous. Models adjusted for age, gender, tribes, total kcal dietary intake
and activity
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2
a
OR=Odds Ratio
b
CI=Confidence Intervals
c
Statistically significant, P < .05
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Table 8: Association of FTO rs8050136 with Body Composition and HIV disease
Progression in a Dominant Model*
Variable
ORa
95% CIb
P-value
BMI groups**
1.584
.776, 3.231
.207
BMI (kg/m2)a
1.071
.988, 1.162
.097
a
Waist (inches)
1.084
.980, 1.199
.117
Waist-to-hip ratio
1.641
.002, 1142.635
.882
Lean mass (%)
.928
.878, .981
.008c
Fat mass (%)
1.078
1.021, 1.140
.007c
CD4 cell count (cells/µL)
1.001
.998, 1.002
.825
CD4%
1.013
.972, 1.057
.534
CD8 cell count (cells/µL)
1.001
.999, 1.001
.390
CD8%
.981
.952, 1.010
.190
CD4/CD8 ratio
1.347
.473, 3.835
.577
HIV viral load (log10 copies/mL)
.705
.481, 1.035
.074
**Dominant model: homozygous and heterozygous for the variant were compared to the
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal, and
activity
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2
a
OR=Odds Ratio
b
CI=Confidence Intervals
c
Statistically significant, P < .05
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Table 9: Association of FTO rs9939609 with Body Composition and HIV disease
Progression in a Dominant Model*
Variable
ORa
95% CIb
P-value
BMI groups**
.956
.455, 2.007
.904
BMI (kg/m2)
.991
.918, 1.070
.818
Waist (inches)
1.501
.056, 39.884
.808
Waist-to-hip ratio
1.018
.926, 1.118
.716
Lean mass (%)
1.029
.975, 1.087
.294
Fat mass (%)
.971
.920, 1.025
.290
CD4 cell count (cells/µL)
1.001
.998, 1.002
.868
CD4%
.982
.940, 1.026
.424
CD8 cell count (cells/µL)
1.001
1.000, 1.001
.159
CD8%
1.013
.983, 1.043
.405
CD4/CD8 ratio
.861
.310, 2.394
.774
HIV viral load (log10 copies/mL)
1.204
.811, 1.788
.357
**Dominant model: homozygous and heterozygous for the variant were compared to the
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal and
activity
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2
a
OR=Odds Ratio
b
CI=Confidence Intervals
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Table 10: Association of FTO rs17817449 with Body Composition and HIV disease
Progression in a Dominant Model*
Variable
ORa
95% CIb
P-value
BMI groups**
1.732
.885, 3.388
.109
BMI (kg/m2)
1.082
1.001, 1.169
.047c
Waist (inches)
1.093
.954, 1.203
.067
Waist-to-hip ratio
.132
.000, 59.237
.516
Lean mass (%)
.921
.874, .971
.002c
Fat mass (%)
1.086
1.031, 1.145
.002c
CD4 cell count (cells/µL)
1.002
1.001, 1.004
.136
CD4%
1.013
.979, 1.060
.360
CD8 cell count (cells/µL)
1.001
.999, 1.001
.862
CD8%
.986
.959, 1.013
.290
CD4/CD8 ratio
1.500
.552, 4.076
.426
HIV viral load (log10 copies/mL)
.781
.550, 1.111
.169
*Dominant model: homozygous and heterozygous for the variant were compared to the
wild-type homozygous. Models adjusted for age, gender, tribes, total dietary kcal and
activity
**BMI groups: 0=BMI 18.0-24.9 kg/m2 and 1=BMI ≥ 25 kg/m2
a
OR=Odds Ratio
b
CI=Confidence Intervals
c
Statistically significant, P < .05
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Table 11: Adjusted Hazard Ratios on the Effect of rs1121980 Using the Dominant Model
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up
Period of 18 Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
1.326
.837, 2.100
.230
CD4 cell count ≤ 250/μL
1.875
.544, 6.469
.320
AIDS Defining Conditions**
1.536
.165, 14.264
.706
CD4 cell count ≤ 250/μL & AIDS
1.203
.416, 3.475
.733
Defining Conditions
*Cox proportional hazards model were used to examine the effect of rs1121980 on
individual HIV disease progression outcomes. Dominant model used for rs1121980:
homozygous and heterozygous for the variant were compared to the wild-type
homozygous. All individual HIV disease progression outcomes were analyzed as
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral
load, total dietary kcal, and activity.
**
Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total
dietary kcal and activity
a
Statistically significant, P<.05
b
HR=Hazard Ratio
c
CI=Confidence Interval
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Table 12: Adjusted Hazard Ratios on the Effect of rs8050136 Using the Dominant Model
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up
Period of 18 Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
.946
.610, 1.468
.805
CD4 cell count ≤ 250/μL
1.269
.394, 4.082
.690
AIDS Defining Conditions**
.279
.042, 1.854
.187
CD4 cell count ≤ 250/μL & AIDS
.842
.303, 2.339
.742
Defining Conditions
*Cox proportional hazards model were used to examine the effect of rs8050136 on
individual HIV disease progression outcomes. Dominant model used for rs8050136:
homozygous and heterozygous for the variant were compared to the wild-type
homozygous. All individual HIV disease progression outcomes were analyzed as
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral
load, total dietary kcal, and activity.
**
Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total
dietary kcal, and activity
a
Statistically significant, P<.05
b
HR=Hazard Ratio
c
CI=Confidence Interval
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Table 13: Adjusted Hazard Ratios on the Effect of rs9939609 Using the Dominant Model
on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a Follow-up
Period of 18 Months*
Outcome
HRb
95% CIc
P-value
≥ 25% decline in CD4 cell count
1.039
.631, 1.709
.881
CD4 cell count ≤ 250/μL
1.141
.350, 3.712
.827
AIDS Defining Conditions**
CD4 cell count ≤ 250/μL & AIDS
1.399
.443, 4.412
.567
Defining Conditions
*Cox proportional hazards model were used to examine the effect of rs9939609 on
individual HIV disease progression outcomes. Dominant model used for rs9939609:
homozygous and heterozygous for the variant were compared to the wild-type
homozygous. All individual HIV disease progression outcomes were analyzed as
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral
load, total dietary kcal, and activity.
**
Model did not converge all AIDS defining conditions occurring in group with risk alleles
a
Statistically significant, P<.05
b
HR=Hazard Ratio
c
CI=Confidence Interval
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Table 14: Adjusted Hazard Ratios on the Effect of rs17817449 Using the Dominant
Model on HIV Disease Progression Outcomes in HIV+ Adults in Botswana During a
Follow-up Period of 18 Months*
Outcome
HRb
95% CIc
P-value
≥25% decline in CD4 cell count
.977
.641, 1.489
.913
CD4 cell count ≤ 250/μL
1.517
.520, 4.421
.445
AIDS Defining Conditions**
.387
.060, 2.490
.317
CD4 cell count ≤ 250/μL & AIDS
1.205
.468, 3.101
.700
Defining Conditions
*Cox proportional hazards model were used to examine the effect of rs17817449 on
individual HIV disease progression outcomes. Dominant model used for rs17817449:
homozygous and heterozygous for the variant were compared to the wild-type
homozygous. All individual HIV disease progression outcomes were analyzed as
separate models and adjusted for age, gender, tribe, baseline CD4 count, baseline viral
load, total dietary kcal, and activity.
**
Models adjusted for age, gender and baseline CD4 cell count, baseline viral load, total
dietary kcal, and activity
a
Statistically significant, P<.05
b
HR=Hazard Ratio
c
CI=Confidence Interval
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CHAPTER V: ASSOCIATION OF INFLAMMATORY MARKERS WITH HIV DISEASE
PROGRESSION IN ART NAÏVE HIV+ ADULTS IN BOTSWANA

Abstract
Objective: This study evaluated the relationship between inflammatory markers
including C-reactive protein, leptin, and bacterial endotoxin lipopolysaccharide (LPS) and
body composition and HIV disease progression in HIV+ asymptomatic adults not on ART
in Botswana over 18 months.
Methods: This is a retrospective analysis of data and specimens from a nutritional
study, henceforth called parent study. Current study was conducted in 144 HIV+ ART
naïve adults who were in the early stages of HIV disease in Botswana. CRP was
measured by the parent study and plasma leptin and LPS were determined in a subset
of 60 participants at baseline and 18 months. Linear and logistic multivariable
regression analyses were conducted and adjusted for age, gender, smoking and body
fat mass%.
Results: CRP was positively associated with BMI and waist circumference and
inversely with CD4%. Leptin had significant relationships with BMI, fat mass%, and
waist circumference. Higher HIV viral load was significantly associated with lower levels
of leptin. LPS was inversely associated with BMI and fat mass%. Higher levels of LPS
were also associated with higher viral load.
Conclusions: HIV disease progression was predictive of inflammation and found to be
independent of body fat. These findings suggest that at least one explanation for the
obesity paradox may be accounted for by increased LPS and lower leptin among those
with lower BMI which was associated with higher HIV viral load. The mechanisms
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affecting HIV disease progression through inflammation are complex and still not entirely
understood, which warrants further prospective investigation.

Keywords: HIV infection, ART naïve, disease progression, CRP, leptin, LPS,
inflammation
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Introduction
Chronic inflammation and immune activation are related to HIV disease
progression as documented in the literature.1-3 Inflammation is also associated with other
HIV co-morbidities and non-HIV related complications such as cardiovascular and
metabolically-related diseases/conditions.4-6 Inflammation is involved in the depletion of
T-cells, and chronic immune activation drives the general and HIV-specific losses of
immune function.7 Continuous inflammation induces pro-inflammatory cytokines which
has been shown to produce thymic and T cell progenitor dysfunction.8 It has also been
shown that triggered or activated CD4 cells are favored targets for viral infection and
replication. Inflammation can also set up non-infected CD4 cells and other immune cells
for death by programmed cell death or apoptosis.9 The biomarkers of inflammation
examined in this study were C-reactive protein, leptin, and lipopolysaccharide (LPS).
Obesity is known to be associated with a chronic state of low grade inflammation.
Inflammation in obesity is due to many mechanisms which include disordered secretion
of adipokines within adipose tissue, resulting in insulin resistance and metabolic
disorders.10 There seems to be controversy in the literature regarding obesity and
inflammation and its relationship to HIV disease, which requires further research. A
nutrition transition in sub-Saharan Africa is occurring with an increase in obesity,11 along
with being the most affected region by the HIV epidemic.12 The interplay of body
composition, inflammation and its effect on HIV disease progression warrant
investigation to provide relevant clinical treatment for patients.
C-reactive protein or CRP is considered a sensitive systemic marker of
inflammation and an acute phase reactant.13 Higher levels of CRP have also been
associated with obesity and specifically abdominal obesity.14 CRP > 3 mg/dL has been
associated with a higher risk for inflammation and mortality.15 In HIV, CRP has been
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shown to be a sensitive marker beyond cardiovascular disease;16 it has been
demonstrated to be an important predictor of higher risk of AIDS and mortality after ART
initiation in ART naïve patients.17
Leptin is considered to be a pleiotropic molecule, with not only metabolic roles
but also endocrine and immune regulation.18 In some studies, higher levels of leptin
were found to be present during infection and inflammation; however, the results in
human studies have been inconsistent in various diseases, including HIV.18 Leptin is
involved in the proliferation of T- cells, including CD4 and CD8 cells.19 Higher levels of
leptin have been found in obese individuals20 which may enhance the immunity through
its role in proliferation and anti-apoptotic effects on lymphocytes. Leptin has been
inversely associated with HIV viral load, independent of adipose tissue.21
Microbial translocation or bacterial products that crossed the gastrointestinal
mucosa into circulation, is thought to have a role in persistent immune activation in HIV
infection and can provoke pro-inflammatory reactions.22 Lipopolysacchride (LPS), an
endotoxin, is a constituent of Gram-negative bacterial cell walls and known to produce
proinflammatory responses.23 During HIV, microbial translocations may occur due to
epithelial damage to the intestine, loss of T-helper-17 cells and a reduced removal of
microbial products by phagocytes.22 Increased secretion of pro-inflammatory cytokines
can also contribute to increased T cell activation and specifically can increase CD8 T cell
activation and depletion of CD4 T cells.22 LPS has also been implicated in obesity and
insulin resistance and high levels may affect inflammation and promote weight gain.25
Although microbial translocation is associated with immune activation and disease
progression in developed countries,26-28 whether it contributes to HIV disease
progression in African HIV+ individuals is not well understood. Sequestration of LPS by
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higher circulating lipoproteins in obesity has been suggested as mechanism for the
obesity paradox29 and warrants further investigation in HIV.
Most of the studies looking at the relationship between inflammation and HIV
have been conducted in settings where patients are taking ART, and mostly in
developed nations. Both of these conditions may confound findings. Few longitudinal
studies are available in African populations. The objective of this study was to evaluate
over 18 months the relationship of inflammatory markers (C-reactive protein, leptin, and
LPS) with body composition and laboratory markers of HIV disease infection and
progression in HIV+ asymptomatic adults who are not receiving ART in Botswana.
Methods
Study Design and Participants
A retrospective study was conducted to examine data and specimens from 144
HIV-positive men (n=34) and women (n=110) from the placebo group of a multifactorial,
randomized, double-blinded, placebo-controlled clinical trial in Botswana, which
investigated whether supplementation with multivitamins and selenium could enhance
immune function and delay the time to AIDS in ART naïve HIV+ adults.30 The study was
conducted between December 2004 and July 2009. This parent study originally
included 219 participants in the placebo group, however our retrospective study only
included 144 participants with available data on high sensitivity C-reactive protein (hsCRP). The placebo group was used to avoid any confounding effects from the
micronutrient supplementation on the outcome measures. Participants were eligible for
the study with confirmation of HIV status, CD4 cell count >350 cells/µL, BMI >18 kg/m2
for women and 18.5 kg/m2 for men, age ≥ 18 years, lack of a past history of AIDSdefining conditions, and were not participating in another blinded clinical trial or taking
ART. Women were excluded if pregnant or had intention to become pregnant. All
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participants provided informed consent and approval to use their stored blood for future
studies. Participants were recruited from the Botswana-Harvard AIDS Initiative
Partnership (BHP) in Gaborone, Botswana. We obtained approval to use their stored
blood for leptin and LPS from the Florida International University Institutional Review
Board (IRB), the Harvard School of Public Health IRB and the Botswana Health
Research Unit of the National Ministry of Health.
Clinical Data
At baseline and every three months, physical examination and medical history
were performed by a trained nurse or a physician. Anthropometrics were also obtained
and body mass index (BMI) was calculated by dividing the participants’ weight in kg by
their height in meters2. Waist and hip circumference was measured using a nonstretchable tape measure and following standardized procedures. Waist circumference
was measured at the narrowest part of the waist between the lowest rib and the iliac
crest and the hip circumference at the widest portion of the buttocks. Bioelectrical
impedance analysis (BIA) was measured using the Biodynamics body composition
analyzer (model BIA-310; Biodynamics Corp., Seattle, WA), which provides a print-out of
measured impedance and calculated body fat and lean mass. Subjects were measured
without shoes and socks, and electrodes were placed on the participant’s right hand and
wrist and right foot and ankle. Morbidity information was collected by questionnaires at
screening, and at every monthly visit, and confirmed by documentation in the medical
chart. Participants received their medical care in the same facilities to improve retention.
Laboratory Data
At baseline and every six months, blood was also drawn to evaluate HIV viral
load, lipid panel, and blood chemistry. Every three months blood was drawn for CD4 and
CD8 cell counts. The remaining plasma was centrifuged, aliquoted into cryovials and
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stored at -80° C for future studies. Lymphocyte phenotype was determined with a fourcolor immunophenotyping panel of monoclonal antibodies. Differential counts were
determined using a Coulter MaxM hematology instrument and corroborated with
cytocentrifuge smears. HIV-viral load was determined using an in-vitro nucleic acid
amplification test (Amplicor reagents and protocol, Roche-Diagnostics, Branchburg, NJ).
Inflammatory Markers
A total of 144 participants had high sensitivity-C reactive protein (hs-CRP) levels
from the parent study that was analyzed using protein-latex assay (Roche, Basel,
Switzerland) in the Botswana-Harvard HIV Reference Laboratory in Gaborone,
Botswana. A subset of 60 participants were randomly selected with available samples to
measure plasma leptin and LPS levels at baseline and 18 months. Plasma leptin levels
were measured using the Quantikine Human Leptin Immunoassay kit by R&D systems
(Minneapolis, MN, USA), a sandwich ELISA designed to measure soluble human leptin
in plasma, according to manufacturer’s instructions. Plasma LPS or endotoxin levels
were measured using the Limulus Amebocyte Lysate (LAL) by Lonza (Walksersville,
MD, USA), a chromogenic quantitation of bacterial endotoxin, according to
manufacturer’s instructions with the following modifications: Samples were diluted 1:20
with endotoxin-free water to avoid interference with background color and preheated to
70°C for 10 minutes prior to analyses to inactivate plasma proteins. Duplicates were
assessed for each sample, for both leptin and LPS. The coefficient of variation or CV%
was calculated and CVs greater than 10% were reanalyzed.
Statistical Analysis
Laboratory markers of HIV infection and disease progression included in the
analyses were CD4 cell count, CD4%, CD8 cell count, CD8%, CD4/CD8 ratio and HIV
viral load. Descriptive statistics such as frequencies, percentages, medians and
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interquartile ranges were used to characterize the participants at baseline and its relation
between laboratory markers of HIV infection and inflammatory markers. Mann Whitney
U was used to determine differences in laboratory markers of HIV infection and body
composition between the BMI groups and by inflammatory marker groups. BMI was
stratified into two groups: Group 1: normal weight (BMI=18.0-24.9 kg/m2) and Group 2:
overweight/obese (BMI=≥ 25 kg/m2) for the statistical analyses. Viral load was also
stratified into <4 log10 copies/mL or 10,000 copies/mL and ≥ 4 log10 copies/mL as a
measure of further disease progression and infectivity.31, 32 Linear and logistic
regressions were used to assess the relationship between body composition, laboratory
markers of HIV infection, and inflammatory markers. The linear multivariable regression
analysis also included a measure to check for multicollinearity known as variance
inflation factor (VIF). All models had a VIF <5, therefore multicollinearity was ruled out.
Multicollinearity was also checked for the logistic regression models and variables with
correlations r >.75 were not included. Models were adjusted for covariates that included
age, gender, smoking and fat mass%. Logistic regression models included dependent
inflammatory markers at the following cut-offs: hs-CRP < or ≥ 3mg/L; leptin< or ≥ median
and LPS < or ≥ median. Smoking tobacco was used a covariate since it has
immunomodulatory effects and may affect T-cell activation.33,34 Variables that were not
normally distributed were natural log transformed, except for CD4 and CD8 cell counts
that were square-root transformed. For all analyses, a two sided test was used and
P<0.05 was considered statistically significant. Statistical analyses was completed using
SPSS version 21.
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Results
Demographics
Table 1 displays the demographics of the population included for the analyses
conducted below. In summary, the median age was 33 years with an IQR of 29-39
years and 76.40% were women. The median CD4 cell count and HIV viral load were
409.03 (IQR: 329.79-552.58) and 4.33 (IQR:3.58-4.83), respectively. The inter-assay
CV for Leptin was 7.45 and for LPS 4.38%. The intra-assay CV for leptin ranged
between 6.76-8.69% and for LPS between 2.41-5.87%.
Spearman Correlations
A positive correlation was seen between hs-CRP and leptin (r=.404, P=.010)
(Table 2). Leptin was also correlated with LPS (r=.357, P=.005). There was no
significant correlation between hs-CRP and LPS. Hs-CRP was not correlated with
measures of body composition and HIV disease progression. However, trends were
seen between hs-CRP and BMI, waist circumference, lean body mass and fat mass.
Strong positive correlations were observed between leptin and BMI (r=.734, P<.001),
waist circumference (r=.603, p<.001) and fat mass % (r=.838, P<.001). LPS was
inversely correlated with BMI (r=.288, P=.025), waist circumference (r=.493, P=.003) and
fat mass % (r=.362, P=.004). Lean mass % was inversely correlated with leptin (r=.836, P<.001) and LPS (r=-.361, P=.005). No correlations were observed between
inflammatory markers and laboratory markers of HIV infection. The correlations
between LPS and CD8% and viral load were approaching significance at r=.253, P=.052
and r=.246, P=.060, respectively.
Relationship between BMI and Inflammatory Markers
BMI was categorized into two groups: normal BMI (18.0-24.9 kg/m2) and
overweight/obese BMI (≥ 25 kg/m2) and its association with inflammatory markers were
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examined. Those who were overweight/obese had higher median (IQR) levels of hsCRP (P=.028) and leptin (P<.001) compared to the normal BMI group, (Table 3).
Conversely, lower levels of LPS were seen in the overweight/obese group compared to
the normal BMI group (P=.001).
Inflammatory Markers, Body Composition and Laboratory Markers of HIV Infection
Table 4 demonstrates that having a CRP at or above 3 mg/L is associated with
higher median (IQR) of waist circumference (P=.036), and CD8 cell count (P=.030) and
lower levels of CD4% (P=.013), and CD4/CD8 ratio (P=.015). A trend was observed in
the relationship of having a hs-CRP ≥ 3 mg/L and higher CD8% (P=.078). As shown on
Table 5, those who had higher median levels of leptin (≥ 13,304 pg/mL) had higher
median (IQR) BMI (P<.001), waist circumference (P=.003), and fat mass (P<.001).
Levels below the median of leptin, were associated with higher lean body mass
(P<.001). None of the parameters for HIV disease progression were significantly
associated with median levels of leptin. Having LPS levels below the median (<.0582
EU/mL) were significantly related to higher BMI (P=.001), waist circumference (P=.005),
and fat mass% (P=.002) (Table 6). Levels above the median were associated with
higher viral load (P=.023) and lean body mass % (P=.002).
Regression Analyses of Inflammatory Markers and Laboratory Markers of HIV
Infection and Disease Progression
Linear regression models were conducted to examine the relationship of body
composition and HIV disease progression markers with hs-CRP, leptin, and LPS at
baseline, 18 months and the change over 18 months. All models were adjusted for age,
gender, smoking and fat mass%. Log transformed BMI at baseline was the only
measure of body composition associated with continuous hs-CRP at baseline (β=1.905;
95% CI= .281, 3.530; P=.022) (Table 7). No markers of HIV infection were associated
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with continuous hs-CRP at baseline or 18 months. Log transformed leptin was
associated with continuous BMI at baseline (β=1.764; 95% CI= .788, 2.739; P=.022) and
18 months (β=2.739; 95% CI= 1.133, 3.075, P<.001) (Table 8). Higher leptin was also
associated with higher fat mass% at baseline (β=.112; 95% CI= .090, .135; P<.001) and
18 months (β=.403; 95% CI= .017, .069; P=.002). For every unit increase in
transformed leptin there was a significant 2.103 unit increase in waist circumference at
18 months (β=2.103; 95% CI= .806, 3.400; P=.002). Having a viral load of <4 log10
copies/mL was associated with higher leptin levels (β= -.305; 95% CI= -.579, -.031;
P=.030) at baseline. Only waist circumference at baseline had a significant relationship
with log transformed LPS (β=-1.940; 95% CI= -3.397, .483; P=.011) (Table 9).
A separate linear regression analysis stratified by BMI groups was conducted. In
those who had a BMI ≥ 25kg/m2, higher log transformed leptin was associated with lower
viral load (β=-.205; 95% CI= -3.94, -.016; P=.035) at baseline.
Hs-CRP ≥ 3 mg/L was significantly related to higher BMI at baseline
(OR=60.960; 95% CI= 2.784, 1334.723; P=.009), waist circumference at 18 months
(OR=98.811; 95% CI= 1.697, 5755.086; P=.027), CD4% at baseline (OR=.949; 95% CI=
.902, .998; P=.042) (Table 10) and waist circumference over 18 months (OR=65.078;
95% CI: 1.490, 2842.157; P=.030). Lower CD8 count change over 18 months was
associated with CRP ≥ 3 mg/L (OR=.906; 95% CI=.831, .988; P=.025). A trend
association was seen in the relationship between hs-CRP ≥ 3 mg/L and BMI ≥ 25 kg/m2
(OR=2.407; 95% CI= .941, 6.156; P=.067). Leptin above the median (13,304 pg/mL)
was related to several body composition measures at baseline and 18 month; however,
there were no association with measures of HIV disease progression (Table 11). Leptin
above the median was associated with a higher odds of having higher BMI at baseline
(OR=2.073; 95% CI= 1.194, 3.601; P=.010) and 18 months (OR=1.554; 95% CI= 1.125,
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2.146; P=.008). Overweight/obese BMI category was also associated with leptin above
the median at baseline (OR=58.572, 95% CI= 2.187, 1568.688; P=.015) and 18 months
(OR=79.634; 95% CI= 4.607, 1376.659; P=.003). Additionally, a higher odds of having
more fat mass% was seen in the group that had leptin levels at or above the median at
baseline (OR=1.580, 95% CI= 1.214, 2.055; P=.001) and 18 months (OR=1.231; 95%
CI= 1.070, 1.416; P=.004). The likelihood of higher leptin increased with higher waist
circumference (OR=1.267; 95 CI= 1.016, 1.580; P=.036). Leptin above the median was
also associated with having an increase in CD4% over 18 months (OR1.456; 95%
CI=1.456, 1.025, 2.069; P=.036). Lastly, Table 12 displays the relationships between
body composition and laboratory markers of HIV infection and disease progression for
those at or above the median of LPS (.0582 EU/mL). BMI and having BMI ≥ 25 kg/m2
was protective of having LPS above the median at baseline (OR=.790, 95% CI= .630,
.990; P=.041; and OR=.035, 95% CI= .004, .283; P=.002, respectively) and BMI at 18
months (OR=.799, 95% CI= .655, .976; P=.028). Fat mass% was also shown to be
protective of having higher LPS at baseline (OR=.852, 95% CI= .757, .958; P=.007). At
baseline LPS at or above the median was associated with higher viral load (OR=2.608,
95% CI= 1.111, 6.124; P=.028) and having a viral load ≥ 4 log10 copies/mL (OR=8.005,
95% CI= 1.762, 36.357; P=.007). The relationships between LPS as a continuous
variable and viral load ≥ 4 log10 copies/mL was approaching significance (OR=3.776,
95% CI= .959, 14.869; P=.057).
Discussion
The results presented here suggest a strong association between inflammatory
markers and body composition and HIV disease progression in ART naïve adult
participants in Botswana. To our knowledge, no study has assessed leptin or LPS in a
population from Botswana with or without HIV infection.
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CRP has previously been shown to be associated with CD4 cell count and HIV
viral load in ART naïve HIV+ adults.35-37 Our study did not confirm these associations
with measures of HIV disease progression, except for CD4%. CRP levels ≥ 3 mg/L
were associated with lower CD4%. CD4% is considered to be a more stable measure
than absolute CD4 cell counts and is thought to provide a better prognostic information
before ART is initiated in HIV infection.38,39 Thus, this study showed that CD4%, as a
measure of HIV disease progression, was an independent predictor of higher CRP levels
after adjusting for age, gender, smoking and fat mass%.
CRP and its association with mortality were investigated in HIV+ populations in
Botswana;40,41 however, these previous reports did not asses its relationship with
parameters of disease progression such as CD4 cell count or viral load. CRP levels
were found to be higher 4 weeks after initiation of ART in patients who died compared to
those who survived, in another HIV+ adult cohort in Botswana.40 Baseline levels of CRP
were also higher in those who died after ART initiation compared to matched controls in
Botswana.41
Azzoni et al.21 was the first to show that leptin levels were inversely associated
with viral replication independent of the amount of adipose tissue. Their cohort of
exclusively ART naïve women from South Africa also demonstrated an association
between viral load and immune activation. We confirmed an inverse relationship
between leptin levels and viral load at baseline, independent of body fat. These
associations were found in HIV+ male and female participants. These results are in
agreement with those of Azzoni and colleagues21 who hypothesized that high viral
replication and immune activation could result in chronic inflammation that would cause
lipoatrophy, therefore, lowering leptin levels.
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Leptin is involved in the proliferation of CD4 and CD8 cells,42 however, we did not
find any significant relationships between leptin and CD4 or CD8 cell counts, even while
adjusting for fat mass%. However, leptin above the median was associated with a
greater increase in CD4% over 18 months. Other researchers21,43,44 examining leptin in
HIV+ ART naïve individuals did not find significant relationship with CD4 cell counts.
The lack of an association of CD4 cell count and leptin may be due to the early stage of
the disease and healthier status in these participants. The parent study’s enrollment
criteria included having CD4 ≥ 350 cells/µL and BMI >18 kg/m2, which may have
precluded the chance of examining the associations with lower levels of CD4 counts and
BMI in the range of undernutrition at baseline. Additionally, ART-naïve participants
usually present uncontrolled viral loads.
Previous studies evaluating LPS and HIV disease progression in ART naïve
HIV+ adults have shown conflicting findings. In a cohort of HIV-positive, ART-naïve
adults, Marchetti el al. 28 reported a significant relationship between LPS and disease
progression as a composite outcome that included, AIDS defining conditions, death,
CD4 cell counts < 200 cells/µL, or start of ART in HIV+ ART naïve adults, who were
followed for approximately 3 years. This relationship was independent of CD4 cell counts
and HIV viral load. Conversely, a study examining LPS and HIV disease progression in
ART naïve Ugandans and Americans was not able to detect sufficient LPS levels in their
samples for analyses.45 A recent study conducted in Kenyan women demonstrated that
LPS levels were associated with chronic HIV infection, whether treated or not with ART;
however, no direct associations with CD4 cell count or viral load was found.46 This
present study did not find a significant association between LPS and CD4 cell count, but
LPS was significantly and inversely associated with viral load. LPS levels above the
median were associated with higher viral load and those with LPS levels ≥ the median

122

were 8 times more likely to have viral load > 4log10 copies/mL or 10,000 copies/mL.
Interestingly, LPS was also inversely associated with measures of body composition,
therefore being overweight or obese was protective of having higher levels of LPS.
Timmons et al.47 did not show significant association between LPS and body
composition; however, they did report relationship with sCD14. Soluble CD14 is a
measure of microbial translocation, which is freed from monocytes by LPS stimulation.48
There was an inverse association between sCD14 and limb and trunk fat in 178 HIV+
adults that included ART treated and non-treated patients. The authors suggest that
microbial translocation may be involved in muscle and fat loss during HIV disease.
Unfortunately, the result could not be separated from the effect of ART treatment since
the analyses included both ART treated and non-treated. In animals, it has been
demonstrated that the quality of diet, rather than weight, was a better predictor of the
composition of intestinal bacteria.49 A high fat diet has been shown to be associated with
higher LPS levels.50 Diet composition of those with a higher BMI may have affected
inflammation and should be researched further.
A possible explanation for the lower levels of LPS observed in those with higher
BMI might be the endotoxin lipoprotein hypothesis. Rauchhaus et al.29 were the first to
describe the endotoxin-lipoprotein hypothesis as a way to explain the paradox of higher
cholesterol levels being beneficial in congestive heart failure. Higher circulating
lipoproteins may modulate inflammation by binding to lipopolyssachrides and reduce
their effect on release of proinflammatory cytokines. LPS is sequestered during micelle
creation under the direction of lipoproteins. Since higher BMI is associated with higher
risk of elevated cholesterol, triglycerides and LDL,51,52 more circulating lipoproteins may
be available to capture LPS.

123

The limitations of our study include the study design, which was retrospective
and observational. A larger sample size may have also showed significant relationships
between inflammatory markers and disease progression. A selection bias may also
have been present since we chose to complete leptin and LPS in a random subset that
had samples available at baseline and 18 months. In HIV, bioimpedance (BIA) has been
shown to be an effective method for detecting fat mass;53 however, BIA has limitations,
since its values can be influenced by body arrangement, hydration, ingestion of food and
drinks, air and body temperature and exercise.54 Our BIA measurement protocol
countered these limitations by giving detailed instructions to the participants on their
preparation for their visit, and standardizing the measurement parameters.
Conclusions
Body composition and HIV disease progression affected inflammation in this
HIV+ adult population in Botswana, early in their disease. Laboratory markers of HIV
infection and disease progression was predictive of inflammation, independent of body
fat. Higher LPS was associated with lower BMI and higher viral load, while higher leptin
was associated with higher fat mass and lower viral load. These are new and thoughtprovoking findings that might help explain the obesity paradox often observed in HIV+
ART adults. The mechanisms affecting HIV disease progression through inflammation
are complex and still not entirely understood, which warrants further prospective
investigation before and after initiation of ART.
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Table 1: General Characteristics of the Sample Population
Variable

Total
(N=144)
33.00 (29.00-39.00)

Age (years)
Gender a
Male (%)
34 (23.60)
Female (%)
110 (76.40)
BMI (kg/m2)
22.70 (20.70-26.93)
Waist (inches)
32.28 (29.92-35.81)
Waist to hip ratio
.82 (.79-.88)
Lean mass (%)
71.30 (66.30-76.00)
Fat mass (%)
28.70 (24.00-33.70)
CD4 cell count (cells/µL)
409.03 (329.79-552.58)
CD4 %
26.35 (19.64-31.04)
CD8 cell count (cells/µL)
844.35 (621.96-1189.17)
CD8 %
51.70 (43.58-58.30)
CD4/CD8 Ratio
.53 (.36-.68)
HIV viral load (Log10 copies/mL)
4.33 (3.58-4.83)
CRP (mg/L)
1.69 (.80-4.74)
Leptin (pg/mL)b
13,304.75 (5649.13-24,430.50)
LPS (EU/mL) b
.058 (.053, .068)
a
Reported as n (%); all other variables reported as median (interquartile range)
b
Completed in a subset of 60 participants
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Table 2: Baseline Spearman Correlation Coefficients and P-values
Variables
CRP (mg/L)
Leptin (pg/mL)
LPS (EU/mL)
BMI (kg/m2)
Waist (inches)
Waist-to-hip ratio
Lean body mass (%)
Fat mass (%)
CD4 cell count (cells/µL)
CD4%
CD8 cell count (cells/µL)
CD8%
CD4/CD8 Ratio
HIV viral load (log10 copies/mL)
a

CRP
r=.404
p=.010**
r=-.042
p=.796
r=.150
p=.073
r=.179
p=.072
r=.151
p=.129
r=-.154
p=.066
r=.155
p=.065
r=-.083
p=.647
r=-.144
p=.175
r=.088
p=.294
r=.076
p=.365
r=-.104
p=.216
r=.092
p=.271

Completed in a subset of 60 participants
*P<0.05, **P<0.01
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Leptina
r=.404
p=.010**
r=-.357
p=.005**
r=.734
p<.001**
r=.603
p<.001**
r=-.023
p=.895
r=-.836
p<.001**
r=.838
p<.001**
r=.005
p=.969
r=-.044
p=.740
r=-.090
p=.496
r=-.240
p=.065
r=.096
p=.464
r=-.145
p=.273

LPSa
r=-.042
p=.796
r=-.357
p=.005**
r=-.288
p=.025*
r=-.493
p=.003**
r=.082
p=.638
r=.361
p=.005**
r=-.362
p=.004**
r=.015
p=.912
r=-.134
p=.308
r=.157
p=.232
r=.253
p=.052
r=-.134
p=.308
r=.246
p=.060

Table 3: Relationship Between BMI Groups and Measures of Inflammatory Markers at
Baseline*
Inflammatory
Markers
CRP (mg/L)a
Leptin (pg/mL) b

BMI (18-24.9 kg/m2)

BMI >25kg/m2

P-value

1.41 (.70-4.15)
2.37 (1.20-5.89)
.028c
5,687.05 (2,799.6322,894.90 (14,147.43<.001c
11,366.73)
33,943.33)
b
LPS (EU/mL)
.068 (.061-.079)
.055 (.053-.058)
.001c
*Data reported as median (interquartile range)
a
BMI group; BMI (18-24.9 kg/m2) included 95 participants and BMI group >25kg/m2
included 49
b
BMI group; BMI (18-24.9 kg/m2) included 30 participants and BMI group >25kg/m2
included 30
c
Statistically significant, P<.05
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Table 4: Relationship Between CRP Groups and Body Composition and Measures of
Inflammatory Markers at Baseline*
Variables
CRP<3 mg/L
BMI (kg/m2)
22.40 (20.50-25.90)
Waist (inches)
31.79 (29.92-34.44)
Waist to hip ratio
.81 (.78-.88)
Lean mass (%)
71.70 (67.20-75.90)
Fat mass (%)
28.30 (24.10-32.80)
CD4 cell count
419.05 (332.48-553.63)
(cells/µL)
CD4 %
27.56 (22.02-31.56)
CD8 cell count
773.28 (586.65-1163.89)
(cells/µL)
CD8 %
48.98 (42.91-57.64)
CD4/CD8 Ratio
.56 (.39-.71)
HIV viral load
4.14 (3.47-4.82)
(Log10 copies/mL)
*Data reported as median (interquartile range)
a
Statistically significant, P<.05
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CRP ≥3 mg/L
24.40 (20.70-28.95)
33.86 (30.71-38.29)
.83 (.80-.89)
69.25 (64.25-79.53)
30.75 (20.48-35.78)
401.30 (323.92-555.39)

P-value
.094
.036a
.139
.254
.248
.591

22.95 (18.42-29.85)
925.36 (712.481213.74)
54.67 (44.68-61.18)
.41 (.29-.62)
4.57 (3.66-5.08)

.013a
.030a
.078
.015a
.141

Table 5: Relationship Between Median Groups of Leptin and Body Composition and
Measures of Inflammatory Markers at Baseline*
Variables
Leptin<13,304 pg/mL
BMI (kg/m2)
21.30 (20.00-23.60)
Waist (inches)
30.51 (29.82-35.04)
Waist to hip ratio
.83 (.79-.90)
Lean mass (%)
75.50 (69.85-80.40)
Fat mass (%)
24.50 (19.60-29.75)
CD4 cell count
394.41 (318.82-478.95)
(cells/µL)
CD4 %
24.74 (19.22-28.60)
CD8 cell count
941.90 (677.67-1255.15)
(cells/µL)
CD8 %
54.75 (47.93-61.33)
CD4/CD8 Ratio
.44 (.32-.57)
HIV viral load
4.31 (3.64-4.87)
(Log10 copies/mL)
*Data reported as median (interquartile range)
a
Statistically significant, P<.05
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Leptin ≥13,304 pg/mL
27.10 (25.60-31.10)
36.24 (32.87-38.39)
35.24 (32.87-38.39)
64.40 (62.40-66.00)
35.60 (32.00-37.60)
393.17 (316.36-543.87)

P-value
<.001a
.003a
.804
<.001a
<.001a
.842

23.60 (18.92-30.04)
889.52 (693.89-1271.36)

.988
.912

48.37 (41.06-61.06)
.47 (.30-.75)
4.06 (3.50-4.60)

.108
.589
.275

Table 6: Relationship Between Median Groups of LPS and Body Composition and
Measures of Inflammatory Markers at Baseline*
Variables
LPS<.0582 EU/mL
BMI (kg/m2)
26.70 (25.05-31.15)
Waist (inches)
36.32 (34.35-39.37)
Waist to hip ratio
.80 (.79-.87)
Lean mass (%)
64.70 (62.55-70.08)
Fat mass (%)
35.30 (29.93-37.45)
CD4 cell count
424.03 (336.23-545.24)
(cells/µL)
CD4 %
24.14 (19.16-30.34)
CD8 cell count
848.30 (688.51-1276.73)
(cells/µL)
CD8 %
48.13 (42.73-59.26)
CD4/CD8 Ratio
.53 (.32-.67)
HIV viral load
3.93 (3.15-4.46)
(Log10 copies/mL)
*Data reported as median (interquartile range)
a
Statistically significant, P<.05
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LPS ≥.0582 EU/mL
22.40 (20.70-25.00)
31.50 (29.92-35.42)
.82 (.78-.90)
71.90 (67.03-80.03)
28.10 (19.98-32.98)
392.09 (311.12-459.95)

P-value
.001a
.005a
.748
.002a
.002a
.301

23.75 (18.49-28.42)
961.51 (685.781253.53)
54.81 (47.65-62.10)
.44 (.31-.61)
4.36 (3.92-4.82)

.433
.412
.089
.375
.023a

Table 7: Linear Regression at Baseline, 18 Months and the Change Over 18 Months by CRP*
Baseline
18 Months
Variable
β
95% CI
P-value
β
95% CI
BMIb
1.905
.281, 3.530
.022d
.646 -1.839, 3.131
BMI > 25 kg/m2
.398
-.143, 939
.148
.665
-.353, 1.683
a
Fat mass%
.020
-.009, .050
.177
.010
-.043, .062
b
Waist
-.175 -2.316, 1.965
.871
2.491 -1.108, 6.090
CD4 cell countc
-.002
-.057, .053
.947
.016
-.078, .111
CD4%
-.013
-.041, .015
.368
-.016
-.066, .034
b
HIV viral load
.084
-.151, .320
.480
.296
-.165, .756
HIV viral load
.091
-.342, .523
.679
.709
-.111, 1.529
≥ 4log10 copies/mL
CD8 cell countc
.008
-.019, .034
.565
.025
-.027, .077
CD8%
.004
-.017, .024
.709
.008
-.029, .046
CD4/CD8 Ratio
-.169
-.952, .613
.669
-.581
-2.080, .917
*Models adjusted for age, gender, smoking, and fat mass percentage
a
Model adjusted for age, gender, and smoking
b
Log transformed
c
Square root transformed
d
Statistically significant, P<.05
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P-value
.603
.195
.709
.170
.730
.520
.203
.089
.335
.650
.438

Change Over 18 Months
β
95% CI
P-value
.949
-2.579, 4.477
.983
.014
-.030, .057
.536
1.736
-.145, 3.617
.070
-.027
-.114, .060
.536
.035
-.024, .093
.243
.103
-.226, .432
.620
-.037
-.046
.737

-.085, .012
-.098, .006
-1.214, 2.688

.137
.085
.455

Table 8: Linear Regression at Baseline, 18 Months, and the Change Over 18 Months by Leptin*
Baseline
18 Months
Variable
β
95% CI
P-value
β
95% CI
BMIb
1.764
.788, 2.739
.001d
2.104
1.133, 3.075
BMI > 25 kg/m2
.584
.260, .908
.001d
.864
.498, 1.230
a
d
Fat mass%
.112
.090, .135
<.001
.043
.017, .069
b
Waist
.394
-1.546, 2.333
.681
2.103
.806, 3.400
CD4 cell countc
.027
-.010, .065
.151
-.016
-.062, .030
CD4%
.006
-.014, .026
.551
-.003
-.028, .022
b
HIV viral load
-.145
-.311, .022
.087
-.129
-.335, .078
HIV viral load
-.173
-.541, .194
-.305
-.579, -.031
.030d
≥ 4log10 copies/mL
CD8 cell countc
.005
-.014, .024
.599
-.008
-.031, .014
CD8%
-.002
-.015, .010
.685
.001
-.017, .017
CD4/CD8 Ratio
.156
-.429, .740
.595
-.117
-.950, .716
*Models adjusted for age, gender, smoking, and fat mass percentage
a
Model adjusted for age, gender, and smoking
b
Log transformed
c
Square root transformed
d
Statistically significant, P<.05
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P-value
<.001d
<.001d
.002d
.002d
.495
.816
.217
.348
.459
.990
.780

Change Over 18 Months
β
95% CI
P-value
.493 -1.463, 2.450
.615
-.016
-.057, .025
.437
.247 -1.073, 1.567
.704
.026
-.036, .089
.402
.020
-.010, .049
.194
.107
-.177, .331
.344
-.010
-.019
.509

-.040, .019
-.044, .006
-.451, 1.470

.493
.140
.292

Table 9: Linear Regression at Baseline, 18 Months, and the Change Over 18 Months by LPS*
Baseline
18 Months
Variable
β
95% CI
P-value
β
95% CI
BMIb
-.483
-1.208, .243
.188
-.023
-.399. .354
BMI < 25 kg/m2
-.273
-.506, -.040
.022d
-.017
-.160, .127
a
Fat mass%
.001
-.014, .016
.892
.001
-.008, .009
b
d
Waist
-1.940 -3.397, -.483
.011
-.005
-.477, .467
CD4 cell countc
.009
-.017, .034
.509
-.004
-.019, .011
CD4%
.003
-.011, .017
.648
-.006
-.014, .002
b
HIV viral load
.054
-.059, .168
.337
.047
-.020, .113
HIV viral load
.121
-.067, .309
.201
.064
-.056, .183
≥ 4log10 copies/mL
CD8 cell countc
.003
-.010, .016
.660
.004
-.003, .011
CD8%
.003
-.005, .011
.432
.001
-.004, .007
CD4/CD8 Ratio
.019
-.377, .415
.924
-.193
-.458, .072
*Models adjusted for age, gender, smoking, and fat mass percentage
a
Model adjusted for age, gender, and smoking
b
Log transformed
c
Square root transformed
d
Statitically significant, P<.05
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P-value
.904
.818
.950
.982
.569
.165
.168
.289
.290
.643
.150

Change Over 18 Months
β
95% CI
P-value
-2.979
-1.771, .822
.466
.004
-.013, .020
.673
.051
-1.088, 1.190
.927
.003
-.038, .045
.876
-.010
-.030, .010
.319
.012
-.135, .159
.869
.006
-.002
-.115

-.013, .026
-.019, .015
-.757, .526

.512
.809
.719

Table 10: Logistic Regression at Baseline, 18 Months, and Change Over 18 Months by CRP Groups (< and ≥ 3 mg/L)*
Variable
BMIb
BMI ≥ 25
kg/m2
Fat mass%a
Waistb

Baseline
OR
60.960

18 Months
OR
95% CI
8.685
.550, 137.236

Change Over 18 Months
OR
95% CI
1.012
.002, 213.705

P-value
.009d

2.407

95% CI
2.784,
1334.723
.941, 6.156

.067

1.719

.623, 4.746

.296

-

-

-

1.023
.223

.973, 1.076
.006, 7.968

.366
.411

1.010
98.811

.960, 1.063
1.697,
5755.086
.874, 1.090

.697
.027d

1.006
65.078

.868
.030d

.976

.909

.935, 1.083
1.490,
2842.157
.786, 1.052

.732
.400

1.066
1.100

.965, 1.179
.630

.209

.282

-

-

-

.811

.906

.831, .988

.025d

.633
.605

.933
3.544

.852, 1.022
.142, 88.638

.137
.441

CD4 cell
.971
.881, 1.071
.560
.976
countc
CD4%
.949
.902, .998
.042d
.990
.937, 1.047
HIV viral
1.289
.851, 1.951
.231
1.231
.785, 1.999
loadb
HIV viral load 1.568
.732, 3.359
.247
1.681
.652, 4.334
≥ 4log10
copies/mL
CD8 cell
1.030
.984, 1.078
.207
.993
.935, 1.054
countc
CD8%
1.023
.988, 1.060
.203
1.010
.970, 1.052
CD4/CD8
.292
.063, 1.363
.117
.621
.102, 3.787
Ratio
*Models adjusted for age, gender, smoking, and fat mass percentage
a
Model adjusted for age, gender, and smoking
b
Log transformed
c
Square root transformed
d
Statistically significant, P<.05
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P-value
.125

P-value
.599

.201

Table 11: Logistic Regression at Baseline, 18 Months, and the Change Over 18 Months by Leptin Groups (< and ≥ Median)*
Variable
BMI

Baseline
OR
95% CI
2.073 1.194, 3.601

P-value
.010d

18 Months
OR
1.554

.015d

79.634

1.580

2.187,
1568.688
1.214, 2.055

.001d

1.231

<.001

<.001,<.001

.998

1.267

BMI ≥ 25
kg/m2
Fat mass%a

58.572

Waist

CD4 cell
1.074
.833, 1.385
.581
1.168
countb
CD4%
1.022
.902, 1.157
.737
1.110
HIV viral loadc
.654
.231, 1.850
.424
.615
HIV viral load
.308
.039, 2.408
.261
.180
≥ 4log10
copies/mL
CD8 cell
1.013
.878, 1.169
.861
.960
countb
CD8%
.982
.913, 1.057
.628
.961
CD4/CD8
5.405
.124,
.381
73.701
Ratio
235.292
*Models adjusted for age, smoking, and fat mass percentage
a
Model adjusted for age and smoking
b
Square root transformed
c
Log transformed
d
Statistically significant, P<.05

95% CI
1.125,
2.146
4.607,
1376.659
1.070,
1.416
1.016,
1.580
.864, 1.581

P-value
.008d

Change Over 18 Months
OR
95% CI
1.438
.819, 2.524

P-value
.206

.003d

-

-

-

.004d

.985

.887, 1.093

.775

.036d

.967

.000, -

1.000

.313

1.279

.837, 1.956

.256

.971, 1.270
.209, 1.812
.018, 1.816

.127
.378
.146

1.456
.855
-

1.025, 2.069
.186, 3.928
-

.036d
.840
-

.848, 1.088

.522

.872

.698, 1.089

.228

.886, 1.042
.393,
13808.169

.338
.107

.867
133.567

.709, 1.061
.116,
154108.571

.165
.174
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Table 12: Logistic Regression at Baseline, 18 Months, and the Change Over 18 Months by LPS Groups (< and ≥ Median)*
Baseline
18 Months
Variable
OR
95% CI
P-value
OR
95% CI
BMI
.790
.630, .990
.041d
.799
.655, .976
BMI ≥ 25
.321
.076, 1.351
.035
.004, .283
.002d
kg/m2
Fat mass%a
.852
.757, .958
.007d
.932
.854, 1.017
Waist
.727
.446, 1.187
.203
.907
.778, 1.056
CD4 cell
.915
.763, 1.098
.339
.915
.763, 1.098
countb
CD4%
.971
.888, 1.061
.971
.942
.861, 1.029
HIV viral loadc 2.608
1.111, 6.124
.028d
1.691
.782, 3.656
HIV viral load
8.005
1.762,
.007d
3.776
.959, 14.869
≥ 4log10
36.357
copies/mL
CD8 cell
1.003
.925, 1.087
.941
1.038
.956, 1.126
b
count
CD8%
1.025
.972, 1.081
.362
1.038
.977, 1.103
CD4/CD8
.630
.051, 7.857
.720
.120
.005, 2.860
Ratio
*Models adjusted for age, gender, smoking, and fat mass percentage
a
Model adjusted for age, gender, and smoking
b
Square root transformed
c
Log transformed
d
Statistically significant, P<.05
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P-value
.028d
.121

Change Over 18 Months
OR
95% CI
.875
.603, 1.270
-

P-value
.482
-

.113
.209
.339

1.046
.795
1.092

.944, 1.158
.555, 1.140
.825, 1.444

.391
.212
.538

.185
.182
.057

.905
.637
-

.784, 1.045
.247, 1.638
-

.173
.349
-

.376

1.124

.982, 1.266

.089

.228
.190

1.061
.032

.941, 1.197
.000, 3.912

.330
.161
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CHAPTER VI: SUMMARY AND CONCLUSIONS
This study investigated the obesity paradox in HIV+ ART naïve adults who were
in early stage of HIV disease in Botswana. The impact of obesity on HIV disease
progression over time was explored. An obesity paradox has been documented in many
conditions including HIV, where those who are obese may have a survival advantage or
improved disease outcomes.1 The genetic propensity for being overweight or obese was
examined using SNPs of the FTO gene, which is reported to be most associated with
BMI, and its association to HIV disease progression. In addition, inflammatory markers
and their relationship to body composition and HIV disease progression were
investigated.
Studies on HIV and obesity are mainly conducted in settings where the patients
are treated with ART, which may confound some of the findings and interpretations, as
ART has been associated with lipodystrophy and obesity.2 Rising rates of obesity have
been documented in countries with limited resources;3 however, studies conducted in
African settings on the relationship between HIV and obesity are lacking. Studies
conducted to investigate obesity and its effect on HIV disease progression have so far
been inconclusive, with some studies reporting an association and others reporting no
association between CD4 cell counts and obesity.1, 4-7 Studies on the relationship
between BMI and body composition on HIV disease progression are needed to reveal
possible mechanisms for the obesity paradox in HIV. The examination of such
interrelationships is important for translation of results into clinically relevant
recommendations for people living with HIV.
Our results demonstrated a protective effect of BMI and fat mass in delaying the
time to the first AIDS defining condition in HIV+ ART naïve adults in Botswana during 18
months of follow-up. Higher BMI was also associated with a higher CD4%, another
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marker of HIV disease progression over 18 months. In addition, higher fat mass was
also associated with the combined outcome of CD4 cell count ≤ 250/μL and AIDS
defining conditions. Survival analysis showed a positive trend with the outcome of a
decline in the CD4 cell count of 25% or greater and association with fat mass and
negative association with lean body mass. Findings from these analyses indicate that
higher fat may provide protection from advanced HIV disease. The fat stores would have
provided the extra energy needed to maintain the innate immune system responding to
protect against opportunistic infections and delaying wasting. Extra available energy for
use in times of emergency during the HIV disease may reduce the use of protein for
energy8 and also assist to conserve the immune system, especially the innate immunity
that is not directly affected by the infection.9,10
This study provides preliminary data on the genetic association between FTO
SNPs on the genetic risk of being overweight/obese and HIV disease progression in
HIV+ adults in Botswana. There were no significant findings between the FTO SNPs
and markers of HIV disease progression; however, a trend between the risk allele for
rs8050136 was protective of having higher HIV viral load. The variant rs17817449 had a
significant association with BMI, showing a greater odds of having higher BMI when the
risk allele was present. The risk alleles for rs1121980, rs8050136, and rs17817449
were associated with fat mass and lean mass. A higher percentage of fat mass and
lower lean body mass were associated with these risk alleles compared to homozygosity
for the non-risk allele. Although the exact mechanism for the effect of FTO on weight is
unknown, it is hypothesized that it may affect food intake and energy expenditure.11 FTO
is highly expressed in the hypothalamus region of the brain, where food intake is
controlled.12,13 The FTO still remains the gene most consistently associated with obesity
in various populations,14 but its associations have not been replicated in many African
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populations. GWAS studies in African populations are lacking, and identifying SNPs that
are relevant to this population is of importance since the SNPs showing associations in
European and Asian populations may be different from SNPs that will show associations
in African populations.
The relationship of inflammatory markers such as C-reactive protein, leptin, and
bacterial endotoxin lipopolysaccharide (LPS) with body composition and HIV disease
progression in HIV+ asymptomatic adults not on ART in Botswana over 18 months was
also evaluated. To our knowledge, no study has assessed leptin or LPS in a population
from Botswana with or without HIV infection. The results from this study suggest a strong
association of inflammation markers with body composition and HIV disease progression
in ART naïve adult participants in Botswana. Higher levels of inflammation as measured
was associated with a more progressed state of the disease. The relationships were
found to be independent of body fat. Our findings support the hypotheses in the
literature that high viral replication and immune activation could result in chronic
inflammation that would cause lipoatrophy, therefore, lowering leptin levels.15 LPS levels
above the median were associated with higher viral load and those with LPS levels ≥ the
median were 8 times more likely to have viral load > 4log10 copies/mL or 10,000
copies/mL. In addition, LPS was also inversely associated with measures of body
composition, therefore being overweight or obese was protective of having higher levels
of LPS. The endotoxin lipoprotein hypothesis or theory may provide a possible
explanation for the lower levels of LPS observed in those with higher BMI. Higher
circulating lipoproteins may modulate inflammation by binding to lipopolyssachrides and
reduce their effect on release of proinflammatory cytokines.16
Current study demonstrated that an obesity paradox may be present in early HIV
infection. We investigated and suggest several mechanisms for this paradox. Fat
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accumulation was found to be protective against further HIV disease progression in HIV+
adults who were early in the disease state and ART naïve. Higher levels of leptin and
lower levels of LPS were associated with being overweight/obese and higher amounts of
body fat mass percentage. Concurrently, lower leptin and higher LPS levels had
significant relationships to higher HIV viral load, a marker of HIV disease progression.
Additionally, a trend association was demonstrated with one of the FTO SNPs and HIV
viral load. The risk allele was associated with lower HIV viral load, therefore having a
protective effect. Establishment of mechanisms for this paradox are needed in order to
allow for translation of results into meaningful clinical recommendations and care
guidelines for resource limited settings.
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Table 1: Study Hypotheses and Results
Hypothesis #
1a

Hypothesis
(Primary outcome) The overweight/obese group will
present less clinically significant CD4 cell count
decline from Baseline (≥ 25%) over 18 months than
the normal weight group.

1b

The overweight/obese will have significantly lower
levels of HIV viral load over 18 months than the
normal weight group.
Significantly less AIDS defining conditions will occur
over 18 months in the overweight/obese group
compared to the normal weight group.

1c

2a
2b1
2b2

2b3
3a1

The FTO gene SNPs will be associated with being
overweight/obese.
The FTO gene SNPs will be associated with
significantly higher CD4 cell count.
The FTO gene SNPs will be associated with
significantly lower HIV viral load.

The FTO gene SNPs will be associated with
significantly less AIDS-defining conditions.
Higher levels of inflammatory markers will be
147

Study Results
There were no significant differences between BMI
groups in the main outcome ≥ 25% decline in CD4 cell
count over 18 months (HR= .744; 95% CI= .489, 1.131;
P=.166) after controlling for age, gender, marital status
children (yes/no), baseline CD4 cell count and baseline
HIV viral load.
BMI groups at baseline, 18 months and the change
over 18 months were not statistically associated with
HIV viral load.
There were no significant differences between BMI
groups in the outcome of AIDS defining conditions
(HR= .500; 95% CI= .047, 4.465; P=.500) after
controlling for age, gender, marital status, children
(yes/no), baseline CD4 cell count and baseline HIV viral
load. However, continuous BMI was associated with
AIDS defining conditions (HR=.218, 95% CI=.068, .701,
P=.011).
The FTO SNP rs17817449 was associated with BMI
(OR=1.082; 95%CI= 1.001, 1.169; P=.047).
There were no significant associations with between
FTO SNPs and CD4 cell count.
None of the FTO SNPs were significantly associated
with HIV viral load. However, there was a trend
towards significance with rs8050136 and HIV viral load
in a dominant model (OR=.705; 95% CI=.481, 1.035;
P=.074) after controlling for age, gender, tribes, total
dietary kcal, and activity.
There were no significant associations between FTO
SNPs and AIDS-defining conditions.
There were no significant associations with between

3a2

3a3

associated with lower levels of CD4 cell count.
Higher levels of inflammatory markers will be
associated with higher HIV viral load.

Higher levels of inflammatory markers will be
associated with greater AIDS-defining conditions.
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inflammatory markers and CD4 cell count.
Leptin was associated with HIV viral load >4 log10
copies/mL (OR=-.305; 95%CI=-.579, -.031; P=.030) at
baseline. LPS above the median was associated with
HIV viral load (OR=2.608, 95% CI=1.111, 6.124,
P=.028) and HIV viral load >4 log10 copies/mL (OR=8.005; 95%CI= 1.762, 36.357; P=.007) at baseline and
HIV viral load >4 log10 copies/mL (OR=-3.776; 95%CI=
.959, 14.869; P=.057) at 18 months.
There were no significant associations with between
inflammatory markers and AIDS-defining conditions.
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CHAPTER VII: STRENGTHS AND LIMITATIONS
The results from this study could be translated into clinically relevant nutrition and
care recommendations for HIV+ adults who are antiretroviral (ART) naïve in limited
resource settings. This is the first study to examine the effect of the genetic propensity to
become overweight/obese and inflammatory markers on HIV disease progression in an
HIV+ population in Botswana early in their disease. Both inflammatory markers, leptin
and LPS, have not previously been investigated in Botswana, with or without HIV.
Additionally, the FTO gene has never been genotyped in an HIV -infected population
and its association to HIV disease progression examined.
The strengths of this study consists of capturing and analyzing longitudinal data
from HIV+ participants in Botswana, that was collected from the early asymptomatic
stage through later stages with well-defined health outcomes. This type of information is
lacking in African populations. Considering that most of the HIV+ cases are within sub
Saharan Africa,1 more research in this area is warranted. This was also the first known
study to assess the role of FTO in the obesity paradox that often occurs in HIV+ adults.
Trends were noted in the relationship of some of the FTO SNPs with markers of HIV
disease progression, which may suggest a role in the obesity paradox and needs further
investigation in a larger cohort with adequate sample size.
Sample Size
The limitations of this study may have contributed to some of the null findings
observed. The sample size was insufficient to be able to examine differences between
overweight and obese groups separately. A larger sample size would have allowed for
the examination of the relationship of the FTO SNPs and body mass in further stratified
subgroups of overweight and obese separately. BMI in the range of underweight
category was not studied since underweight individuals were excluded from participation
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in the parent study, as those ranges are strong prognostic of AIDS.2 Inadequate sample
size may have also contributed to find non-significant associations between
inflammatory markers and CD4 cell count. In addition, there was a predominance of
women among the participants. Botswana is known to be a heterogeneous population
with many ethnic groups.3 The heterogeneity present in this population may also be a
limitation for this study.
Study Design
Study limitations also include a weaker study design, which was retrospective
and observational. The exact time since HIV diagnosis or infection were not available;
however, it was known that the participants were asymptomatic, never had a diagnosis
of AIDS and did not qualify for ART. The majority were referred from the clinics where
they were diagnosed. This HIV population was in the early stage of the disease and its
finding cannot be generalized to all HIV patients, and may be one of the reasons why we
did not see a significant decline of CD4 as a main outcome. Findings from this study
cannot be generalized to other HIV+ populations, including ART-treated patients, but
may be used in resource limited settings were ART is being slowly rolled out.
Methods
In HIV, bioimpedance (BIA) has been shown to be an effective method for
detecting fat mass; however, BIA have limitations, since its values can be influenced by
body arrangement, hydration, ingestion of food and drinks, air and body temperature and
exercise.4 Our BIA measurement protocol minimized the potential for variability by
providing detailed instructions to the participants on their preparation for their visit, and
standardizing the measurement parameters.
Selection bias may have contributed to null findings since we chose to complete
leptin and LPS in a subset that had samples available at baseline and 18 months.
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Participants who had both samples were those who maintained their CD4 cell counts
above the cut-off for eligibility for ART and were still followed by the parent study.
Therefore, those excluded may have been rapid progressors, with different genetic
makeup. Interestingly, despite these limitations, we had findings with CD4% and CRP
and leptin and LPS with viral load.
LPS measured by the Limulus amebocyte lysate (LAL) method is the most widely
used method; however, it may be affected by inhibition or interference of other
compounds.5 To prevent interference, dilution and heating methods were incorporated
into the LPS assay methodology for this study. The LAL method for measuring LPS is
currently only recommended for research purposes and not for a clinical setting.
The obesity paradox is present in the literature in a variety of diseases that
include HIV.6 Controversies exist on both sides of the dispute on whether this paradox
is real, a query that has implications for HIV management and public health efforts.
Equipoise in the literature regarding obesity paradoxes should drive the need for more
research to provide the appropriate care and advice for patients. The results from this
study may be used as preliminary data for future research in this topic.
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CHAPTER VIII: FUTURE RESEARCH
The results from this study demonstrated that fat may provide protection against
further HIV disease progression in HIV+ adults who are early in the disease and ART
naïve. Higher levels of leptin and lower levels of LPS were associated with being
overweight/obese and higher amounts of body fat mass percentage. At the same time,
higher leptin and lower LPS levels had significant relationships to higher HIV viral load, a
marker of HIV disease progression. There was a trend association with one of the FTO
SNPs and HIV viral load. However, genetic association studies generally require large
sample sizes.1 It seems there is an obesity paradox present in the HIV+ ART naïve
cohort we investigated. An obesity paradox is present in several diseases and
conditions2 and mechanistic studies are needed in this area of obesity and HIV to
establish the nature and cause for this paradox in order to develop clinical
recommendations. The preliminary results from the analyses conducted with FTO SNPs,
inflammatory markers, and measures of HIV disease progression will be useful to
calculate sample size for future studies. Further examination of the mechanisms and
best approaches for translation of findings into recommendations into care of people
living with HIV are needed.
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